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  8U Summary 
Summary 
I.1  German summary (short) 
Prionenerkrankungen sind neurodegenerative Erkrankungen, zu denen Scrapie beim 
Schaf, Bovine Spongiforme Enzephalopathien beim Rind und beispielsweise die 
Creutzfeld-Jakob-Erkrankung beim Menschen zählen. Bei dem Erreger der 
Erkrankung handelt es sich um ein infektiöses Protein, das sogenannte Prionen 
Protein PrP
Sc. Die primäre Sequenz des PrP
Sc ist identisch zur Sequenz eines weit 
verbreiteten zellulären Proteins PrP
c. Es wird angenommen, dass die Vermehrung 
durch die Umfaltung des zellulären Gegenspielers PrP
c stattfindet. Als möglicher 
therapeutischer Ansatz gegen diese Erkrankungen wird eine Vakzinierung diskutiert. 
Eine krankheitsverlangsamende Wirkung durch passive Immunisierung mit 
spezifischen Antikörpern, die die zelluläre Form des Proteins PrP
c erkennen, wurde 
bereits im Tiermodell gezeigt. Die Erzeugung einer Immunantwort gegen PrP
c 
erfordert die Umgehung der wirtsspezifischen Toleranz gegen das Selbstantigen PrP
c. 
Ziel der vorliegenden Arbeit war die Entwicklung von Impfstoffkandidaten für eine 
aktive Immunisierung gegen Prionenerkrankungen. 
 
Es wurden Vakzine auf der Basis von Virus-ähnlichen Partikeln (Retropartikel) 
entwickelt, die vom murinen Leukämievirus (MLV) bzw. vom humanen 
Immundefizienzvirus (HIV) abgeleitet wurden. Sowohl die Präsentation der zellulären 
Form PrP
c als auch der pathogenen Form PrP
Sc wurde adressiert.  
Zur Präsentation auf Retropartikeln wurde PrP
c entweder an die 
Transmembrandomäne des Plättchen-abgeleiteten Wachstumsfaktor Rezeptors 
(PDGFR) oder an den N-terminus des retroviralen Hüllproteins (Env) von MLV 
fusioniert wurde. In beiden Fällen konnten die entsprechenden PrP
D- bzw. PrP
E-
Retropartikel erfolgreich hergestellt werden, die des Weiteren mittels 
Immunfluoreszenzfärbung, Western Blot Analyse, Immunogold-Elektronen-
mikroskopie sowie ELISA Methoden charakterisiert wurden. Sowohl für PrP
D- als auch 
für PrP
E-Retropartikel konnte gezeigt werden, dass PrP
c inkorporiert und auf der 
Oberfläche der viralen Partikel präsentiert wurde, wenn N-terminal trunkierte Formen 
von PrP
c verwendet wurden. Die für PrP
c typischen Glykosylierungsmuster konnten 
durch spezifischen Glykosidase-Verdau nachgewiesen werden. Die präsentierten 
PrP
c-Varianten wurden unter nativen Bedingungen von PrP-spezifischen Antikörpern 
erkannt. Im Gegensatz zu den N-terminal trunkierten Varianten wurde das komplette 
PrP
c nicht in Retropartikel inkorporiert. Mittels Elektronen-Mikroskopie konnte bei der 
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Inkorporation von PrP
c-Varianten keine Veränderung der charakteristischen 
retroviralen Morphologie der Partikel festgestellt werden.  
MLV-abgeleitete PrP
D-Retropartikel wurden anschließend erfolgreich zur 
Immunisierung von Mäusen eingesetzt. Dabei wurden, im Gegensatz zur 
Immunisierung mit Vakzinen, die auf bakteriell hergestelltem PrP
c basierten, 
spezifische Antikörpertiter erhalten.  
Versuche zur Präsentation der pathogenen Form wurden zum einen durch 
Konvertieren der Proteinase K-sensitiven in die Proteinase K-resistente Form des PrP 
auf der Oberfläche der PrP
D-Retropartikel durchgeführt. Der Nachweis mittels 
Proteinase K-Verdau wurde hier speziell für virale Partikel adaptiert, die Umwandlung 
der PrP
D-Retropartikel in Proteinase K-resistent Formen konnte jedoch nicht 
beobachtet werden. Zum anderen wurde ein PrP
c-codierendes 
replikationskompetentes MLV-abgeleitetes Retrovirus erzeugt. Dieses konnte über 
sechs Passagen genetisch stabil auf murinen Fibroblasten propagiert werden, zeigte 
allerdings nach Infektion einer Prionen-infizierten Zelllinie, die PrP
Sc stetig 
propagierte, keine Replikation. 
Neben virus-ähnlichen Partikeln standen damit MLV-abgeleitete 
replikationskompetente Viren zur Verfügung, die PrP
c stabil im viralen Genom 
enthalten und auf ihrem Hüllprotein präsentieren. 
 
Basierend auf Hinweisen aus der Literatur war die Inkorporation von PrP
c in Virus-
ähnliche Partikel zu erwarten, da es sich um ein Zelloberflächenprotein handelt. Der 
fehlende Einbau des kompletten PrP in retrovirale Partikel war daher unerwartet. 
Anders als für die trunkierten PrP
c-Varianten war sowohl die Fusion mit PDGFR als 
auch die N-terminale Env-Fusion für PrP
c inhibiert. Das komplette PrP
c unterliegt im 
Vergleich zu trunkierten Formen einem erhöhten Zelloberflächen-Umsatz und weist 
eine geringere Halbwertszeit auf. Diese beiden Faktoren können einen Beitrag zur 
verminderten Inkorporation in retrovirale Partikel leisten. 
Die in der vorliegenden Arbeit beschriebenen PrP
D-Retropartikel stellen das erste 
erfolgreiche System zur Erzeugung PrP-spezifischer Immunantworten gegen die 
native Zelloberflächen-Form des PrP
c dar. Ein möglicher Mechanismus zur Erklärung 
basiert auf der Induktion der T-Zellhilfe sowie eines Beitrags des angeborenen 
Immunsystems. Eine weitere Verbesserung der Immunantwort sollte sich mit den in 
dieser Arbeit hergestellten MLV- und HIV-abgeleiteten Partikeln, die zusätzlich mit 
PrP-codierenden Sequenzen ausgestattet wurden sowie mit den 
replikationskompetenten MLV-Varianten verwirklichen lassen. 
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I.2  German summary (long) 
Prionenerkrankungen sind neurodegenerative Erkrankungen, zu denen Scrapie 
beim Schaf, Bovine Spongiforme Enzephalopathien beim Rind und beispielsweise 
die Creutzfeld-Jakob-Erkrankung beim Menschen zählen. Bei dem Erreger der 
Erkrankung handelt es sich um ein infektiöses Protein, das sogenannte Prionen 
Protein PrP
Sc. Die primäre Sequenz von PrP
Sc ist identisch zur Sequenz des 
zellulären Proteins PrP
c. Dieses zelluläre Protein, das in allen Säugetieren stark 
konserviert ist, zeigt hohe Expressionsraten im zentralen Nervensystem sowie in 
den Zellen des Immunsystems. Anhand von Experimenten mit PrP
c-knock-out 
Mäusen konnte die Unerlässlichkeit des PrP
c für die Entwicklung der 
Prionenerkrankungen abgeleitet werden. Es wird daher angenommen, dass die 
Vermehrung durch die Umfaltung des zellulären Gegenspielers PrP
c stattfindet.  
Als möglicher therapeutischer Ansatz gegen diese Erkrankungen wird eine 
Vakzinierung diskutiert. Eine krankheitsverlangsamende Wirkung durch passive 
Immunisierung mit spezifischen Antikörpern, die die zelluläre Form des Proteins 
PrP
c erkennen, wurde bereits im Tiermodell gezeigt. Die Erzeugung einer 
Immunantwort gegen PrP
c erfordert die Umgehung der wirtsspezifischen Toleranz 
gegen das Selbstantigen PrP
c. Das Verständnis der Toleranzmechanismen des 
Immunsystems ist die Grundvoraussetzung zur erfolgreichen Immunisierung 
gegen PrP
c. Diesbezüglich konnte gezeigt werden, dass die relativ geringe B-Zell-
basierte Toleranz gegen PrP
c prinzipiell die Entstehung spezifischer Antikörper 
ermöglicht. Allerdings muss ein zu entwickelndes Vakzin eine hohe T-Zell-
Toleranz gegen PrP
c überwinden.  
Ziel der vorliegenden Arbeit war die Entwicklung von Impfstoffkandidaten für 
eine aktive Immunisierung gegen Prionenerkrankungen. 
 
Es wurden Vakzine auf der Basis von Virus-ähnlichen Partikeln (Retropartikel) 
entwickelt, die vom murinen Leukämievirus (MLV) bzw. vom humanen 
Immundefizienzvirus (HIV) abgeleitet wurden. Sowohl die Präsentation der 
zellulären Form PrP
c als auch der pathogenen Form PrP
Sc wurde adressiert.  
Zur Präsentation auf Retropartikeln wurde PrP
c entweder an die 
Transmembrandomäne des Plättchen-abgeleiteten Wachstumsfaktor Rezeptors 
(PDGFR) oder an den N-terminus des retroviralen Hüllproteins (Env) von MLV 
fusioniert. In beiden Fällen konnten die entsprechenden PrP
D- (PrP-PDGFR) bzw. 
PrP
E-Retropartikel (PrP-Env) erfolgreich hergestellt werden, die des Weiteren 
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mittels Immunfluoreszenzfärbung, Western Blot Analyse, Immunogold-
Elektronen-mikroskopie sowie ELISA Methoden charakterisiert wurden.  
Sowohl für PrP
D- als auch für PrP
E-Retropartikel konnte gezeigt werden, dass PrP
c 
inkorporiert und auf der Oberfläche der viralen Partikel präsentiert wurde, wenn 
N-terminal trunkierte Formen von PrP
c verwendet wurden. PrP
c wies nach 
Expression ein typisches Glykosylierungsmuster bestehend aus un-, mono- und 
diglykosyliertem Protein auf. Dieses typische Muster konnte für beide 
Präsentations-Systeme durch spezifischen Glykosidase-Verdau nachgewiesen 
werden. Des Weiteren wurden die präsentierten PrP
c-Varianten in 
Immunfluoreszenz-Färbungen unter nativen Bedingungen von PrP-spezifischen 
Antikörpern erkannt.  
Im Gegensatz zu den N-terminal trunkierten Varianten wurde das komplette PrP
c 
nicht in Retropartikel inkorporiert. Sowohl die Fusion zum PDGFR als auch die N-
terminale Präsentation auf dem viralen Env Protein führten zur Inhibition der 
PrP
c-Inkorporation in MLV- und HIV-abgeleitete Partikel. Mittels Western Blot 
Analyse konnte ein Einfluss bereits auf die Expression der Fusionsproteine in den 
Zielzellen gezeigt werden, die für komplettes PrP
c an sich stark reduziert war und 
in den aus den Zielzellen entstehenden Partikeln nicht nachgewiesen werden 
konnten. 
Der Vergleich der beiden verschiedenen Präsentationssysteme zeigte 
unterschiedliche Inkorporationsraten. Dabei konnte für PrP
D-Retropartikel, die 
von MLV abgeleitet waren und N-terminal trunkierte Formen des PrP
c 
präsentierten, die höchste Inkorporationsrate erhalten werden. PrP
E-Retropartikel 
zeigten deutlich reduzierte Einbau-Raten. Generell erfolgte der Einbau in HIV-
abgeleitete Partikel weniger effizient als in MLV-Partikel.  
Mittels Elektronen-Mikroskopie konnte nach der Inkorporation der PrP
c-Varianten 
keine Veränderung der charakteristischen retroviralen Morphologie der Partikel 
festgestellt werden. Sowohl PrP
D- als auch PrP
E-Retropartikel zeigten nach 
Inkubation mit einem PrP-bindenden monoklonalen Antikörper spezifische 
Markierungen an der Virushülle. Neben den an ihrer Morphologie erkennbaren 
Viruspartikel enthielten die Präparationen Vesikel-ähnliche Strukturen. Die in 
Form und Größe variablen Vesikel enthielten ebenfalls die PrP
D- bzw. PrP
E-
Proteine. Die Vesiklebildung war für PrP
D-Retropartikel verstärkt, für PrP
E-
Retropartikel jedoch nur in geringem Maß zu beobachten. 
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MLV-abgeleitete PrP
D-Retropartikel, die aufgrund ihrer besonders hohen 
Inkorporationsrate ausgewählt wurden, wurden anschließend in einer 
Kooperation mit U.Kalinke und P.Bach (Abt. Immunologie, Paul-Ehrlich-Institut) 
erfolgreich zur Immunisierung von Mäusen eingesetzt. Dabei wurden, im 
Gegensatz zur Immunisierung mit Vakzinen, die auf bakteriell hergestelltem PrP
c 
basierten, spezifische Antikörpertiter erhalten. Die Bindung dieser erhaltenen 
Antikörper an die sogenannte native Form des PrP, die mittels eines speziellen 
Bindungsassays auf murinen T-Zellen gezeigt werden konnte, stellte dabei ein 
wichtiges Kriterium zur Bestimmung der Qualität der erhaltenen Seren dar. 
Aktuelle Studien zur Immunisierung gegen Prionenerkrankungen zeigten, dass 
nur derartige Antikörper Protektion zu vermitteln vermögen.  
Versuche zur Präsentation der pathogenen Form wurden zum einen durch 
Konvertieren der Proteinase K-sensitiven in die Proteinase K-resistente Form des 
PrP auf der Oberfläche der PrP
D-Retropartikel durchgeführt. Der Nachweis mittels 
Proteinase K-Verdau wurde hier speziell für virale Partikel adaptiert, die 
Umwandlung der PrP
D-Retropartikel in die Proteinase K-resistente Form konnte 
jedoch nicht beobachtet werden. Zum anderen wurde ein PrP
c-codierendes 
replikations-kompetentes ecotropes MLV erzeugt. Es konnte erneut die 
Beobachtung gemacht werden, dass nur N-terminal trunkierte PrP
c-Varianten in 
das Virus inkorporiert wurden. Das komplette PrP
c inhibierte die Replikation des 
Virus. Wurden jedoch trunkierte Varianten eingesetzt, konnte die Virus-Variante 
über sechs Passagen genetisch stabil auf murinen Fibroblasten propagiert 
werden. Die genetische Stabilität wurde sowohl anhand von Immunfärbungen 
der infizierten Zellen als auch anhand der Präparation des Virusgenoms und sich 
anschließender spezifischer Amplifikation der PrP-codierenden Sequenzen 
durchgeführt. Des Weiteren wurde der Tropismus der replikations-kompetenten 
Virus-Variante auf verschiedenen murinen und humanen Zielzellen untersucht. Es 
wurde ein verstärkter Zelleintritt der PrP
c-tragenden Variante auf humanen T-
Zellen beobachtet, die möglicherweise auf das Vorhandensein des PrP 
zurückzuführen war. Eine erweiterung des Virudtropismus auf humane T-Zellen 
Die ecotrope Virus-Variante konnte jedoch nicht in den humanen T-Zellen konnte 
jedoch nicht festgestellt werden.  
Nach Infektion einer Prionen-infizierten Zelllinie, die PrP
Sc stetig propagierte, 
konnte, im Gegensatz zur schnellen Ausbreitung in murinen Fibroblasten, keine 
Replikation beobachtet werden. Diesbezüglich wurde die Integration der Variante 
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ins Zellgenom und das Vorhandensein viraler RNA nachgewiesen. Allerdings 
konnte keine Expression des viralen env-Gens gezeigt werden. 
Neben virus-ähnlichen Partikeln standen damit MLV-abgeleitete replikations-
kompetente Viren zur Verfügung, die PrP
c stabil im viralen Genom enthalten und 
auf ihrem Hüllprotein präsentieren. Diese ecotropen Virus-Varianten replizierten 
auf murinen Fibroblasten, jedoch nicht auf den bisher getesteten scrapie-
infizierten Zelllinien. 
 
Der Einbau zellulärer Membranproteine in retrovirale Partikel ist ein bekanntes 
Phänomen. Die Inkorporation der PrP
D-Proteine in Virus-ähnliche Partikel war 
insofern zu erwarten. Der fehlende Einbau des kompletten PrP
C in retrovirale 
Partikel dagegen war eher unerwartet. Anders als für die trunkierten PrP
c-
Varianten war der Einbau sowohl der PrP
c-Fusion mit PDGFR als auch der Fusion 
mit Env für das komplette PrP
c inhibiert. Das komplette PrP
c unterliegt im 
Vergleich zu trunkierten Formen einem erhöhten Zelloberflächen-Umsatz und 
weist eine geringere Halbwertszeit auf. Diese beiden Faktoren könnten den 
beobachteten Effekt erklären. 
Ein weiterer Aspekt im Zusammenhang mit der Wechselwirkung von PrP
c mit der 
Enstehung retroviraler Partikel, war die Beeinflussung der viralen Gen-Expression 
durch PrP
c. Aktuelle Publikationen zeigen, dass PrP
c die Expression einiger HIV-
Gene inhibieren kann. Dies betrifft das virale Hüllprotein, akzessorische Proteine 
sowie in geringem Maße auch das virale Kapsid-Protein. Ein derartiger Einfluss 
von PrP
c kann ebenfalls zur Erklärung der in dieser Arbeit beobachteten Inhibition 
der MLV-Replikation und Partikelbildung herangezogen werden. Sobald das 
komplette PrP
c in Zielzellen exprimiert wurde, ob als endogenes, zelluläres PrP 
oder als Fusionsprotein im PrP
D- bzw. PrP
E-System, war die Enstehung viraler 
Partikel und vor allem die Produktion des viralen Hüllproteins stark reduziert. 
Einzig die Verwendung der N-terminal trunkierten PrP
c-Varianten in Zielzellen, 
die nur geringe Expression des PrP
c zeigen, führte zur erfolgreichen Produktion 
von Viruspartikeln. Diese Beobachtungen deuten auf eine Interferenz des N-
terminus von PrP
c mit der viralen Genexpression oder der Entstehung und 
Abschnürung viraler Partikel hin. 
Die N-terminale Präsentation Virusfremder Polypeptide kann generell 
unterschiedliche Auswirkungen auf den viralen Tropismus haben. Nur in 
Ausnahmefällen wurde eine Tropismuserweiterung (Infektion humaner Zellen 
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durch ecotropes MLV) beobachtet, üblicherweise kommt es zu einer Tropismus 
verengung. Letztere kann durch Bindung der Viruspartikel an den zellulären 
Rezeptor des präsentierten Polypeptids, gefolgt von Endozytose geschehen. 
Alternativ kann es auch zu einer sterischen Beeinträchtigung der Erkennung des 
viralen Rezeptors kommen, wenn trimere Polypeptode präsentiert werden. Im 
Falle des trunkierten PrP
c wurde auf PrP
c-negativen Zellen keine Blockierung des 
viralen Zelleintritts beobachtet, ein genereller Blockierungsmechanismus durch 
PrP
c konnte somit ausgeschlossen werden.  
 Die in der vorliegenden Arbeit beschriebenen PrP
D-Retropartikel stellen das erste 
erfolgreiche System zur Erzeugung PrP-spezifischer Immunantworten gegen die 
native Zelloberflächen-Form des PrP
c dar. Ein möglicher Mechanismus zur 
Erklärung basiert auf der Induktion der T-Zellhilfe. Virus-ähnliche Partikel, die 
von HIV abgeleitet waren, wurden bereits zur Immunisierung gegen HIV und 
andere Virus-basierte Erkrankungen eingesetzt. Diese Antigene wiesen stets eine 
Partikel-abhängige T-Zellantwort der CD4-positiven T-Helferzellen auf. Obwohl 
dies in der vorliegenden Arbeit nicht getestet wurde, könnte dieser Mechanismus 
auch bei der mit PrP
D-Retropartikeln ausgeführten Immunisierung zur Erzeugung 
PrP-spezifischer IgG-Antikörper beigetragen haben. Des Weiteren kommt hierfür 
auch ein Beitrag des angeborenen Immunsystems in Betracht. Die Stimulierung 
von Antigen-präsentierenden Zellen kann über sogenannte Toll-like Rezeptoren 
einen Einfluss auf die T-Zellantwort des Organismus haben. Viral verpackte RNA 
kann dabei extrazellulär an die Rezeptoren binden und eine verstärkte 
Immunreaktion bewirken. 
Eine weitere Verbesserung der Immunantwort sollte sich aus diesem Grund auch 
mit den in dieser Arbeit hergestellten MLV- und HIV-abgeleiteten Partikeln, die 
zusätzlich mit PrP-codierenden Sequenzen ausgestattet wurden, sowie mit den 
replikationskompetenten PrP-MLV-Varianten verwirklichen lassen. 
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I.3  English summary 
Prion diseases, also called transmissible spongiform encephalopathies, are a 
group of fatal neurodegenerative conditions that affect humans and a wide 
variety of animals. To date there is no therapeutic or prophylactic approach 
against prion diseases available. The causative infectious agent is the prion, also 
termed PrP
Sc, which is a pathological conformer of a cellular protein named prion 
protein PrP
c. Prions are thought to multiply upon conversion of PrP
c to PrP
Sc in a 
self-propagating manner. Immunotherapeutic strategies directed against PrP
c 
represent a possible approach in preventing or curing prion diseases. 
Accordingly, it was already shown in animal models, that passive immunization 
delays the onset of prion diseases. The present thesis aimed at the development 
of a candidate vaccine towards the active immunization against prion diseases, 
an immune response, which has to be accompanied by the circumvention of host 
tolerance to the self-antigen PrP
c. 
 
The vaccine development was approached using virus-like particles (retroparticles) 
derived from either the murine leukemia (MLV) or the human immunodeficiency 
virus (HIV). The display of PrP on the surface of such particles was addressed for 
both the cellular and the pathogenic form of PrP. 
The display of PrP
c was achieved by either fusion to the transmembrane domain of 
the platelet derived growth factor receptor (PDGFR) or to the N-terminal part of the 
viral envelope protein (Env). In both cases, the corresponding PrP
D- and PrP
E-
retroparticles were successfully produced and analyzed via immune fluorescence, 
Western Blot analysis, immunogold electron microscopy as well as by ELISA 
methods. Both, PrP
D- and PrP
E-retroparticles showed effective incorporation of N-
terminally truncated forms of PrP
c but not for the complete protein. PrP
c at this 
revealed the typical glycosylation pattern, which was specifically removed by a 
glycosidase enzyme.  Upon display of PrP
c on retroparticles the protein remained 
detectable by PrP-specific antibodies under native conditions. Electron microscopy 
analysis of PrP
c-variants revealed no alteration of the characteristic retroviral 
morphology of the generated particles.  
MLV-derived PrP
D-retroparticles were successfully used in immunization studies. 
Contrary to approaches using bacterially expressed PrP
c, the immunization of mice 
resulted in a specific antibody response. 
The display of the pathogenic isoform was aimed by two different strategies. The first 
one was directed at the conversion of the proteinase K (PK) sensitive from of PrP on 
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the surface of PrP
D-retroparticles into the PK resistant form. Albeit specific adaption 
of the PK digestion assay detecting resistant PrP, no PrP conversion was observed for 
PrP
D-retroparticles. The second approach utilized a replication competent variant of 
the ecotropic MLV displaying PrP
c on the viral Env protein. This MLV variant was 
stable in cell culture for six passages but did not replicate on scrapie-infected, PrP
Sc-
propagating neuroblastoma cells. 
Thus, besides PrP
c-displaying virus-like particles a replication competent MLV variant 
was obtained, which stably incorporated PrP
c at the N-terminus of the viral Env 
protein. 
 
The incorporation of the cell-surface located PrP
c into particles was expected from 
previously obtained data on protein display in the context of retrovirus-derived 
particles. Thus, the lack of incorporation observed for the complete PrP
c sequence 
was rather unexpected and was found to be inhibited at both, fusion to PDGFR and 
the viral Env. In contrast to N-terminally truncated PrP
c, the complete PrP
c was 
shown to exhibit increased cell surface internalization rates and half-life times 
eventually contributing to the observed results. 
The PrP-vaccination approach described in this work represents the first 
successful system inducing PrP-specific antibody responses against the prion 
protein in wt mice. Explanations at this are based on the induction of specific T cell 
help or effects of the innate immunity, respectively. MLV-and HIV-derived particles 
bearing the PrP-coding sequence or being replication competent variants generated 
during this thesis might help to further improve the PrP-specific immune response. 
 
 
II 
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Introduction 
II.1   Prion diseases 
II.1.1  Prions 
Prions are the causative agent for certain neurodegenerative diseases named 
prion diseases or transmissible spongiform encephalopathies (TSE) (Prusiner, S B 
1982), e.g. bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep, 
chronic wasting disease (CWD) in deer and elk, and Creutzfeldt-Jakob disease 
(CJD) in humans. The term prion is identical with PrP
Sc, which is a pathological 
conformer of a cellular protein named cellular prion protein PrP
c encoded by the 
Prnp gene (Oesch, B et al. 1985). This protein is widely expressed in mammals, 
high levels are particularly present in the central nervous system and in cells of 
the immune system (Ford, M J et al. 2002), and it is essential for the replication 
of prions and disease development (Bueler, H et al. 1993), (Prusiner, S B et al. 
1993).  
The precise nature of the transmissible agent, later named prion, has been long 
debated and was earlier believed to consist of a protein-encapsidated nucleic acid 
(Weissmann, C 2004). This VIRINO hypothesis asserts that the infectious agent 
contains an agent-specific nucleic acid enveloped in a host-specified protein 
explaining the lack of an immune response in disease development. However, 
although intense efforts have been made, no nucleic acid, long enough to encode 
even a small protein, could be identified in infectious fractions. This and several 
more findings finally have provided support for an updated version of the 
“protein-only” hypothesis (Griffith, J S 1967). A comparison of the different 
hypothesis is illustrated in Figure 1 (derived from (Weissmann, C 2004)).  
The host protein PrP
c, which typically occurs in un-, mono- and diglycosylated 
forms, is attached to the outer surface plasma membrane by a glycosyl 
phosphatidyl inositol (GPI) anchor and can be released from the cell surface by 
cleavage with phosphatidyl inositol specific phospholipase C (PIPLC) (reviewed in 
(Weissmann, C 2004)). As an example, the murine PrP gene structure is 
described in Figure 2, including characteristic regions of the protein. 
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Figure 1  Models for the propagation of the TSE agent (prion). a in a normal cell, PrP
c (yellow 
square) is synthesized, transported to the cell surface and eventually internalized. b The protein-only model 
postulates that the infectious entity, the prion, is congruent with an isoform of PrP, here designated as PrP
Sc 
(blue circle). Exogenous PrP
Sc causes catalytic conversion of PrP
c to PrP
Sc, either at the cell surface or after 
internalization. c The virino model postulates that the infectious agent consists of a TSE-specific nucleic acid 
associated with or packaged in PrP
Sc. The hypothetical nucleic acid is replicated in the cell and associates with 
PrP
c, which is thereby converted to PrP
Sc (Weissmann, C 2004). 
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Figure 2  Anatomy and structure of the prion protein. A) The cellular prion protein consists of a 
flexible N-terminal and a globular C-terminal domain. The C-terminal structure containing mainly α-helical 
arrangements and two small β-sheet secondary elements has been determined. The N-terminus possesses the 
copper-binding octarepeats; the protein has a signal peptide for membrane targeting and is post-translationally 
modified by addition of two glycosylations as well as a glycosyl phosphatidyl inositol (GPI) membrane anchor 
(Jones, I). B) The nuclear magnetic resonance (NMR) structure of mouse PrP (121-231) contains a two-
stranded antiparallel beta-sheet and three alpha-helices (Riek, R et al. 1996).  
 
The protein is highly susceptible to proteinase K (PK) digestion, whereas the 
term PrP
Sc was originally defined as a form of PrP that is largely resistant to PK 
digestion, although it is now also used for the designation of the infectious 
isoform of PrP. The digestion of PrP
Sc by PK leads to a characteristic 
electrophoretic mobility shift, caused by cleavage at residue 87-91 (depending 
on the prion strain), which results in the so-called PrP27-30. Notably, PK 
resistance is a relative concept, depending on the concentration of PK, on the PK 
to protein ratio as well as on the prion strain. Also forms of PrP, which are more 
resistant to PK but nonetheless remain non-infectious, can exist (Weissmann, C 
2004). 
The conversion of PrP
c to PrP
Sc has been proposed to be a self-propagating 
conversion, for which two models can be assumed as shown in Figure 3 
(Weissmann, C 2004). 
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Figure 3  Models for the conversion of PrPc to PrPSc. a The refolding model. The conformational 
change is kinetically controlled, a high activation energy barrier preventing spontaneous conversion at 
detectable rates. Interaction with exogenously introduced PrP
Sc (blue circle) causes PrP
c (yellow square) to 
undergo an induced conformational change to yield PrP
Sc. This reaction could be facilitated by an enzyme or 
chaperone. In the case of certain mutations in PrP
c, spontaneous conversion to PrP
Sc can occur as a rare event, 
explaining why familial Creutzfeldt-Jakob disease (CJD) or Gerstmann-Sträussler-Scheinker syndrome (GSS) 
arise spontaneously, albeit late in life. Sporadic CJD (sCJD) might arise when an extremely rare event 
(occurring in about one in a million individuals per year) leads to spontaneous conversion of PrP
c to PrP
Sc. b The 
seeding model. PrP
c (yellow square) and PrP
Sc (or a PrP
Sc-like molecule, shown as blue circle) are in equilibrium, 
with PrP
c strongly favoured. PrP
Sc is only stabilized when it adds onto a crystal-like seed or aggregate of PrP
Sc. 
Seed formation is rare; however, once a seed is present, monomer addition ensues rapidly. To explain 
exponential conversion rates, aggregates must be continuously fragmented, generating increasing surfaces for 
accretion (derived from (Weissmann, C 2004)). 
 
The seeding or nucleation model has found convincing experimental support in 
the case of yeast prions, and recently also with mammalian prions (reviewed in 
(Weissmann, C 2004)).  
A few cell lines, including the murine neuroblastoma cell line N2a, can propagate 
scrapie prions such as the so-called RML murine scrapie prion strain. It is not 
clear so far, which parameters and properties are rendering cells susceptible to 
prion infection; differences in the sequence of PrP
Sc and PrP
c as well as some 
unknown, eventually epigenic, mechanisms seem to play a role. The capacity of 
such cells to replicate prions can be described by the recently proposed “dynamic 
susceptibility” model ((Weissmann, C 2004)), in which the susceptibility depends 
on the ratio of prion synthesis to degradation and can therefore even lead to 
elimination of infection (in case the degradation rate is higher than the formation 
rate). 
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Under “natural” circumstances, e.g. in sheep scrapie, the prion agent is likely to 
be transmitted by ingestion of contaminated foodstuff, as it has been shown to 
be the case in cow-to-human transmissions of the BSE strain in the end of the 
21
th century in Great Britain (Taylor, D M 2003). 
The spread of prions entering an organism via the food chain, has been shown to 
appear by the infection of immune and lymphoreticular cells and subsequent 
infection of the peripheral and the central nervous system, a process termed 
“prion neuroinvasion” as reviewed in (Aguzzi, A et al. 2003). This route of 
infection is the basis of therapeutic approaches relying on antibody responses to 
the cellular PrP, as described in the following chapter, which seem to interfere 
with prion replication already but maybe not exclusively in early states of 
infection before neuroinvasion takes place.  
II.1.2  PrP-vaccination 
Humoral immune responses to the prion protein can antagonize prion infection, 
even when they do not selectively target PrP
Sc but PrP
c only (Heppner, F L and 
Aguzzi, A 2004). Chronically scrapie-infected cultures of N2a cells (ScN2a) can 
rapidly be cured when exposed to a monoclonal PrP antibody or to phospholipase 
C (PIPLC), pointing to the possibility that depletion of PrP
c can interrupt the 
propagation of PrP
Sc (Enari, M et al. 2001). Furthermore, anti-PrP antisera reduce 
the titer of infectious hamster brain homogenates as it has been shown in an in 
vitro experiment (Gabizon, R et al. 1988). The formation of PrP
Sc is abolished by 
anti-PrP antibodies in a cell-free system (Horiuchi, M and Caughey, B 1999). The 
use of antibody antigen-binding fragments (Fabs) in PrP
Sc-infected 
neuroblastoma cells abolished prion replication and reduced the level of pre-
existing PrP
Sc in a dose-dependent manner (Peretz, D et al. 2001). 
Inhibitory effects on prion replication could also be demonstrated in mouse 
models. In a murine scrapie model, administration of monoclonal antibodies at 
the point of near maximal accumulation of PrP
Sc in the spleen lead to the delay of 
prion disease onset for more than 300 days when the treatment was continued 
(White, A R et al. 2003).  
A study in which an anti-PrP µ-chain was expressed in Prnp
0/0 mice followed by 
introduction of the Prnp
+ allele did not show suppressed anti-PrP titers, although 
PrP expression in spleen and brain was present. This finding indicated that PrP, 
when expressed at physiological levels, can be coexpressed with PrP-specific 
antibodies without inducing autoimmune disease or haematological disorders 
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(Heppner, F L et al. 2001). However, protection is restricted to intraperitoneal 
prion infection and is inefficient when prions are administered intracerebrally 
(White, A R, Enever, P et al. 2003; Polymenidou, M et al. 2004), most likely due 
to limited influx of immunglobulins into the CNS.  
Various studies including immunization experiments with PrP-derived peptides 
(Hanan, E et al. 2001; Souan, L et al. 2001; Schwarz, A et al. 2003; Rosset, M B 
et al. 2004), DNA-based vaccines (Krasemann, S et al. 1996), bacterially 
expressed recombinant murine PrP (Koller, M F et al. 2002; Sigurdsson, E M et 
al. 2002; Gilch, S et al. 2003; Polymenidou, M, Heppner, F L et al. 2004) or PrP-
PrP polyproteins (Gilch, S, Wopfner, F et al. 2003; Polymenidou, M, Heppner, F L 
et al. 2004) resulted in low antibody titers, when testet against the 
corresponding PrP antigens. Different adjuvants including e.g. Freund´s 
adjuvants and CpG-oligonucleotides were used as summarized in Table 1 
(Heppner, F L and Aguzzi, A 2004).  
Previous immunization studies could show, that particular peptides seem to be 
immunogenic in mice, resulting in reduction of the PrP
Sc level compared to non-
PrP derived peptide immunization, when an ScN2a tumour model was used 
(Souan, L, Tal, Y et al. 2001). Also, vaccination with recombinant mouse prion 
protein with complete Freund´s adjuvant could delay the onset of prion disease 
by a few days (10-15 d) in mice after intraperitoneal exposure to a mouse-
adapted prion strain (Sigurdsson, E M, Brown, D R et al. 2002). In the latter, a 
correlation between the anti-prion protein titers and the incubation period of 
disease onset was observed but notably, control groups did not receive CFA. 
On the contrary, other studies failed to induce an immune response in Prnp
+/+ 
mice (Krasemann, S, Groschup, M et al. 1996).  
Overall, in all of the above listed studies, anti-PrP titers were rather low, never 
directed against the native cell surface form of PrP
c and the prionostatic in vivo 
effect was only moderate. More importantly, all of these studies were challenged 
by the observation, that the use of certain adjuvants, e.g. Freund´s adjuvant, is 
questionable, because an antiprion activity has been shown for the adjuvant 
itself (Tal, Y et al. 2003).  
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Table 1 PrP immunization studies in wild-type mice 
immunogen  cross-
linked 
adjuvant  response ag. 
antigen 
anti-native 
PrP
c response 
antiprion 
in vivo 
effect 
Ref. 
PrP
REC DnaK  CFA  yes  n.d.  n.d.  (Koller, M F, 
Grau, T et al. 
2002) 
PrP
REC ____  CFA  yes  n.d.  Yes  (Sigurdsson, 
E M, Brown, 
D R et al. 
2002) 
PrP
REC/PrP-
PrP 
____  CFA  yes  no  No  (Polymenido
u, M, 
Heppner, F L 
et al. 2004) 
PrP
REC/PrP-
PrP 
____  CFA/ 
TiterMax/ 
CpG 
yes  n.d.  n.d.  (Gilch, S, 
Wopfner, F 
et al. 2003) 
PrP peptides  KLH  CFA  yes  n.d.  n.d.  (Hanan, E, 
Priola, S A et 
al. 2001) 
PrP peptides  ____  CFA  yes  n.d.  Yes  (Souan, L, 
Tal, Y et al. 
2001) 
PrP peptides  KLH  Montanid
e IMS-
1313 
yes  n.d.  Yes  (Schwarz, A, 
Kratke, O et 
al. 2003) 
PrP peptides  ____  CpG  yes  n.d.  n.d.  (Rosset, M B, 
Ballerini, C et 
al. 2004) 
PrP α–helix 
poly-
peptides 
____  CFA/ 
bacterio-
phage 
yes  n.d.  n.d.  (Arbel, M et 
al. 2003) 
Prnp genes  ____  ____  no  n.d.  n.d.  (Krasemann, 
S, Groschup, 
M et al. 
1996) 
n.d.: not described 
DnaK heat shock protein (Hsp)70 homolog, KLH keyhole limpet hemocyanine, CFA complete 
Freund´s adjuvant 
 
Recently, a correlation between the recognition of native, cell-surface PrP and 
the effect on prion replication has been proposed (Heppner, F L and Aguzzi, A 
2004), underlined by the finding that antibodies, which exclusively bind to 
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recombinant PrP, are not sufficient to confer prionostatic effects in wild-type mice 
upon peripheral prion challenge (Polymenidou, M, Heppner, F L et al. 2004). This 
argument would also explain the modest effects on prion pathogenesis of the 
above listed studies (Souan, L, Tal, Y et al. 2001; Sigurdsson, E M, Brown, D R et 
al. 2002; Schwarz, A, Kratke, O et al. 2003), in which binding to native PrP
c has 
not been examined.  
 
II.2  Virus-like particles 
Historically, the field of vaccinology has experienced sustained  success in 
developing prophylactic vaccines against a variety of infectious diseases. Besides 
attenuated and inactivated microorganisms, also toxoids and protein subunits 
have been used. Within the last decades, several vaccine components, suitable 
for the induction of strong cellular immunity have been developed, e.g. 
attenuated viruses, recombinant viral vectors and DNA based vaccines, as 
reviewed in (Deml, L et al. 2005). These vaccine components have their 
advantages in prolonged antigen production within the host cell and 
immonostimulatory effects of the delivery system. Especially for virus-like 
particles (VLPs), that include all immunologically relevant structures of viruses 
but lack unwanted regulatory proteins and genetic information, several groups 
have shown induction of more effective humoral and cellular immune responses 
as compared to subunit vaccines, as summarized in (Deml, L, Speth, C et al. 
2005). 
To date, numerous types of VLPs have been produced utilizing the ability of more 
than 30 different viruses to self-assemble into highly organized particulate 
structures (Deml, L, Speth, C et al. 2005). Some of the most prominent among 
them are hepatitis B virus cores, displaying i.e. influenza, human 
immunodeficiency, polio- and hantavirus derived immunodominant epitopes 
(reviewed in (Pumpens, P and Grens, E 2001)), as well as human 
immunodeficiency virus (HIV) Gag proteins, used as carrier to present foreign 
polypeptides and immunological epitopes (Deml, L, Speth, C et al. 2005). 
Detailed knowledge of spatial structures and molecular mechanism of assembly 
and morphogenesis also led to the use of phage particles, e.g. the RNA phage Qβ 
(Kozlovska, T M et al. 1996), as display scaffold.  
Retrovirus-based VLPs (in this case derived from HIV) have been studied in detail 
concerning their immunological properties (Deml, L, Speth, C et al. 2005).   
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Vectors displaying foreign polypeptides were classified into two groups: type I 
and type II VLPs, differing in the region, in which the antigen is presented. 
Whereas type I VLPs display via fusion to the Gag polyprotein, type II VLPs 
present the antigen at the outer particle surface (Deml, L, Speth, C et al. 2005). 
Incorporation of the foreign polypeptides or proteins can thereby be achieved 
using either the retrovirally derived envelope (Env) protein or by taking 
advantage of the fact that retroviruses unspecifically package host membrane 
proteins into their envelope (Hammarstedt, M et al. 2000; Hammarstedt, M and 
Garoff, H 2004). 
Overall, retrovirus-based VLPs are highly immunogenic subunit vaccines, because 
they facilitate introduction of antigens in the MHC class I and II processing and 
presentation pathway and additionally act as “danger signals” to activate the 
innate immune system. Thus, they initiate strong TH1-biased humoral and 
cellular immune responses (Deml, L, Speth, C et al. 2005). 
Sendai-virus based nucleocapsid particles have not been used for immunization 
studies up to date. This virus belongs to the family of paramyxoviridae 
(enveloped dsRNA viruses) and consists of a nucleocapsid enveloped by a lipid 
membrane, which contains genomic viral RNA surrounded by the three structural 
proteins NP, P and L (Choppin, P W and Compans, R W 1970; Finch, J T and 
Gibbs, A J 1970). The nucleocapsid protein NP is the main component of the 
nucleocapsid structure, which is composed of a left-handed helix of 1 µm length 
and 14-17 nm diameter containing 11-13 protein subunits (mainly NP) per 
winding. The protein subunits exhibit a rotated arrangement, so that they point 
towards one end of the complex like arrowheads (Finch, J T and Gibbs, A J 
1970). The nucleocapsid contains 2400-2800 molecules of NP packaging 6 
nucleotides of viral RNA per protein subunit (Hosaka, Y and Hosoi, J 1983) (Figure 
4).  
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Figure 4  Structure of Sendai nucleocapsid (NC). Fragments of flexible helical nucleocapsids (NC) of 
Sendai virus, a paramyxovirus, are seen either within the protective envelope (E) or free, after rupture of the 
envelope. The intact nucleocapsid is about 1,000 nm long and 17 nm in diameter; its pitch (helical period) is 
about 5 nm. (x200,000) (A. Kalica, N I o H 1996) 
The percentage of P and L molecules in nucleocapsids is much lower with about 
300 molecules P and 30 molecules L (Lamb, R A et al. 1976). They are not 
essential for nucleocapsid formation, as NP synthesized in the absence of other 
viral components assembles into nucleocapsid-like particles. Furthermore it was 
observed previously, that the highly immunogenic C-terminal part of NP, 
comprising about 120 amino acids (aa), can be deleted without affecting the NP 
assembly (Buchholz, C J et al. 1993). 
II.3  Retroviruses 
II.3.1  Structure and life cycle 
Retroviruses are enveloped viruses with a diploid genome, which is packaged as 
single (+)-stranded RNA of almost 10 kb. The viral genome resembles eukaryotic 
mRNA (Buchholz, C J, Spehner, D et al. 1993). The viral genes are flanked by so 
called long terminal repeats (LTRs) which are required for their integration into 
the host cell genome and for efficient transcription. In addition, a sequence 
termed psi-site (ψ) ensures efficient packaging of the viral RNA into the particles. 
The viral genome includes the structural genes gag/pol and env, which are 
common genes, present in all retroviruses. As an example, the organization 
(Figure 5) and assembly (Figure 6) of the murine leukemia virus MLV, which belongs 
to the C-type retroviruses, are briefly described. 
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Figure 5  Genomic organization of the murine leukaemia virus MLV. The viral genome integrated 
into the host chromosome consists of two flanking regions named long terminal repeats (LTR). The signal 
relevant for packaging of the viral RNA is also termed psi-site (Ψ) and is adjacent to the structural genes gag 
(abbreviation of group-specific antigen) and pro (protease) as well as pol (polymerase). The env (envelope) 
gene is present in a different reading frame. The gag precursor protein code for the structural proteins matrix 
(MA), p12, capsid (CA) and nucleocapsid (CA), whereas the pro/pol gene can be divided into the viral protease 
(PR), the reverse transcriptase (RT) and the intergrase (IN) enzymes. The envelope protein consists of two 
subunits named soluble unit (SU) and transmembrane unit (TM). (Coffin, J M et al. c1997) 
 
The viral structural proteins including the core forming capsid (CA), the RNA-
binding nucleocapsid (NC) and the membrane associated matrix proteins (MA) 
are encoded within the gag gene. In addition, the pol gene provides all viral 
enzymes, namely the reverse transcriptase (RT), the protease (PR) and the 
integrase (IN). The env gene encodes the Env polyprotein, which mediates host 
cell entry and thereby determines the tropism of the virus. The Env protein 
consists of two non-covalently linked polypeptides, the surface unit (SU) and the 
transmembrane domain (TM).  
The life cycle of retroviruses starts by infection of the host cell followed by 
reverse transcription of the viral genome into double stranded DNA. This step is 
catalyzed by the RT. Afterwards integration of the DNA into the host cell genome 
is mediated by IN. The resulting so called provirus is transcribed by the host cell 
machinery in the same way as endogenous genes. Expression is promoted by the 
viral LTR, which serves as efficient promotor.  
The retroviral structural proteins, but not the Env, are translated as polyprotein 
precursors, which are cleaved by the viral protease into the corresponding 
proteins. These posttranslational modifications occur during budding or 
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maturation of already released particles. The polyprotein which is synthesized at 
the earliest stage of replication is Gag, including CA, MA and NC. The Gag 
polyprotein has been shown to initiate the budding process even in absence of 
any other viral protein. Pol is also synthesized as a polyprotein in dependence of 
Gag expression. The Pol-encoded proteins RT, PR and IN are then directed by 
Gag to the site of assembly, close to the host cell membrane.  
 
 
Figure 6  Schematic cross section through a retroviral particle. The viral envelope is formed by a 
cell-derived lipid bilayer into which proteins encoded by the env region of the viral genome are inserted. These 
consist of the transmembrane (TM) and the surface (SU) components linked together by disulfide bonds. 
Internal nonglycosylated structural proteins are encoded by the gag region of the viral genome. They are the 
matrix (MA) protein, capsid (CA) protein, and nucleocapsid (NC) protein. Major products of the pol-coding 
region are reverse transcriptase (RT) and integrase (IN). The protease (PR) is derived from the pro gene 
between gag and pol (Coffin, J M, Hughes, S H et al. c1997) 
In contrast to these viral proteins, the Env polyprotein is a translation product of 
spliced viral mRNA. It includes the SU and TM subunits and an additional N-
terminal signal peptide, which ensures routing to the secretory pathway. Within 
the ER, the Env precursor protein is heavily glycosylated at Asn residues and 
oligomerizes into trimers.  Then, upon passage through the Golgi apparatus, 
cleavage between SU and TM is performed by furin, a cellular protease. 
Subsequently, the Env trimers are directed to the cell surface by vesicular 
transport, where they diffuse laterally to the site of budding.  
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For most retroviruses the budding takes place in so called lipid rafts, as it was 
observed for HIV (Holm, K et al. 2003). Here, the Env molecules are assembled 
onto particles containing the gag/pol products and two full length RNA 
transcripts. These functional particles are subsequently released and the 
remaining Gag/Pol polyproteins are cleaved during a further maturation step. In 
conclusion, infectious retroviral particles able to initiate the next replication cycle 
are generated. 
 
 
 
Figure 7 Life cycle of retroviruses. Upon binding to the cell surface receptor, particle and cell membranes 
fuse. Subsequently, the uncoated particle penetrates the cytosol, where disassembly takes place. Viral RNA is 
reverse transcribed into DNA which homes to the nucleus. Here, it is stably integrated into the host genome. 
Thus, transcription and translation of retroviral proteins begins. The Env protein is directed to the cell surface 
whereas all other retroviral proteins accumulate in the cytosol at the site of budding. Finally, particles are 
released which undergo a further maturation step before getting infective (Hughes, S H 2002). 
 
II.3.2   Retroviral vectors and display systems 
In contrast to retroviruses, retroviral vectors are by definition non-replicative and 
can thus be used for single round delivery, only. Instead of the wild type (wt) 
genome, the gene of interest, e.g. therapeutic or marker genes, are packaged 
into the particles which can then be transferred into target cells, a procedure 
termed “transduction”. For this purpose, the gene of interest has to be flanked 
by appropriate LTRs and the Ψ-signal, to ensure specific packaging into the 
applied particle species and subsequent integration into the host genome. Thus, 
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long term expression of the transgene is achieved, which is a major advantage of 
retroviral vectors in comparison to other gene delivery systems. A further 
advantage is the possibility to specifically transduce certain cell types. To alter 
the tropism of a given vector system, envelope proteins of other viral species can 
be incorporated into the particle surface, a technique also referred to as 
pseudotyping. For this purpose, packaging cells are generated that 
simultaneously express Gag/Pol of one viral species and the Env protein of 
another. In conclusion, so called pseudotype particles are generated, which 
incorporate the heterologous Env protein and exhibit the corresponding tropism. 
This way, highly effective gene delivery systems can be generated.  
Since retroviruses tolerate insertions in their envelope protein, foreign 
polypeptides can be readily displayed at the N-terminus of SU (N-terminal 
display) represents one possible way to display foreign sequences (Buchholz, C J 
et al. 1999). Experience has been made with insertions like growth factors, 
cytokines, antigenic epitopes and antibody molecules. Examples for such N-
terminal display approaches are the human epidermal growth factor (hEGF) 
(Cosset, F L et al. 1995) as well as CD40L (Morling, F J et al. 1997) and others. 
Also single chain variable fragments (scFvs) have been recently used to establish 
selection of functional human antibodies from retrovirus-based display libraries  
(Urban, J H et al. 2005). 
 
II.4  Objective 
The primary objective of this thesis was the development of a retrovirus particle 
based display system for PrP. Such particles will be of high value for the 
development of vaccination strategies against TSEs and also as tool to address 
basic questions about the molecular properties of the infectious PrP agent. 
Basically, this goal will be addressed by displaying either i) the cellular form of 
the protein (PrP
c) or ii) the pathogenic isoform PrP
Sc. 
i) To develop a system which allows efficient incorporation of the cellular murine 
prion protein (PrP
c) into either retrovirus-based virus-like particles (shortly 
referred to as retroparticles) or nucleocapsid-based particles (NPs), three 
different approaches will be chosen. 
High amounts of PrP
c in retroparticles could be expected from a commercially 
available system using the transmembrane domain (TMD) of the platelet derived 
growth factor receptor (PDGFR). Foreign proteins expressed in this setting are 
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expressed and targeted to the plasma membrane in particular high amounts 
(Chesnut, J D et al. 1996; Douglas, J T et al. 1999). The presence of this 
transmembrane domain on the surface of a retroviral packaging cell line has 
been demonstrated to facilitate the incorporation of the EGF domain into 
retroviral vector particles in the host laboratory just before the start of this thesis 
(Merten and Buchholz, unpublished data). 
Secondly, PrP
c will be displayed on top of the viral Env, as it was previously 
described for various polypeptides in the host laboratory (see chapter II.3.2).  
Addressing the amount of mPrP per particle surface area, the third approach 
deals with fusion to the Sendai virus nucleocapsid protein (NP). At this, several 
hundred protein subunits arrange around RNA molecules resulting in 
substantially dense particles (Buchholz, C J, Spehner, D et al. 1993; Curran, J et 
al. 1993). 
The different particle systems to display the PrP
c have to be established, the 
particles have to be produced in high amounts and subsequently have to be 
characterized biochemically. Immunization studies using the most promising 
particle type have to be performed in collaboration with the Division of 
Immunology at the Paul Ehrlich Institute. 
ii) As a second aim of the thesis, the display of the pathologic isoform of the 
prion protein (PrP
Sc) on VLPs and replication competent retroviruses is 
addressed. Since it is rather difficult to generate or even isolate the pathogenic 
isoform purely in vitro, this approach is by far more ambitious than the display of 
cellular PrP. Nevertheless, there are in vitro conversion protocols available to 
generate PrP resistant to proteinase K (PrP
res) (Caughey, B 2003), a form which 
resembles the pathogenic form of PrP.  
From this approach strategies for the generation of a PrP
Sc-based vaccine are 
expected as well as novel insights into interactions between PrP and retroviruses.  
III 
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Material and methods 
III.1   Molecular biology 
III.1.1  Plasmids and vectors 
All plasmids used and generated during the thesis are described in detail in the 
Appendix. 
 
Table 2  Origin of used plasmids and vectors 
plasmids  coding region  reference  provided by 
cloning plasmids
phgPrP  murine Prion protein (mPrP)  (Fischer, M et 
al. 1996) 
Fabio Montrasio,  
Paul-Ehrlich-Institut 
Langen, Germany 
parental plasmids 
pDisplay (pD)  platelet derived growth factor receptor 
(PDGFR) 
©  Invitrogen Catalog no. 
V660-20 
 
plenti-V5-lacZ  HIV-packagable lacZ protein  ©  Invitrogen Catalog no. 
K4955-10 
 
pGem-NP  nucleocapside protein of the Sendai virus  (Buchholz, C J, 
Spehner, D et 
al. 1993) 
Christian Buchholz (Paul-
Ehrlich-Institut, Langen) 
pFB-EASALF  hEGF/amphotropic Env fusion protein  (Peng, K W et 
al. 1997) 
F.-L. Cosset (INSERM 
U412, Lyon, Frankreich) 
pNCA  ecotropic MLV  (Colicelli, J and 
Goff, S P 1988) 
Christian Buchholz (Paul-
Ehrlich-Institut, Langen) 
retroviral vector plasmids
pHit60  murine leukemia virus gag/pol genes (MLVgp)  (Soneoka, Y et 
al. 1995) 
A.J. Kingsman (University 
of Oxford, UK) 
pCMV∆R8.2  human immunodeficiency virus gag/pol genes 
(HIVgp) 
(Naldini, L et 
al. 1996) 
U. Blömer (University 
Hospital, Kiel, Germany) 
pMD.G  VSV-G protein  (Naldini, L, 
Blomer, U et al. 
1996) 
U. Blömer (University 
Hospital, Kiel, Germany) 
pD-EGF  human epidermal growth factor (hEGF) fused 
to PDGFR-TMD 
(Merten, C A et 
al. 2003) 
Christoph Merten (Paul-
Ehrlich-Institut, Langen) 
pLP1  human immunodeficiency virus gag/pol genes 
(HIVgp) 
©  Invitrogen Catalog no. 
K4950-00 
 
pLP2  human immunodeficiency virus ref gene   ©  Invitrogen Catalog no. 
K4950-00 
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pLPVSVG  VSV-G protein  ©  Invitrogen Catalog no. 
K4950-00 
 
nucleocapside plasmids
pSCT7  T7 polymerase  (Radecke, F et 
al. 1995) 
Christian Buchholz (Paul-
Ehrlich-Institut, Langen) 
 
 
III.1.2  Polymerase chain reaction 
The polymerase chain reaction (PCR) allows to amplify specific DNA sequences of 
different origins, such as plasmid, genomic or complementary DNA (Saiki, R K et 
al. 1985; Mullis, K B and Faloona, F A 1987).  The amplified fragment can 
subsequently be used for further molecular biological methods. Current PCR 
protocols make use of a DNA-dependent DNA polymerase isolated from 
Thermophilus aquaticus (Taq Polymerase), which shows a temperature optimum 
of 72 °C. Using appropriate buffers, primers, desoxynucleotides and cycling 
conditions the Taq polymerase can amplify a DNA fragment bordered by the two 
primer sequences. Under optimal conditions this amplification takes place in an 
exponential manner. 
 
A typical PCR cycle contains a denaturation step at 94 °C, leading to the 
dissociation of the double stranded template. The following hybridization step 
allows primer annealing to the resulting single stranded template. The 
hybridization temperature TD is adjusted according to length and composition of 
the DNA template. It can be calculated roughly corresponding to the Wallace rule 
(Suggs, S V et al. 1981) as follows: TD = 4x(G+C) + 2x(A+T). After 
hybridization, DNA elongation is performed at 70-75 °C. The elongation time is 
chosen in pursuance with the template length, approximately 1 min/1 kb DNA. 
By repeating the cycle sequence the template is amplified in an exponential 
manner.  
 
In this work, the Taq Polymerase (Qiagen, Hilden, Germany) and the Vent 
proofreading polymerase (NEB, Schwalbach, Germany) with 3´-5´ exonuclease 
activity have been used. For amplification of PrP fragments a standard PCR mix 
(100 µl) contained the following ingredients:   
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1x  PCR buffer (20 mM Tris/HCl, pH 7.5; 100 mM KCl; 
1.5 mM MgCl2; 1 mM DTT; 0.1 mM EDTA, 0.5% Tween 
20; 0,5% Nonidet P40;  0.01% gelatine) 
    1-2  µM  (+)-primer  and  (-)-primer,  respectively 
    200  µM  of  each  desoxynucleotid 
    2  units  Taq  /Vent  polymerase 
0.05 µg template (plasmid or genomic DNA) 
 
PCR conditions 
94 °C 5 min  
94 °C 30 sec 
55 °C 45 sec     25 cycles 
72 °C 1 min 
72 °C 10 min; subsequent cool down to 4°C 
 
All PCR reactions were performed using an PerkinElmer/Eppendorf Mastercycler 
gradient (PerkinElmer, USA)   
  
III.1.3  Oligonucleotides 
 
Table 3 sequences of used oligonucleotides 
oligonucleotide  5´-sequence-3´  published  
cloning
PrP23Sfi+  GTATGGCCCAGCCGGCCAAAAAGCGGCCAAAGC  forward 209 
PrP121Sfi+  GACTGGCCCAGCCGGCCGTGGGGGGCCTTGGTGGCTACATGC  forward 111 
PrP231SacII-  GACTCCGCGGCCTTCCCTCGATGCTGGATCTTCTCCCGTC  reverse PrP 
PrP90Sfi+  GTATGGCCCAGCCGGCCCAAGGAGGGGGTAC  forward 142 
PrPNotI-  GAGCGCGGCCGCCCTTCCCTCGATGCTGGATCTTCTCCCGTCGTA   
PrP121MscI+  GCGATGGCCACGGCGGTGGTGGATCAATCGAGGGAAGGGTGGGGGGCCTTGGTGGCTACATGC   
PrP121EcoRV+  GCGAGATATCGGCGGTGGTGGATCAATCGAGGGAAGGGTGGGGGGCCTTGGTGGCTACATGC   
PrP231EcoRI-  GGATGAATTCTCATGCTGGATCTTCTCCCGTCGTAATAG   
fullNP-HA+  GTGGTGGCCACTTTGTCACACTACATGGGGCTGAACG   
fullNP-HA-  GCATGAATTCGAGCTCGGTACCTCAATAATCTGGAACATCATATGGATACATATGCTCGAGGATT 
CCTCCTATCC 
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Sequencing and Screening
CB6  CCCCTAATCCCCTTAATTCTTC   
EASeq  CAAGATGCCTTCCCAAAATTATA   
EMoSeq  GGTAACCAATGGAGATCGGGAGACG   
EMoSeq2  CCAGTCCTCATCAAGTCTA   
CMVforw  CGCAAATGGGCGGTAGGCGTG   
V5reverse  ACCGAGGAGAGGGTTAGGGAT   
 
 
III.1.4  Working with plasmid DNA 
 
All DNA restrictions were performed using commercially available restriction 
endonucleases from New England Biolabs (NEB, Schwalbach, Germany) 
according to the manufacturer’s instructions. 
 
III.1.4.1.1   Standard restriction for preparative purposes  
10 µg DNA 
10 u restriction enzyme 
5 µl 10x buffer (NEB buffer 1-4, corresponding to the used restriction enzyme) 
5 µl BSA (NEB; only if required by the applied enzyme) 
add 50 µl aqua bidest 
The restriction sample was incubated at the temperature optimum of the used 
restriction enzyme for two hours. In case of double digests the restriction 
enzymes were added sequentially (2.5 µl at maximum) and incubation was 
performed at the respective temperature optimum for two hours, each. If two 
different buffers were required, DNA was purified after the first digest using the 
Qiagen PCR purification Kit according to the manufacturer’s instructions (Qiagen, 
Hilden, Germany) or the GeneClean purification Kit  (QBiogene, Irvine, USA), 
followed by incubation with a new reaction mixture for the second digest.  
 
III.1.4.1.2  Standard restriction for analytic purposes 
0.5 µg DNA 
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5 u restriction enzyme 
2 µl Puffer (NEB buffer 1-4, corresponding to the used restriction enzyme) 
2 µl BSA (NEB; only if required by the applied enzyme) 
add 20 µl aqua bidest 
Incubation was performed at the temperature optimum of the applied enzyme for 
90 min. Double digests were done as described for preparative purposes. 
 
III.1.4.1.3   Ligation and dephosphorylation of digested DNA 
Recombination of DNA is usually performed by ligation of two double stranded 
nucleic acid molecules, exhibiting complementary overhangs or blunt ends. This 
reaction can be accomplished using T4 DNA ligase, which catalyzes the formation 
of phosphodiester-bonds between the fragments, under consumption of ATP. The 
following reaction mixture has been used as standard sample: 
0.05 µg DNA (molar ratio of backbone to insert = 1:2) 
2 µl ligase buffer (NEB) 
0.5 µl T4-DNA-ligase (200 U) 
add 20 µl aqua bidest 
To avoid recirculation of linearized plasmids, these were dephosphorylated using 
alkaline phosphatase (CIP, NEB, Schwalbach, Germany). For this purpose, 10 U 
CIP were added to the restriction digestion sample after heat inactivation (75 °C 
for 10 min). Subsequently, the resulting mixture was incubated for 1 h at 37 °C 
before it was inactivated at 75 °C for 10 min. 
 
III.1.4.1.4   Transformation of competent bacteria 
Transformation of E. coli (K12-derived safety strains) is the method of choice to 
amplify plasmid DNA through cellular replication. For this purpose, bacteria have 
to be pretreated in a special manner to become competent, thus allowing 
introduction of foreign DNA. 
2.5 ml of an over night culture were used to inoculate 100 ml of fresh LB-Media 
which was subsequently incubated at 37 °C in a bacteria shaker. Cells were 
allowed to grow up to an OD600nm of about 0.5 – 0.55, hence reaching the 
logarithmic growth phase. Then the culture was incubated on ice for 5 minutes, 
divided into two portions and pelleted at 6000 rpm for 10 minutes at 4 °C. The 
cells were resuspended in 20 ml TFB1-buffer (sterile, filtrated solution of 30 mM 
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KOAc, 100 mM RbCl2, 10 mM CaCl2, 50 mM MnCl2, 15% glycerin, pH adjusted to 
5.8 with HAc) respectively, incubated on ice for 5 minutes and once again 
pelleted as above. Subsequently the cells were resuspended each in 2 ml TFB2-
buffer (sterile filtrated solution of 10 mM MOPS, 75 mM CaCl2, 10 mM RbCl2, 
15% glycerine, pH adjusted to 6.5 using KOH-solution) and incubated on ice for 
15 minutes. Afterwards the suspension was portioned into Eppendorf tubes of 
100 µl and frozen at –80 °C. 
To transform E. coli, transformation of the chemically competent cells described 
above has been performed. For this, the cells were thawed on ice and 
approximately 50 ng DNA were added. After further incubation on ice for 30 min, 
a heat shock at 42 °C for 45 sec was performed in a thermoblock. Then 250 µl of 
prewarmed (37 °C) SOC medium (Invitrogen, Carlsbad, USA) was added and the 
sample was incubated for 60 min at 37 °C. The bacteria suspension was plated 
onto LB-AMP-plates (1 % (w/v) Bacto-Trypton, 0.5 % (w/v) yeast extract, 1 % 
NaCl, 50 µg/ml ampicilin 1.5 % (w/v) agar agar). 
 
III.1.4.1.5   Plasmid preparation 
Preparation of plasmids from bacteria was performed using the Qiagen plasmid 
kits (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The 
basic principle of this method is binding of DNA to anion exchange columns. 
Thus, all cellular compounds such as proteins can be washed away whereas the 
DNA is retained within the columns.  
For purification of low amounts of DNA (Miniprep), 5 ml over night cultures were 
inoculated using LB-AMP-Medium (1 % (w/v) Bacto-Trypton, 0.5 % (w/v) yeast 
extract, 1 % NaCl, 50 µg/ml ampicillin). The next day, bacteria were harvested 
at 5000 rpm for 5 min (Minifuge RF, Heraeus, Hanau, Germany). The resulting 
pellet was lysed using solutions delivered by the manufacturer (P1 & P2). 
Chromosomal DNA and cellular fragments were excluded by centrifugation 
(13000  rpm for 5 min in an Eppendorf table centrifuge). Subsequently the 
supernatant was applied to anion exchange columns (Qiaprep-8-strips) according 
to the manual.  
For extraction of larger amounts of DNA (Maxiprep), 200 µl LB-AMP-Media were 
inoculated and cultivated over night. Bacterial yield was performed at 5000 rpm 
for 10 min (JS-13.1-rotor; J2-21-centrifuge; Beckman, Munich, Germany). 
Afterwards cells were lysed and the remaining cell debris and chromosomal DNA 
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was removed by centrifugation (10000 rpm for 20 min). The resulting 
supernatant was subsequently purified via an anion exchange column according 
to the manufacturer’s instructions. Finally, concentration and purity of the DNA 
was determined photometrically.  
 
III.1.4.1.6   Agarose gel electrophoresis   
Agarose gel electrophoresis allows to separate DNA molecules by their size. The 
principle is based on the properties of polymerized agarose, which acts like a 
molecular sieve. Since DNA is negatively charged, it migrates through such gels 
upon application of electric current in a size dependent manner. 
For fragments with a size of 1 kb – 14 kb, 1% agarose gels were used, whereas 
1.5 – 2 % agarose gels were used for smaller fragments (according to the 
fragment of interest). The gels were generated by adding the corresponding 
amount of agarose to 120 ml TAE buffer. The resulting emulsion was then heated 
in a microwave oven until the solid agarose became solved. 50 µg/ml ethidium 
bromide were added and the gel was casted into the tray. DNA samples were 
mixed with 0.2 volumes 5 x sample buffer (30 % glycerin and 1 % brome phenol 
blue in 5 x TAE buffer) and applied to the gel. As marker, either the 2-log ladder 
(NEB, Schwalbach, Germany) was used according to the fragment size. 
Electrophoresis was then performed at 130 V for approximately 45 minutes. 
Afterwards fragment bands were photographically documented under UV light 
and, if desired, bands were cut out for purification as described below.  
 
TAE buffer 
Tris-Acetat 40  mM 
EDTA   1 mM 
adjusted to pH 7.5 
 
III.1.4.1.7   Isolation of DNA fragments from agarose gels 
Purification of DNA fragments from agarose gels was performed using the Jetsorb 
gel extraction kit (Genomed, Löhne, Germany) or the GeneClean Purification Kit 
(QBiogene, Irvine, USA) according to the manufacturer’s instructions. These 
methods are based on the intrinsic adhesion of DNA to glass powder or on 
binding of DNA to appropriate anionic columns.  
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After electrophoretic separation, the DNA band of interest was cut out of the gel 
and transferred into an Eppendorf tube. These samples were purified according 
to the manual. 
 
III.1.5  DNA and RNA methods 
III.1.5.1  Preparation of genomic DNA 
Genomic DNA was isolated from cultured adherent cells using the QIAamp DNA 
Mini Kit (Qiagen, Hilden, Germany) according to the manufacturers instructions. 
This method is based on binding of nucleic acids to silica-gel-membrane columns. 
In addition, RNA is excluded from purification through RNAse H digestion. Thus, 
DNA is retained, whereas all other cellular components can be washed away. 
Genomic DNA was also prepared on the basis of Phenol/Chloroform extraction 
using Trizol reagent [Invitrogen Catalogue number 15596018, (Chomczynski, P 
and Sacchi, N 1987)] according to the manufacturer`s instructions. 
Cells were trypsinized within the culture flasks and the resulting cell suspension 
was centrifuged at 3000 rpm in an Eppendorf table centrifuge. Approximately 1-
3.0 x 10
6 cells were resuspended in 200 µl PBS and applied to the purification 
procedure as described in the manual with the following modification: For elution 
of the DNA from the columns 50 µl of buffer AE were used instead of 200 µl to 
increase the DNA concentration for the subsequent PCR.   
 
III.1.5.2  Preparation of RNA from viral particles 
Viral RNA was isolated from virus particles using the QIAamp Viral RNA Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. This 
method is based on binding of nucleic acids to silica-gel-membrane columns. To 
be sure that RNA is purified specifically; the procedure was extended to a DNAseI 
digestion step. 
 
Virus particles from 140 µl filtered (0.45 µm Filter) cell culture supernatants were 
treated according to the manufacturer’s instructions with the following 
modification: 
Column-bound RNA was washed once with 500 µl AW1. Then a mixture of 10 µl 
DNAse I and 70 µl RDD buffer (available from Qiagen for on-column-digestions) 
  40U Material and methods 
was pipetted directly onto the membrane. Subsequently the sample was 
incubated at room temperature for 15 min. Afterwards the column was washed 
twice with 500 µl AW1 before it was proceeded corresponding to the manual 
(AW2 washing step). 
III.1.5.3  cDNA synthesis of viral RNA 
After RNA isolation, cDNA synthesis was performed. During this step the purified 
viral RNA is transcribed into complementary single stranded DNA by the enzyme 
reverse transcriptase (RT). The cDNA obtained this way can subsequently be 
used for amplification within usual PCR protocols, as described above (III.1.2). 
Reactions for cDNA synthesis were set up as follows: 
Mastermix  Sample
4 µl 5x buffer 
1 µl 20 mM dNTPs 
0.5 µl RNAsin 
0.5 µl RT 
2 µl DTT 
5 µl H2O  
4 µl RNA solution (within     
         AVE buffer) 
1 µl (10 pmol) reverse 
Primer  
2 µl H2O 
The sample was incubated at 80 °C for 1 min and subsequently cooled down on 
ice. Then, the mastermix was added and the resulting mixture was incubated at 
37 °C for 1 h. For subsequent PCR reactions, 2 µl of the cDNA sample were used 
as template. 
 
III.1.5.4  Isolation of cellular RNA 
Cellular RNA was isolated on the basis of Phenol/Chloroform extraction using 
Trizol reagent [Invitrogen Catalogue number 15596018,  (Chomczynski, P and 
Sacchi, N 1987)] according to the manufacturer`s instructions. 
 
 
III.1.6  Nucleic acid sequencing 
Nucleic Acid sequencing was performed at MWG Biotech (Ebersberg, Germany). 
For this purpose, DNA samples containing approximately 2 µg plasmid DNA were 
sent to the company via regular mail, where they were sequenced using 
appropriate primers.  
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III.2   Cell culture 
III.2.1  Cells and media 
All cell lines were grown in Dulbecco´s Modified Eagles Medium (DMEM; Gibco 
BRL, Eggenstein, Germany) supplemented with 10 % fetal calf serum (FCS; 
Biochrom KG, Berlin, Germany), 2 mM L-glutamine and antibiotics (0.1 mg/ml 
neomycin, 100 units/ml penicillin, 50 mg/ml streptomycin; Biochrom KG, Berlin, 
Germany). Cells were cultivated in an incubator (Heraeus, Hanau, Germany) at 
37 °C, 5 % CO2 and saturated water atmosphere. Cells were trypsinized (0.25 % 
trypsin in PBS, 1 mM EDTA) for passaging. A fraction of the resulting suspension 
was seeded into new culture flasks and fresh medium was added.  
The following cell lines were cultivated:        
HT1080    human fibrosarcoma cell line   
HEK293    human embryonal kidney cell line 
HEK293T  human embryonal kidney cell line expressing the large T 
antigen 
293 STAR  human embryonal kidney cell line expressing HIV gag/pol 
NIH3T3    murine fibroblast cell line   
N2a      murine neuroblastoma cell line  
ScN2a/PK1   scrapie-infected  murine neuroblastoma derived from N2a 
 
III.2.2  Freezing and thawing of cultured cells 
For storage, cells were kept at –80 °C or, long term storage was performed in 
liquid nitrogen. 
Freezing 
Cells were trypsinised and resuspended in DMEM. Subsequently a centrifugation 
step (1200 rpm for 10 min at 4 °C in a Heraeus centrifuge) was carried out to 
pellet the cells. These were then resuspended in freezing medium (90 % FCS, 
10 % DMSO), divided into cryotube aliquots of approximately 5 x 10
6 cells and 
frozen.  
Thawing 
Cryotubes were incubated in a water bath at 37 °C until the ice thawed. Then the 
cell suspension was immediately transferred into a falcon tube with 15 ml 
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prewarmed medium. To exclude the cytotoxic DMSO, cells were subsequently 
centrifuged (1200 rpm for 6 min at room temperature) and resuspended in fresh 
medium and seeded into appropriate culture flasks. 
 
III.2.3  Cell transfection  
To express plasmids within eukaryotic cells, transfection using the Lipofectamin 
Plus Kit or Lipofectamin 2000 (Invitrogen, Karlsruhe, Germany) was performed. 
The corresponding method is based on a complex formation between plasmid 
DNA and liposomes which subsequently fuse with the cellular membrane. Hence, 
the DNA is taken up by endocytotic mechanisms.  
For the generation of VLPs and vector particles as well as virus stocks, 3 x 10
6 
cells were seeded into a 175 cm² flask at the day before transfection. After 
cultivation over night, the transfection was performed as follows: 30 µg of total 
plasmid (10 µg PrP–fusion protein + 10 µg gag/pol and 10 µg transfer vector; 15 
µg PrP–fusion protein + 10 µg gag/pol and 5 µg VSV-G coding plasmid) were 
either mixed in a triple transfection or (15 µg PrP–fusion protein + 15 µg 
gag/pol) in a double transfection, respectively. In case of full-length virus 
production, the virus-coding plasmid was transfected in a single-transfection (30 
µg). The resulting plasmid mixture was diluted in 2 ml serum free DMEM, in case 
of Lipofectamin Plus Kit before 180 µl Plus reagent were added. In parallel, 90 µl 
Lipofectamin or Lipofectamin 2000 were suspended in another 2 ml serum free 
DMEM (without any supplements). After incubation for 15 min (Lipofectamin Plus 
Kit) or 5 Min (Lipofectamin 2000) at room temperature, both samples were 
mixed. This solution was then incubated for further 15 min (Lipofectamin Plus 
Kit) or 20 Min (Lipofectamin 2000). Afterwards, medium was exchanged against 
the transfection mixture (4 ml + 8 ml serum free DMEM) and the cells were 
incubated for 4 h at 37 °C. Then, the transfection mixture was exchanged 
against the normal serum-containing DMEM. After 48 and 72 h, VLPs, vectors or 
the virus-stock were harvested and filtered through a 0.45 µm filter.  
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III.3    Virological methods 
III.3.1  Concentration of retroparticles 
VLPs and vectors were further concentrated by low-speed centrifugation [16h-
24h, 3600 rpm (Minifuge RF, Heraeus, Hanau, Germany), 4°C] or by ultra-
centrifugation [1.5 h, 35000 rpm SW-41 rotor, L8-70M-UZ ultracentrifuge, 
Beckman, 4°C] through a 30 % sucrose cushion (4 ml cushion, 8 ml 
supernatant). For standard particle preparations, three T175 flasks were 
transfected, resulting particles were resuspended after low-speed concentration, 
in 1 ml PBS Dulbecco + 1 % FCS and divided into 20 aliquots of 50 µl, each.  
For immune fluorescence cells were transfected in 6-wells containing coverslips 
(1.2 × 10
6 cells per total 6-well, 30 µl Lipofectamin/Lipo2000, 60 µl Plus reagent 
in 750 µl DMEM each) and analyzed after 48 h as described in chapter III.4.4. 
 
III.3.2  Transduction 
Transduction experiments were performed either to determine particle titers or 
to obtain stably transgene-expressing cell lines.  
Infectious titers of vector particles were calculated by the X-Gal assay based on 
ß-galactosidase transfer via the vector particles. Therefore, 1.25 x 10
5 HT1080 or 
N2a target cells were seeded in a 12 well plate and incubated with different 
dilutions of the filtrate for 4 hours. Transduced cells were fixed two days post 
transduction in 2 % formaldehyde and 0.5 % glutaraldehyde. After washing with 
PBS, samples were incubated with the staining solution [4 mM potassium 
ferricyanide, 4 mM potassium ferrocyanide, 2 mM MgCl2 and 80 µg/ml X-Gal 
(Sigma)] at 37 °C overnight. The next day blue colonies were counted under the 
light microscope. 
Titers were calculated by multiplying the number of surviving or blue colonies in 
each well with the dilution factor of the particle containing supernatant.   
Stably transduced cell lines were obtained via transduction of blasticidin encoding 
transgenes. From day two post transduction of 1 × 10
6 N2a, ScN2a and 293 
STAR cells in a T75 flask were treated with DMEM containing 4 µg/ml Blasticidin 
(Invitrogen) for the N2a and 8 µg/ml Blasticidin for the 293 STAR cells for two 
weeks. (ScN2a cells were not selected on Blasticidin). During this period the 
medium was changed on every second day to wash away dead cells, and cells 
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were eventually splitted, if necessary. After two weeks of antibiotic selection cells 
were analyzed and frozen in aliquots.  
 
III.3.3  Infection 
Infection of target cells was performed either to determine the virus titers or to 
obtain stably infected cell lines. 
For this, either or 2.5 × 10
5 cells in a T25 flask were infected with different 
multiplicity of infection (moi, virus per cell), ranging from 1 × 10
-6 to 20 IU/ml. 
Titration of virus stocks thereby required serial dilutions from 10
-3 to 10
-6 IU/ml. 
Infection was carried out in supplemented DMEM containing 10 % FCS for 4 h at 
37 °C. After 24 h, titration experiments were stopped by fixation of the cells with 
Methanol (-20°C) for at least 1 h at -20°C and subsequent immune peroxidase 
assay (IPA, III.4.3) was carried out. Stably infected cells were analyzed at 
different time points ranging from 1 to 10 days post infection and frozen in 
aliquots. 
III.3.4  Titration 
Serial 10fold dilutions (ranging from 10
0 to 10
-6) were therefore added in triplica 
to 5 × 10
4 NIH-3T3 cells per well in a 24 well and viral capsid was stained 24h 
after infection by IPA (III.4.3) to ensure single-round replication of the virus. 
Positive cells were counted in the appropriate dilutions showing infection events 
from 100-500. Therefore four images were taken at 500fold magnification using 
Zeiss AxioVision Software and Camera. Positive as well as negative cells were 
counted in each image area (4 × 0.25 mm
2). Infectious titers per ml were 
obtained by extrapolation of the counted area to the size of one well (3 mm
2) 
including the dilution factor of virus stocks. 
 
III.3.5  Caesium-chloride gradient purification of NPs 
HEK-293 FT producer cells were lysed using hypotonic lysis buffer (10 mM Tris-Cl 
pH 8.0, 1mM EDTA). After 30 min incubation on ice cells were destroyed by 30 
knocks in a douncer. Cells were thereby kept at 4 °C and were subsequently 
loaded on a Caesium-chloride step gradient. An aliquot was kept for Western Blot 
analysis. 
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Caesium-chloride (CsCl) step gradients were generated using 40%, 30% and 
20% solution of CsCl in TNE buffer (25 mM Tris pH 7.5, 50 mM NaCl 2 mM 
EDTA). 3 ml of each solution were pipetted consecutively into an ultracentrifuge 
tube (12.5 ml) starting with 40 % CsCl.  On top of the resulting step gradient 0.5 
ml 30% Glycerol were added followed by pipetting of 2 ml sample volume in 
hypotonic lysis buffer. Gradients were centrifuged at 35.000 rpm (Beckmann 
Ultracentrifuge, Rotor SW41) for 16 h at 4 °C. Gradients were fractionated from 
the bottom of the tube by insertion of a whole and dropwise collection of 1 ml 
portions. Analysis was performed by Western Blot analysis of sample aliquots as 
described in chapter III.4.5 and III.4.6. 
 
III.4   Protein biochemistry 
III.4.1  Antibodies 
All antibodies, dilutions and manufacturers are summarized as follows: 
Table 4  summarization of used antibodies 
Primary antibodies Origin Dilution 
WB
Dilution 
IPA
Dilution 
IF
Dilution 
EM
Source/ 
manufacturer
α-HA (clone 
12CA5) 
mouse  1:5000    1:500    Roche 
α-RLV-SU  goat  1:5000    1:500    Quality, Biotech 
α-p24  mouse  1:2000    1:200    Chemicon 
α-PrP 6H4  mouse  1:10000  1:1000  1:1000  1:750  Prionics 
α-PrP serum  rabbit  1:5000         
α-NP(Sendai) 
serum 
rabbit  1:5000    1:500     
α-p30  goat  1:50000  1:1000  1:1000    Quality, Biotech 
α-EGF  mouse  1:5000    1:500  1:500   
Secondary 
antibodies
Origin Dilution 
WB
Dilution 
IPA
Dilution 
IF
Dilution 
EM
Source/ 
manufacturer
α-mouse-HRP  goat  1:10000  1:1000      Sigma 
α-rabbit-HRP  rabbit  1:5000        Dako 
Cytomation 
α-goat-HRP  rabbit  1:10000  1:1000      Dako 
Cytomation 
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α-mouse-FITC  rabbit      1:500    Dianova 
α-goat-Cy3  rabbit      1:200    Dianova 
α-rabbit-FITC  goat      1:200    Dianova 
α-mouse-10nmgold  rabbit        1:200  Dianova 
 
III.4.2  Reverse Transcriptase activity assay (RT) 
The reverse transcriptase assay (RT) is based on detection of the activity of the 
viral enzyme reverse transcriptase (RT), which converts retroviral genomic RNA 
into double stranded DNA during the viral life cycle (see II.3.2).  
For detection of viruses and viral particles in cell culture supernatants, special 
plates, on which a polyA substrate is bound, are used. By use of a dT primer, the 
enzyme catalyzes incorporation of dUTPs into a newly synthesized strand. 
Subsequently, the reaction is quantified by antibody binding to UTP, to which the 
alkaline phosphatase (AP) is covalently linked. The antibody binding is then 
followed by photometric analysis with an AP-specific substrate at 405 nm. 
Comparison with a MLV RT standard provides the possibility to determine the 
amount of RT present in the samples. Since the average amount of RT per 
particle has been evaluated (Pyra, H et al. 1994), it is possible to calculate 
particle values present per sample using the following equation 
nCP = 3 × 10
9 [p/units] × RT-value [units] 
The RT test solutions are commercially available (Cavidi Tech), for detection of 
MLV particles the C-type RT test, for HIV detection, the lenti RT test has been 
used. 
III.4.3  Immune peroxidase assay (IPA) 
The immune peroxides assay is based on the determination of proteins via 
antibody stain. For this, fixed cells are subjected to first blocking of unspecific 
interactions by a blocking agent and second, specific antibody stain with an 
antibody directed against the protein of interest. Subsequently the cells are 
stained by a second antibody labeled with peroxidase. Detection is carried out by 
the IPA dye, which contains a dye turning to red colour upon incubation with 
Peroxidase. 
The IPA was used to determine the viral capside p30 protein in the infected cells. 
Upon counting positive (red stained) cells in the serially diluted virus stock, the 
calculation of infectious particles per ml is possible. Upon this, the fixation of the 
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target cells early after the infection is necessary to ensure one positive infection 
event per infectious particle. 
The assay was carried out as follows: methanol-fixed, infected cells were blocked 
by 2 % BSA solution in PBS (500 µl) for 1 h at RT and subsequently stained by 
the primary antibody (see Table 4) (300 µl per well) in 1 % BSA/PBS for 1 h at 
37°C. Then, cells were washed three times with PBS and stained with the 
secondary antibody (see Table 4) (300 µl per well) for 1 h at 37°C. Cells were 
again washed three times with PBS and were then stained with the IPA dye 
solution: 
2 mg 3-amino-9-ethyl-carbazol in 500 µl dimethylformamide 
66 µl sodium acetate 3 M 
9.5 ml H2O bidest 
filtered through 0.45 µm filter  
+ 50 µl H2O2 30 % 
Thereby, 300 µl per well were added and samples were incubated until red cells 
could be observed in the microscope (5 to 30 min). 
 
III.4.4  Immune fluorescence (IF) 
The principle of immune fluorescence (IF) staining is the detection of proteins via 
specific antibody stain coupled to a fluorescence antibody. The method is more 
sensitive than IPA due to the detection limit of a visible dye contra a fluorescent 
dye. Nevertheless, the staining protocol is similarly based on blocking, staining 
with a specific first antibody and subsequent stain with a labeled second antibody 
as described for IPA.  
IF was carried out as follows: cells (grown in 6-wells on coverslips) were fixed 
with 2% formaldehyde in PBS at RT or with Methanol (-20°C) at -20°C, the latter 
is discussed to render the cell membranes more permeable, after 48 h post 
transfection. Cells were then blocked with 10 % horse serum in PBS and 
afterwards stained by the primary antibody (see Table 4) in 5 % horse 
serum/PBS at 37°C for 1 h or for double-stains with a mixture of the mentioned 
antibodies in same concentrations (Table 4). After washing (three times with 
PBS) incubation with an FITC- or Cy3-conjugated secondary antibody (see Table 
4) in 5% horse serum/PBS was carried out for 1 h at 37 °C. The cells were again 
washed three times with PBS, embedded using Mowiol on an object holder and 
dried for 30 min. Subsequently the cells were analyzed under a light microscope 
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using a laser light source combined with appropriate fluorescence filters (515 nm 
FITC, 532 nm Cy3). 
 
III.4.5  SDS-polyacrylamide-gelelectrophoresis  
The SDS-polyacrylamide-gelelectrophoresis (SDS-PAGE) (modified after 
(Laemmli, U K 1970)) allows to separate protein mixtures according to their 
apparent molecular weight. The basic principle includes binding of multiple 
molecules of the negatively charged detergent sodium dodecylsulfate (SDS) via 
hydrophobic interactions to denatured protein molecules. That way, the latter 
ones acquire an excess of negative charges on their surface and can thus be 
applied to electrophoresis. For this purpose, the samples are loaded on   
polyacrylamid gels, which act like molecular sieves, similar to agarose gels.  
Samples were mixed with the appropriate amount of 4 x sample buffer (400 mM 
Tris/Cl (pH 6.8), 800 mM dithiothreitol (DTT), 16 % SDS, 0.8 % 
bromephenolblue, 25 % glycerin, 40 % ß-mercapto-Ethanol) and loaded either 
on 10-16 % polyacrylamid gels (see Table 5), within a Biorad Protean II chamber 
(Biorad). 
Table 5  SDS-PAGE ingredients 
ingredient Volume 10 % Volume 12 % Volume 16 % Volume 
collection gel
acrylamide/ 
bisacrylamide 30 % 
33.3 ml  36.4 ml  48.5 ml  16.5 ml 
1 M Tris (pH 6.8)          12.5 ml 
1 M Tris (pH 8.8)    39 ml  39 ml  39 ml   
10 % SDS    1.1 ml  1.1 ml  1.1 ml  1 ml 
Glycerol 50 %  8.2 ml  8.2 ml  8.2 ml   
aqua bidest.  add 100 ml  add 100 ml  add 100 ml  add 100 ml 
10 % APS  50 µl *  50 µl *  50 µl *  50 µl * 
TEMED  25 µl *  25 µl *  25 µl *  25 µl * 
* volume added to 15 ml gel solution, shortly before use 
 
Then discontinuous SDS polyacrylamide gelelectrophoresis (SDS-PAGE) was 
performed according to the manufacturer’s instructions using a Biometra P25 
power supply (Biometra, Göttingen, Germany) with the following running buffer: 
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SDS running buffer  
36 g glycin 
7.75 g Tris 
1.25 ml 20 % SDS 
add 250 ml aqua      
bidest 
 
The RPN 800 Full Range Rainbow marker (Amersham, Little Charlton, UK) was 
used as protein standard.   
Rainbow marker size standards (kD) 
250, 160, 105, 75, 50, 35, 30, 25, 15, 10 
III.4.6  Western blot analysis 
The Western blot technique is a method which enables the transfer of proteins on 
protein-binding surfaces such as nitrocellulose membranes (Towbin, H et al. 
1979). This transfer, also termed blot, enables the specific visualization of 
proteins of interest by immunostaining. Usually, proteins which have been 
separated by SDS-PAGE are applied to Western blot analysis. 
 
III.4.6.1  Blot technique 
Thereby, the transfer was performed electrophoretically onto nitrocellulose 
membranes (Immobilon
TM-P, Millipore) within a Fastblot-device (Biometra), 
according to the manufacturer’s instructions. For this, membranes were shortly 
incubated and blotted in transfer buffer (48 mM  Tris, 39 mM  glycin, 20 % 
methanol, add 1000 ml Aqua bidest). After blotting at 120 mA for 50 min (1 blot) 
or 200 mA for 50 min (2 blots), unspecific binding sites were blocked with 10 % 
horse sera in TBST for at least 45 min. For specific protein staining, antibodies 
diluted in 5 % horse sera in TBST (10 mM Tris pH 8, 150 mM NaCl, 0.05 % 
Tween 20) have been used (see Table 4), staining was performed for at least 3 h 
at RT or overnight at 4 °C. The membranes were washed four times with TBST 
before they were incubated with the appropriate secondary antibodies (see Table 
4). After washing as described above, detection was performed using the 
enhanced chemoluminiscence kit (ECL, Pierce) according to the manufacturer’s 
instructions.  
  50U Material and methods 
The two reagents contain a HRP substrate, that emits light during conversion into 
the product. Hence the signal can be visualized, using chemiluminescence films 
(Amersham) or in an LumiImager (Roche). Signal were collected for 5 sec – 2 h, 
depending on the signal intensities. 
 
III.4.6.2  Preparation of cell lysates 
For preparation of cell lysates, 1 × 10
7 cells were incubated with 0.5-1 ml of the 
the RIPA lysis buffer [50 µl 1 M Tris/pH 8.0, 30 µl 5 M NaCl, 1.5 µl     1 M MgCl2, 
100 µl 10 % NP-40, 5 µl 20 % SDS, 40 µl protease-inhibitor-mix (25 x 
Multicomplete
TM, Roche), 773.5 µl aqua bidest] directly within the culture flasks 
or after centrifugation in a Falcon tube at 970 rpm at 4°C. To get rid of DNA 
contaminations, samples were subsequently filtrated through QIAshredder 
columns according to the manufacturer’s instructions (Qiagen). Protein 
concentration was measured by use of a Brafdford assay (Biorad) and 
subsequent photometrical detection at 595 nm. Lysates were mixed with 4 x 
sample buffer in appropriate amount and incubated at 95 °C for 5-10 min. 
Usually 50-100 µg of cell lysate were then loaded onto the SDS gel. 
 
III.4.6.3  Preparation of virus and vector lysates 
For preparation of viral lysates, supernatant of approximately 3 x 10
7 packaging 
cells (confluent T175 flask) was harvested. After filtration through a 0.45 µm 
filter (Sartorius) the samples were concentrated as described in chapter III.3. 
The appropriate amount of 4 x sample buffer was added, and the samples were 
incubated at 95 °C for 5-10 min and subsequently loaded on the SDS gel. 
 
III.4.6.4  Deglycosylation of Western Blot samples 
Deglycosylation of particles or lysates was performed by treatment with PNGaseF 
(NEB Biolabs) according to the manufacturers instructions. This enzyme 
deglycosylates proteins, as required to obtain distinct bands in Western Blot 
analysis. After incubation at 37 °C for 1 h, the appropriate amount of 4 x sample 
buffer was added and the samples were subsequently treated as described 
above.  
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III.4.6.5  Factor Xa cleavage 
Factor Xa cleavage was carried out on concentrated samples using 1 µl enzyme 
(10  µg/µl NEB, UK) in 25 µl sample volume supplemented with 2 mM 
Calciumchloride. Samples were incubated one hour at 25 °C and were 
subsequently prepared for Western Blot analysis as described in chapter III.4.5. 
III.4.7  Prion conversion methods 
III.4.7.1  Conversion of retroparticles 
The conversion reaction was carried out using the Chandler scrapie strain 
(Chandler, R L 1961). 25 µl of concentrated particles were therefore incubated 
with 1µl of 10% brain homogenate of Chandler-infected mice (lysis buffer: 
100mM NaCl, 10mM EDTA, 0.5% Nonidet P 40 (Nonidet P-40), 0.5% sodium 
deoxycholate, 10 mM Tris-HCl, pH 7.5) overnight at 37 °C in an incubator. 
Samples were subjected to Proteinase K (PK) digestion and were then analyzed 
by Western Blot analysis. 
III.4.7.2  Proteinase K digestion 
Digestion with Proteinase K (PK) was performed using 20 µg/ml PK stocks 
(Qiagen). Vector and VLP stocks were incubated with appropriate amount of PK 
(0.5-5 µl in 20 µl sample volume) at 37 °C for 30 min. Reaction was stopped by 
addition of 4 × SDS sample buffer and incubated for 5-10 min at 95 °C. 
 
 
III.4.8  Electron microscopy 
III.4.8.1  Negative contrast 
For detection of PrP displayed on retrovirus particles, virions concentrated from 
the cell supernatant were used. For immunonegative staining, 20 µl of virus 
suspension was adsorbed to glow discharged carbon coated formvar grids for 2 
minutes. After rinsing in PBS, grids were incubated with 2% BSA for 30 minutes 
and with the primary antibodies 6H4 or anti-EGF at 1:750 dilution for 1h, 
respectively. After washing, grids were incubated with a 1:100 dilution of 10 nm 
gold labeled anti mouse IgG (BioCell, Cardiff, U.K.) for 30 minutes (antibodies: 
see Table 4). Finally, immunolabeled viruses were negatively stained with 2% 
uranylacetate or phosphotungstate for 10 seconds.  
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III.4.8.2  Ultrathin sections 
Ultrathin frozen sections of virus producing cells were fixed with a mixture of 2% 
formaldehyde and 0.1% glutaraldehyde for 1 h. After washing, fixed cells were 
embedded in warm liquid agarose that after gelling could be cut into small 
blocks. These blocks were immersed overnight in 2.3 M sucrose containing 10% 
polyvinylpyrrolidone, frozen in liquid nitrogen and cut into 80-100 nm sections 
with an ultramicrotome (Ultracut E, Reichert, Vienna, Austria) with 
cryoequipment. Sections were mounted on carbon coated formvar grids and after 
thawing washed with PBS. After treatment with 2% BSA, grids were incubated 
with the 6H4 antibody at a 1:750 dilution. After rinsing in PBS, grids were 
incubated with anti-mouse IgG (1:100 dilution), coupled to 10 nm gold particles 
(BioCell). Finally, to embed and stain structures, the grids were floated, sections 
down, on 1.6% methylcellulose containing 0.2% uranylacetate for 5 minutes. 
Excess methylcellulose was aspirated before air drying the resulting thin film. 
EM preparations were examined in a Zeiss EM 109 or 902 electron microscope 
and micrographs were taken on Kodak Estar electron microscope film. 
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IV  Results 
Basically, this thesis is divided into two major chapters, reflecting the two 
strategies for TSE vaccination development i) immune response against the 
cellular form of PrP and ii) immune response against the infective form of PrP. In 
the first chapter, the display of the cellular isoform of the prion protein (PrP
c) is 
addressed using three different approaches.  
The first one deals with monomeric PrP
c display via fusion to a mammalian 
transmembrane domain (Display system). The other two approaches attempt 
trimeric and multimeric display of PrP
c, by selection of trimerizing (Envelope 
fusion system) or multimerizing (nucleocapsid particles) proteins as scaffolds for 
display.  
The second chapter attempts the display of the scrapie isoform of the prion 
protein PrP
Sc. Either PrP
c displayed on the surface of the particles is converted 
into PrP
Sc (Conversion of retroparticles) using scrapie-infective agent or 
retroviruses are produced in scrapie-infected cells (Retroviral infection of scrapie-
infected cells), aiming at the incorporation of PrP
Sc into the viral envelope.  
IV.1  Display of the cellular prion protein 
IV.1.1  Retroparticles 
IV.1.1.1  MLV-derived display retroparticles 
To present the cellular isoform of the murine prion protein (mPrP) on the surface 
of virus-like particles derived from retroviruses, a commercially available 
expression system was used (pDisplay, Invitrogen). The pDisplay system 
functions as multi-fusion protein, in which the target sequence is N-terminally 
flanked by the murine immunglobulin κ chain signal peptide and C-terminally 
flanked by the transmembrane domain of the platelet derived growth factor 
receptor (PDGFR) anchoring the protein into the plasma membrane.  
The Display system also provides HA and myc tags for immunological detection 
and a factor Xa cleavage site for preparation of soluble PrP fusion proteins.  
Upon insertion of the human epidermal growth factor (EGF) coding sequence into 
pDisplay, it had been shown, that the resulting fusion protein EGF
D expressed 
from pD-EGF (Figure 9) is unspecifically incorporated into virus-like particles (VLPs) 
derived from the murine leukemia virus (MLV) (Nikles, D et al. 2005). EGF
D is 
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present on the cell surface in high amounts and seems to be incorporated by 
viral particles in a passive process, while they bud from the cell surface resulting 
in the production of display retroparticles. In this way, viral particles harbouring 
the protein of interest in their membranes are produced. 
As target cells for the production of PrP-displaying particles, the human kidney 
derived cell line HEK-293 was selected, especially a new subclone HEK-293FT, 
which grows faster and expresses the large T antigen (SV40) facilitating optimal 
viral production (293FT-cells manual, Invitrogen). Cotransfection of a plasmid 
coding for the viral structural proteins Gag/Pol and a plasmid coding for the 
transmembrane domain PrP-fusion-protein (PrP
D) should allow the production of 
PrP
D bearing VLPs, which were named PrP
D-retroparticles. 
 
Figure 8  Production of PrP
D retroparticles. Plasmids coding for either the PrP
D sequence or the MLV 
structural proteins Gag and Pol were cotransfected into HEK-293FT producer cells, which will subsequently 
release VLPs incorporating PrP
D into the viral envelope (PrP
D-retroparticles). 
 
IV.1.1.1.1  Generation of the expression plasmids 
The expression plasmids, based on the pDisplay vector system, were constructed 
by ligation of mPrP DNA fragments coding for aa23-231 (mPrP209), aa90-231 
(mPrP142) and aa121-231 (mPrP111) into the SfiI and SacII digested vector, 
respectively. For each DNA fragment two oligonucleotides were designed 
containing either the restriction site SfiI (forward primer) or SacII (reverse 
primer) as well as the factor Xa cleavage signal (reverse primer) and were 
flanked by homologues nucleotides of the PrP gene (Table 3).  
The PrP encoding DNA fragments were synthesised by PCR using the designed 
oligonucleotides and the phgPrP plasmid (Appendix, VI.1.1) as template. The 
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resulting PCR fragments were cleaved by the corresponding restriction enzymes 
SfiI and SacII and inserted into pDisplay. Correct insertion of each of the PCR 
fragments verified by restriction analysis and DNA sequencing (Appendix, VI.3), 
resulted in the PrP-fusion-protein expression plasmids pD-PrP209, pD-PrP142 
and pD-PrP111 (Figure 9). The corresponding protein PrP
D142 was especially 
included as an intermediate candidate between PrP
D209 and PrP
D111, when it was 
observed that the expression of these two forms showed high variation. 
 
Figure  9  Schematic representation of pDisplay derived expression plasmids. The pDisplay 
expression plasmid (Invitrogen) provides the immunoglobuline κ signal peptide (SP), the HA and myc tags, and 
the transmembrane domain of the PDGF receptor (PDGFR- T M ) .  I n  a d d i t i o n ,  a  f a c t o r  X a  c l e a v a g e  s i t e  w a s  
inserted N-terminally of the PDGFR-TM. 
 
IV.1.1.1.2  Expression analysis by immune fluorescence 
The expression of the different PrP
D proteins was examined in HEK-293FT and 
N2a cells. The latter were used to analyze the gene expression of PrP
D in PrP
c-
expressing cells, because in contrast to HEK-293FT cells, the N2a cell line 
expresses PrP endogenously. The expression was analyzed after cotransfection of 
plasmids pD-PrP111 and pD-PrP209 together with the MLV gag/pol coding 
expression plasmid pHit60 (Appendix, VI.1.7), respectively. pD-EGF 
cotransfected with pHit60 served as positive control.  
Transfected HEK-293FT (Figure 10) and N2a (Figure 11) cells were subjected to an 
epi-immune fluorescence analysis, performed by immunostaining by the specific 
anti-PrP antibody (6H4), the anti-EGF antibody or the anti-p30 serum (MLV 
capsid). 
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Figure  10  Cell surface expression of Display constructs encoding PrP fusion proteins. HEK-
293FT cells were transfected with plasmids pD-EGF and pHit60 (A, B), pD-PrP111 and pHIT60 (C, D, G) or pD-
PrP209 and pHIT60 (E, F), respectively. Cells were stained by the anti-PrP antibody 6H4 (B, D, F), with the 
anti-p30 serum (A, C, E), and bound antibody was detected by FITC-conjugated anti-mouse Ig (B, D, F, G) or 
Cy3-conjugated anti-goat Ig (A, C, E). Exposure times used for imaging of A-E and G were 20 sec, for F 200 
sec. Epi-fluorescence is shown. 
Specificity of the staining procedure was demonstrated as follows: HEK-293FT 
cells transfected with pD-EGF/pHit60 showed no immune fluorescence, upon 
staining by the 6H4 antibody (Figure 10, B) but showed signals upon staining with 
anti-EGF antibody (Figure 11, B). Furthermore, cells expressing PrP
D111 proteins 
were negative upon staining by the second antibody, only (Figure 10, G and Figure 11 
H). Strong and specific immune fluorescence signals were obtained for both, 
HEK-293FT and N2a cells expressing, the PrP
D111 protein. This protein was 
detected to a high extend on the cell surface (Figure 10, D and Figure 11, F). In 
contrast, the anti-PrP staining in the PrP
D209 sample was less efficient, and only 
single cells were antigen positive (Figure 10, F and Figure 11, K).  
Both, the PrP samples and the EGF
D sample were equally well stained by the 
anti-p30 antibody detecting the MLV capsid protein (Figure 10 A, C and E as well as 
Figure 11, A, E and I).  
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Figure 11  Cell surface expression of Display constructs encoding EGF and PrP fusion proteins 
on N2A cells. N2A cells were transfected with plasmids pD-EGF and pHIT60 (A-D) or pD-PrP111 and pHIT60 
(E-H), respectively. Cells were stained by the anti-PrP antibody 6H4 (D, F), the anti-EGF antibody (B) or the 
anti-p30 antiserum (A, E), and bound antibody was detected by FITC-conjugated anti-mouse Ig (B, F, D, H) or 
Cy3-conjugated anti-goat Ig (A, E), respectively. The merge of A and B is shown in C, that of E and F in G. 
Exposure times are 20 sec except for I and K (200 sec). Epi-fluorence is shown. 
 
Thus, compared to the endogenous PrP levels strong overexpression of the 
PrP
D111 protein was achieved in HEK-293FT cells as well as in N2a cells. Upon 
coexpression of the MLV gag/pol genes, colocalization of the MLV capsid protein 
with the PrP
D111 or the EGF
D molecules at the cell surface was demonstrated. 
These findings suggest differences in the expression of the PrP
D209 in 
comparison to the PrP
D111 proteins. However, the MLV capsid protein expression 
in these samples is equal, indicating that various expression rates of PrP
D209 and 
PrP
D111 are not due to basic protein expression mechanisms. 
 
IV.1.1.1.3  Expression analysis by Western Blot 
To further verify expression of PrP
D fusion proteins in the cells, cell lysates were 
analyzed by Western Blot. This method allows the specific staining of target 
proteins in dependence of their molecular weight and their separation properties 
on SDS polyacrylamid gels. The PrP
D fusion proteins PrP
D111 (22.5 kD) and PrP
D209 
(32.3 kD) should be distinguishable from endogenous PrP protein (28.0 kD). In 
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addition, for PrP a typical band pattern is expected due to mobility shifts of non-, 
mono- and diglycosylated PrP forms (glycosylation sites: Asn
180 and Asn
196). 
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Figure 12  Expression of PrP
D proteins in HEK-293FT derived cell lysates.  PrP
D proteins and the 
EGF
D control were detected by Western blot analysis using 16% polyacrylamide gels. For this, HEK-293FT cells 
were transfected with the pHIT60 plasmid in combination with either pD-EGF (lane 1), pD-PrP111 (lane 2), pD-
PrP209 (lane 3) or an unrelated control plasmid (lane 4). Cell extracts were analyzed with the anti-HA tag 
antibody. Molecular weights are indicated. 
 
Non-transfected cell lysates of HEK-293FT did not show detectable levels of 
endogenous PrP (Figure 12, lane 4). Whereas a single specific band is observed for 
the EGF
D protein, a panel of specific bands are seen for PrP
D111 as well as for 
PrP
D209 as expected for differently glycosylated PrP forms. In line with the results 
of the immune fluorescence analysis, higher expression levels for the PrP
D111 
protein and significantly lower levels for the PrP
D209 protein were obtained (Figure 
12, lanes 1-3). 
 
IV.1.1.1.4  Expression analysis by electron microscopy 
The immune fluorescence data supported the assumption, that PrP
D111 is present 
on the cell surface. To further verify this assumption, electron microscopic 
analysis of cell sections were performed (Figure 13). Visualization of cell-surface 
located PrP
D was achieved by specific immunostaining with the anti-PrP 6H4 
antibody. Secondary antibodies used for detection in electron microscopy were 
coupled to gold particles of 10 nm diameter. The specificity of the anti-PrP 6H4 
staining was approved by using EGF
D expressing cells as negative control, for 
which no staining was observed (not shown). 
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Figure 13  Immunoelectron microscopic analysis of cell sections. HEK-293FT cells were 
cotransfected with pD-PrP111 and pHit60 coding for MLV Gag and Pol and were then stained by anti-PrP 6H4 
and immunogold labelled secondary antibodies. Bar represents 250 nm. Candidates for budding particles are 
labelled by the arrows. 
 
The analysis for PrP
D111 expressing cells revealed widely marked cell membranes 
stained by anti-PrP 6H4 antibody (Figure 13). In addition to membranes, also 
microvilli and vesicles were stained. The vesicle-like structure on the upper left 
side (marked by the arrow) of the image may represent a budding retrovirus 
particle. 
Taken together, the expression of EGF
D, PrP
D111, and to a minor extend of PrP
D209, 
was observed in transfected HEK-293FT and N2a cells.  
Determination of protein expression of the fusion proteins and colocalization with 
viral structural proteins facilitated the assumption that budding particles may 
incorporate the newly generated PrP
D proteins. 
This hypothesis was addressed using Western Blot analysis (Figure 14) and electron 
microscopy analysis (Figure 15) of retroparticle-containing cell culture 
supernatants.  
IV.1.1.1.5  Cosedimentation with particles  
Cell culture supernatants from cotransfection of pD-EGF, pD-PrP111, pD-PrP142 
or pD-PrP209 plasmids with pHit60, respectively, were harvested and filtered 
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through a 0.45 µm filter to get rid of cell debris and dead cells. After 
concentration of retroparticles via either low-speed centrifugation methods or 
ultracentrifugation methods (III.3), the supernatants were separated on SDS-
polyacrylamid gels and were then analyzed via Western Blot.  
 
 
Figure 14  Incorporation of PrP
D fusion-proteins in VLPs.  PrP
D proteins and the EGF
D control were 
detected by Western blot analysis using 16% polyacrylamid gels. A) Supernatants of cells transfected with 
pHIT60/pD-EGF (lane 1), pHIT60/pD-PrP111 (lane 2) and pHIT60/pD-PrP209 (lane 3) were concentrated by low 
speed centrifugation. Pellets were resuspended in PBS. Western blot was performed using the anti-HA antibody 
in the upper blot and the anti-p30 serum to detect the MLV capsid in the lower blot. Volumes loaded 
corresponded to the following amounts of cell culture supernatant: 0.7 ml (lane 1 upper), 0.35 ml (lanes 2 
upper) and 13.5 ml (lane 3 upper), Volumes loaded on the lower blot corresponded to 1 ml of cell culture 
supernatant, each. B) Supernatants of cells transfected with pHIT60/pD-EGF (lane 1), pHIT60/pD-PrP111 
(lanes 2, 3, 5), pHIT60/pD-PrP209 (lane 4) or pHIT60/pD-PrP142 (lane 6) were detected using the anti-PrP 
antibody 6H4. For PNGaseF digestion, particles were equilibrated in denaturing buffer and incubated in the 
presence (lane 3) or absence of PNGaseF (lane 2). Volumes loaded on the gels corresponded to 0.7 ml (lane 1), 
0.35 ml (lanes 2, 3), 13.5 ml (lane 4), 0.8 ml (lane 5) and 1.2 ml (lane 6) of cell culture supernatants. 
 
The EGF
D expression control was detected by the anti-HA tag antibody as single 
band at the expected molecular weight (Figure 14 A, lane 1). Particle numbers 
budding from the transfected producer cells were similar for EGF
D, PrP
D209 and 
PrP
D111 as revealed by the anti-p30 staining (Figure 14 A, lower panel).  
The proteins PrP
D111 and PrP
D209 were specifically detected by the anti-HA tag 
antibody (Figure 14 A, upper panel, lanes 2 and 3) whereas specific signals upon 
anti-PrP 6H4 staining were obtained for PrP
D111 and PrP
D142 (Figure 14 A, lane 5 and 
6), but not for PrP
D209 (Figure 14 B, lane 4). The signal intensities for the two fusion 
  61ResultsT 
proteins PrP
D111 and PrP
D142 were similar suggesting that both proteins were 
equally well incorporated into retroparticles. Thus, the incorporation levels of 
PrP
D142 and PrP
D111 into retroparticles were substantially higher than that of 
PrP
D209. 
To assure that the PrP
D111 band pattern observed in the immunoblot (Figure 14 B, 
lane 2 and 5) was due to glycosylation of PrP
D111, treatment with Peptide:N-
GlycosidaseF (PNGaseF) was performed (Figure 14 B, lane 3).  A single band was 
obtained after deglycosylation, verifying that three different glycosylated forms 
of PrP, representing un-, mono- and deglycosylated PrP, are present in untreated 
samples (Figure 14 B, lane 2 and 5). 
 
The retroparticles displaying PrP or fragments thereof were named PrP
D-
retroparticles. Further studies focussed on the analysis of PrP
D111-retroparticles 
only, because they represented the most promising candidate for immunization 
studies at that time point. 
IV.1.1.1.6  Characterization by electron microscopy 
The results from Western Blot analysis suggested that the fact that PrP
D fusion 
proteins, especially when PrP is N-terminally shortened, were incorporated into 
retroparticles derived from MLV, but they did not exclude completely the 
possibility that signals in the supernatants were due to vesicle-like structures 
potentially budding from the cell surface. The latter would also penetrate the 
0.45 µm filters and would co-sediment with viral particles upon centrifugation of 
the sample, because of similar weight and density. 
Thus, to find out if PrP
D proteins were present in retroparticles, the cell culture 
supernatants were analyzed by electron microscopy (Figure 15). This method had 
been especially selected to differentiate between VLPs and vesicle-like structures. 
Vesicles vary in form and size whereas virus-like particles are regular, round-
shaped and equal in size. 
Low-speed centrifuged cell culture supernatants were immunostained by anti-PrP 
6H4 and subsequently stained by a gold-labelled anti-mouse antibody, as 
described in detail in chapter IV.1.1.1.4.  
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Figure  15  Immunoelectron microscopic analysis of PrP
D-retroparticles.  PrP
D111-retroparticles 
harvested from the cell culture supernatant and concentrated by low speed centrifugation were stained with the 
PrP specific 6H4 antibody (A, B left panel) and a 10 nm gold particle labelled anti-mouse IgG. EGF retroparticles 
(B middle and right panel) were harvested from pHIT60/pD-EGF transfected 293FT cells and stained with the 
anti-EGF (middle panel) or the 6H4 antibody (right panel). Bars represent 250 nm. Arrowheads indicate 
particles with the typical morphology of C-type retroviruses, arrows indicate pleomorphic vesicles.  Positive 
staining events are visible as dots. 
The specificity of the anti-PrP 6H4 staining was confirmed by using EGF
D particles 
as controls. EGF
D retroparticles revealed specific signals upon staining by an anti-
EGF antibody (Figure 15 B). 
The cell culture supernatants contained morphologically different structures (Figure 
15 A). On one hand particles exhibiting the typical morphology of C-type 
retroviruses were present. On the other hand also pleomorphic vesicle-like 
structures were detectable. Both types of particles were present in roughly 
similar amounts and were surrounded by numerous immunogold particles. 
These results clearly demonstrated that retroparticles incorporate PrP
D111 and 
display the protein on their surface. Moreover, preparations concentrated by low-
  63ResultsT 
speed centrifugation of cell culture supernatant contain vesicles and vesicle-like 
structures, presenting PrP
D111 as well. 
 
IV.1.1.1.7  Quantification of particles 
Since transient transfection may strongly differ in efficiency, a method to 
quantify the amount of PrP
D-retroparticles released from producer cells was 
established. For this, the reverse transcriptase (RT) assay has been used, which 
determines the activity of the RT in stocks of retroviral particles (C-type RT 
activity kit, Cavidi Tech). Various particle preparations concentrated by low-
speed centrifugation were diluted and subjected to RT analysis (Figure 16). 
 
 
Figure  16  Quantification of concentrated particle stocks. Particles were measured in a C-type 
reverse transcriptase (RT) activity assay. Average values of different PrP
D-particle and of EGF
D-particle 
preparations are shown. For particle production, three EGF
D (17/07/02), PrP
D (31/03/03), six (12/11/03) or 
twelve (21/10/03) T175 cell culture flasks of HEK-293FT cells were transfected. Average values of at least three 
measurements are shown.  
The amounts of different particle preparations of PrP
D111-retroparticles, which 
were subsequently used in immunization studies, varied between 20-500 RT 
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units per ml, depending on the amount of cells used for transfection. In addition, 
the variation may be due to different transfection efficiencies and cell densities 
as well as the state of the producer HEK-293FT cells. There was basically no 
difference in the amounts of EGF
D-retroparticles compared to PrP
D111-
retroparticles when they were prepared under similar conditions. 
Based on the RT units obtained, particle numbers of the different preparations 
were calculated as described (Pyra, H, Boni, J et al. 1994) (Figure 17).  
 
Figure 17  Calculated particle numbers in concentrated preparations. Total particle numbers were 
calculated based on the measured RT units described above. For this, the equation nCP = 3 × 10
9 [p/units] × 
RT-value [units] was applied (Pyra, H, Boni, J et al. 1994). nCP represents the number of concentrated particles. 
Each preparation contained at least 10
10 PrP
D111-retroparticles, verifying that the 
concentration methods used in this study were successful.  
In summary, PrP
D111-retroparticles were successfully generated in high 
quantities. However, particle numbers may not directly reflect the amount of 
PrP
D111 protein present in each preparation. Therefore, another method for PrP-
quantification had to be established. 
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IV.1.1.1.8  Quantification of PrP in particle preparations 
For mouse immunization experiments a method for quantitative determination of 
the amounts of PrP, present in different particle preparations, had to be 
established. As the method of choice ELISA was used to compare PrP-specific 
antibody binding in a sensitive assay (Figure 18). The particles were analyzed by 
coating log 3 dilutions of concentrated stocks (100 RT units/ml) on ELISA plates. 
For this purpose, particles were coated on plastic dishes and subsequently 
detected using the anti-PrP 6H4 as first and an anti-mouse-HRP conjugated 
secondary antibody. To quantify the total number of particles anti-p30 sera in 
combination with a goat-specific secondary HRP-labelled antibody was used.  
 
Figure 18  Detection of the amounts of PrP in PrP
D-retroparticles. Analysis of PrP
D111-retroparticles 
(A) and of EGF
D-retroparticles (B) by ELISA. Concentrated stocks of both particle types were coated to ELISA 
plates at the indicated dilutions. Virally expressed antigens were detected by use of the anti-PrP monoclonal 
antibody 6H4 (red rectangles), polyclonal anti-p30 antiserum (orange ovals), or mouse preimmune serum 
(green triangles). Data represent one out of two experiments with similar results. Half-maximal dilution are 
indicated by dotted lines. Figure taken from (Nikles, D, Bach, P et al. 2005).  
 
While EGF
D-retroparticles showed no 6H4 binding but strong anti-p30 binding 
(Figure 18, B), PrP
D111-retroparticles showed strong binding of both, the PrP-specific 
6H4 antibody and of the anti-p30 antibody (Figure 18, A). As dilutions at half-
maximum values for PrP
D111-retroparticles 800fold dilution detected by anti-p30 
serum and 1600fold dilution detected by anti-PrP 6H4 antibody were calculated, 
whereas EGF
D-retroparticles showed 4900fold dilution at half maximum value.  
Throughout this study the ELISA was used to standardize particle preparations 
for immunization purposes. 
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Based on the studies described above, an optimal protocol for particle production 
was determined. According to this protocol, which is described in detail in 
chapter III.3 twelve T175 cell culture flasks were transfected by 
pDPrP111/pHit60, concentrated and separated into small portions followed by 
storage until further use in immunization studies. 
IV.1.1.1.9  Induction of PrP-specific antibody responses 
To verify the antigenicity of the PrP
D111-retroparticles, different types of mice 
were immunized. Firstly, Prnp knock-out mice (Prnp
o/o) were subjected to 
immunization experiments, in which the immune response was expected to be 
high, because PrP is no self-antigen in these animals. Since the main goal was to 
circumvent the tolerance in animals expressing PrP, both Prnp heterozygous mice 
(Prnp
+/o) and wild-type mice (Prnp
+/+) expressing either one or two Prnp alleles 
were included in immunization studies.    
 
Figure 19  Immunization scheme used for PrP
D-retroparticle immunization. Prnp
0/0, Prnp
0/+ and 
Prnp
+/+ mice were immunized with 10
11 particles in 200 µl PBS/1% FCS solution using five mice were per group. 
Bleeding was carried out on day 7 and on day 14 post immunization.  
For this purpose, groups of five mice were i.v. immunized with approximately 
10
11 PrP
D111-retroparticles and serum was taken weekly (Figure 19).  
Already seven days after immunization, Prnp
o/o mice showed high titers of PrP-
specific antibodies as indicated by a n  E L I S A ,  d e t e c t i n g  P r P - s p e c i f i c  
immunoglobulin of the M, G, and A subclasses (Figure 20).  
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Figure 20  Sera of mice immunized with PrP
D-retroparticles specifically bind recombinant PrP in 
ELISA analysis. PrP
D111-retroparticles devoid of adjuvant were i.v. injected into three individual mice of the 
Prnp
o/o (A), Prnp
+/o (B), or Prnp
+/+ (C) genotypes, respectively (open symbols). Seven days after immunization 
serum samples were taken and tested in log 2 serial dilutions (20-fold predilution) for the presence of PrP-
specific total Ig reactive against bacterially expressed PrP
REC121-231. As controls, the anti-PrP monoclonal antibody 
6H4 (filled rectangles), pre-immune serum (filled triangles) or serum from mice injected with EGF
D-
retroparticles (filled circles) was used. One out of two similar experiments is shown. Figure taken from (Nikles, 
D, Bach, P et al. 2005) 
 
Interestingly, despite the expression of one or two Prnp alleles, also Prnp
+/o and 
Prnp
+/+ mice mounted PrP-specific antibody responses, albeit at substantially 
reduced levels when compared to Prnp
o/o mice (Figure 20 C). Essentially similar 
response curves were monitored with sera obtained 14 days after immunization 
(data not shown). PrP-specific antibody responses in Prnp
+/+ mice were slightly 
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lower than in Prnp
+/o mice which might be explained by a higher level of PrP-
specific tolerance in Prnp
+/+ mice than in Prnp
+/o mice. 
 
Next it was studied whether serum antibodies showing PrP-specific binding in an 
ELISA assay also bind the native form of PrP
c as expressed on the cell surface 
(Figure 21).  
 
Figure  21  Schematic representation of FACS assay to detect cell surface PrP binding. T cells 
were isolated out of blood from PrP
c-overexpressing mice (tg33). Sera from immunized Prnp
0/0, Prnp
0/+ and 
Prnp
+/+ mice were analyzed for binding to PrP
c on the surface of the isolated T cells. Analysis was performed 
using FACS method. 
To this end, peripheral blood was taken from tg33 mice overexpressing PrP on T 
lymphocytes (Raeber, A J et al. 1999), and CD3 positive T cells were tested for 
binding of serum IgM or IgG derived from immunized mice by FACS analysis 
(Figure 22). 
  69ResultsT 
 
Figure 22  Sera of mice immunized with PrP-retroparticles specifically bind the native form of 
PrP as expressed on the cell surface of tg33 derived T cells. Serum samples were taken seven (A) or 14 
days (B) after i.v. injection of PrP
D111-retroparticles into Prnp
o/o, Prnp
+/o or wild-type mice (Prnp
+/+) and 
analyzed for their reactivity against PrP as expressed on T cells derived from PrP overexpressing tg33 
transgenic mice. Five individuals per group were analyzed (grey lines). IgM (left panels) and IgG subtypes 
(right panels) were determined. Cells incubated with preimmune serum (green) or 6H4 (red) were used as 
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controls. C) Sera from immunized Prnp
o/o or wild-type mice (Prnp
+/+) were tested for the reactivity of IgG 
subtypes with T cells from Prnp
o/o mice (left panels, grey lines) or with T cells from tg33 mice (right panels, 
grey lines). Preimmune sera are shown in green in left panels. Preimmune sera from five individual Prnp
+/+ 
mice (lower right panel, coloured lines) or pooled preimmune sera from seven Prnp
0/0 mice (upper right panel, 
green line) were tested for IgG reactivity against PrP as expressed on tg33 T cells. D) Prnp
o/o mice immunized 
with PrP
REC in CFA/IFA mounted significant anti-PrP antibodies, whereas Prnp
+/+ were unresponsive to 
immunizations. Bacterially expressed PrP
REC emulsified in CFA and IFA was injected into mice of the Prnp
o/o and 
Prnp
+/+ genotype, respectively (Polymenidou, M, Heppner, F L et al. 2004). 28 days after immunization, serum 
samples were analyzed for their IgG reactivity against PrP as expressed on tg33 derived T cells. Three 
individuals were analyzed per group (grey lines). Cells incubated with preimmune serum (green) or 6H4 (red) 
were used as controls. All histograms (A-D) show PrP-specific binding gated on CD3-positive T cells. Figure 
taken from (Nikles, D, Bach, P et al. 2005) 
 
Seven days after immunization of Prnp
o/o mice, serum showed PrP
c-specific IgM 
binding that was slightly decreased by day 14, whereas strong PrP
c-specific IgG 
binding was detected on day 7, that was further increased by day 14, even 
beyond the binding strength of the positive control 6H4 (Figure 22 A, B). 
Reminiscent of the above ELISA results, 7 days after immunization of Prnp
+/o 
mice, serum showed PrP
c-specific IgM binding that was slightly lower than that of 
Prnp
o/o mice and slightly higher than that of Prnp
+/+ mice (Figure 22 A), whereas 14 
days after immunization PrP
c-specific IgM was not detectable, neither in serum of 
Prnp
+/o nor Prnp
+/+ mice (Figure 22 B). Compared to Prnp
o/o mice, PrP
c-specific IgG 
binding was substantially reduced in the serum of Prnp
+/o and Prnp
+/+ mice, 
whereas serum of Prnp
+/o mice showed slightly higher binding than that of 
Prnp
+/+ mice. Interestingly, some PrP
c-specific IgG was still detectable 14 days 
after immunization (Figure 22 B). To verify the specificity and reliability of the FACS 
method used for determination of PrP
c-reactive antibodies a number of control 
experiments were performed.  
Firstly, N2a neuroblastoma cells and tg33 derived T cells incubated with 6H4 
antibody or various different PrP-reactive immune sera showed very similar 
staining, indicating that the tg33 based FACS method revealed binding of PrP
c as 
expressed on normal cells (data not shown). Secondly, a potential inter-
individual heterogeneity with respect to spontaneous PrP-specific antibody titers 
was assessed. To this end, individual preimmune sera and pools of preimmune 
sera derived from Prnp
+/+ and Prnp
o/o mice were assayed for binding to tg33 cells 
in the tg33 based FACS assay. In no case significant PrP binding of preimmune 
serum was observed (Figure 22 C, right panel; data not shown). Furthermore, the 
very narrow scattering of the blots of staining with individual preimmune sera 
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demonstrated the reliability and reproducibility of the FACS method used (Figure 22 
C, bottom right panel). Thirdly, for further verify the PrP-specificity of serum 
binding, we included Prnp
o/o derived T cells in the FACS analysis as negative 
controls. Even if strong binding of tg33 derived T cells was observed, no IgG 
binding of Prnp
o/o derived T cells was detected, neither with serum from Prnp
o/o 
nor with serum from Prnp
+/+ mice (Figure 22 C, left panels). Finally, sera from 
Prnp
o/o and Prnp
+/+ mice immunized with bacterially produced PrP
REC were 
analysed by the tg33 based FACS assay (Gilch, S, Wopfner, F et al. 2003; 
Polymenidou, M, Heppner, F L et al. 2004). In contrast to the sera obtained from 
immunizations with PrP
D111-retroparticles, we could not detect any antibodies in 
Prnp
+/+ mice recognising the native cell surface exposed PrP (Figure 22 D). This 
failure of PrP
REC to circumvent tolerance in wild-type animals is in line with 
recently published data (Polymenidou, M, Heppner, F L et al. 2004).  
In conclusion, PrP
D111-retroparticles are good B cell antigens as indicated by 
strong antibody responses induced in Prnp
o/o mice. Furthermore, PrP
D111-
retroparticles can induce low but significant native PrP
c-specific IgG antibodies in 
mice carrying one or two Prnp  wild-type alleles, thus being superior to 
recombinant, bacterially expressed PrP. 
 
IV.1.1.2  HIV-derived display retroparticles 
Virus-like particle production, as described above for the C-type retrovirus 
candidate MLV, is in principle also possible with lentiviral particles. Since vector 
systems based on the lentivirus HIV are available and the viral structural 
proteins coded by gag and pol are sufficient for particle budding, these viral 
particles can be produced in the same way as MLV derived VLPs. In terms of 
immunization studies on the basis of PrP
D-retroparticles, the advantage of an 
alternative system, which displays PrP in a different context, lies in the possibility 
to boost antibody titers against PrP by a prime/boost protocol to enhance 
immunization efficiencies. For this purpose, HIV-derived VLPs displaying PrP
D111, 
which were subsequently named PrP
D-lentiparticles, were generated. 
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Figure  23  Comparison of PrP
D-retro- and lentiparticles. PrP
D-retroparticles are derived from the 
murine leukaemia virus MLV (blue capsid). PrP
D-lentiparticles (red capsid) were produced using human 
immunodeficiency virus derived structural proteins encoded by gag and pol genes.  
IV.1.1.2.1  Incorporation analysis by Western Blot 
For the generation of HIV-derived PrP
D111 lentiparticles, the HIV gag/pol coding 
plasmid pCMV∆R8.2 (Appendix, VI.1.7) was cotransfected along with pD-PrP111 
into HEK-293FT cells to produce HIV-derived VLPs bearing PrP
D111 on their 
surface. The expression and incorporation of the fusion protein was addressed by 
Western Blot analysis. 
 
 
Figure 24  Western Blot analysis of PrP
D-lentiparticles.  PrP
D111 and the EGF
D control were detected 
by Western blot analysis using 16% polyacrylamid gels. A) and B) Particles from supernatants of cells 
transfected with pHIT60/pD-EGF (lane 1), pHIT60/pD-PrP111 (lane 2) and pCMV∆R8.2/pD-PrP111 (lane 3) 
were concentrated by low speed centrifugation. Pellets were resuspended in PBS. Volumes loaded corresponded 
to the following amounts of cell culture supernatant: 0.7 ml (lane 1), 0.35 ml (lanes 2) and 0.88 ml (lane 3). 
Western blot was performed using the anti-HA antibody (A) or the anti-PrP 6H4 antibody (B). C) Supernatants 
of cells transfected with pHIT60/pD-EGF (lane 1, 3), pHIT60/pD-PrP111 (lane 2) and pCMV∆R8.2/pD-PrP111 
(lane 4) were loaded. Volumes corresponded to 1 ml of cell culture supernatant, each. Blots were stained by 
anti-p30 serum (left panel) or an anti-p24 monoclonal antibody (right panel), respectively. 
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EGF
D was included as molecular weight marker and as specificity control for the 
anti-PrP 6H4 antibody (Figure 24 A and B, lane 1). Staining against the respective 
capsid proteins (p30 for MLV and p24 for HIV), was performed to demonstrate 
presence of lentiparticles (Figure 24 C). The signals present in the supernatant of 
cotransfected cells were compared to those of MLV-derived PrP
D111 retroparticles 
(Figure 24 A, lane 2 and 3). Roughly twice as much supernatant was loaded 
compared to retroparticles, the signal from PrP
D111 in lentiparticles, for which the 
double amount was loaded, was stronger thus pointing to equal well 
incorporation into lentiparticles. In addition to anti-HA tag antibody stain (Figure 24 
A), detection with the anti-PrP 6H4 antibody was also possible (Figure 24 B).  
 
Thus, the Western Blot data indicated the presence of PrP
D111 fusion protein in 
lentiparticles.  
 
IV.1.1.2.2  Incorporation analysis by electron microscopy 
The incorporation into HIV-deribed lentiparticles was then further investigated by 
electron microscopy to assure presence of PrP
D111. For this, cell culture 
supernatants of pDPrP111/pCMV∆R8.2 cotransfected HEK-293FT cells were 
subjected to immunogold labelling analysis (Figure 25).  
Control particles derived from HIV bearing EGF
D were not stained by anti-PrP 6H4 
(Figure 25 C).  
The PrP
D111 lentiparticles derived from HIV were specifically stained by the anti-
PrP 6H4 antibody in combination with the immunogold labelled second antibody 
(Figure 25 A, B). At this, there were vesicle-like as well as virus-like particles visible 
in the image as it was observed for MLV-derived VLPs before. Overall, the 
amount of particles was lower copared to MLV-derived retroparticles and the 
vesicle to virus-like particle ratio was increased. Nevertheless, both structures 
were equally well labelled by immunogold in comparison to MLV-derived 
retroparticles. 
Taken together these data verify that PrP
D111 fusion protein was incorporated into 
HIV-derived lentiparticles in the same way as it was observed for MLV-derived 
retroparticles. These particles are available for immunization studies. 
Thus, an additional particle type which can be used to boost primary immune 
responses against PrP
D-retropartciles was generated. Nevertheless, the retroviral 
capability to package genetic information offers the possibility to combine nucleic 
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acid and protein vaccination approaches. The hypothesis that particles, which 
additionally package genetic information of PrP may elicit even higher immune 
responses led to the design of retroviral vectors. 
 
 
Figure 25  PrP
D111 protein is present in HIV-derived VLPs. HIV-derived PrP
D111 particles (A, B) and 
HIV-derived EGF
D particles (C) were stained by the anti-PrP 6H4 antibody and a secondary antibody labelled by 
10 nm gold-particles. Bars represent 100 nm. Gold-labelling is marked by arrows. Virus-like particles are 
indicated by filled arrowheads. Vesicle-like structure are indicated by open arrowheads. 
 
IV.1.1.3  Lentiviral vector system 
Besides the insertion of PrP into the membrane of particles, the PrP
D coding 
sequence was also packacked into a lentiviral vector. This should allow transfer 
of the PrP
D coding sequence into cells, which can not easily be transfected with 
plasmids. Moreover, upon transduction with vector particles, stably PrP
D 
expressing cell lines can be established.  
The possibility to directly transduce retroviral packaging cell lines, as e.g. 
Phoenix-gp (Nolan, G), TelCeB15 (Cosset, F L et al. 1995) (both MLV gag/pol 
producer cells) or 293 STAR (Ikeda, Y et al. 2003) (HIV gag/pol producer cells), 
will enable the generation of stably PrP
D-particle producer cell lines. Transduction 
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of the HIV gag/pol packaging cell line 293 STAR would lead to a stable cell line 
generating viral vectors. On the contrary, transduction of Phoenix-gp or 
TelCeB15 packaging cell lines would lead to stable production of VLPs without 
packaged mPrP coding sequence. At this, the budding MLV-derived retroparticles 
do not encapsidate mPrP containng a lentiviral encapsidation signal, because 
retroviral packaging involves specific encapsidation signals (Berkowitz, R et al. 
1996) differing for HIV and MLV (Figure 26). 
 
Figure  26  Schematic representation of the PrP
D-lentiviral vector system and the resulting 
producer cell systems. Lentiviral vectors presenting PrP
D proteins on their surface are additionally 
pseudotyped by the vesicular stomatitis virus G protein (VSVG) to ensure transduction of either MLV Gag/Pol 
producer cells (upper panel) or HIV Gag/Pol producer cells (lower panel). The transduced producer cells will 
subsequently produce MLV-derived PrP
D-retroparticles (upper panel) or HIV-derived PrP
D-lentiparticles 
packaging the PrP coding sequence (lower panel). MLV capsid is shown in blue, HIV capsid is shown in red. 
PrPD is indicated as green squares. 
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The newly available lentiviral expression system (Virapower lentiviral system, 
Invitrogen) allows creation of a replication-incompetent, HIV-1-based lentivirus, 
which can then be used to deliver and express the gene of interest into 
mammalian cells. This expression system was used to generate packagable PrP
D 
genes and obtain lentiviral vector particles.   
The transfer vector of this system, named plenti6-V5 (Appendix, VI.1.4) bearing 
the PrP
D gene, was cotransfected with an optimized mix of the three packaging 
plasmids (pLP1, pLP2, and pLP/VSVG (Appendix, VI.1.11). The mix supplies the 
structural proteins in trans that are required to produce the lentiviral vector. As 
producer cells the HEK-293FT cell line was selected as before. 
IV.1.1.3.1  Strategy 
The two coding sequences for PrP fusion proteins PrP
D111 and PrP
D142 were 
subcloned into plenti6/V5-lacZ (Appendix, VI.1.4) using the restriction sites 
BstXI and XhoI. The procedure resulted in a construct providing the possibility to 
package the fusion protein genes in form of viral RNA into HIV derived particles. 
The genes are flanked by the HIV 5´and 3´LTRs responsible for integration into 
the host cell genome and the HIV packaging site (Ψ) providing packaging of the 
viral genome into particles (Figure 27). 
 
Figure  27  Schematic representation of the plenti6-PrP111 and 142 expression constructs 
derived from pLenti6/V5-GW-LacZ. The PrP
D111 and the PrP
D142 coding sequences were transferred into the 
plenti6/V5-lacZ vector via the BstXI and the XhoI restriction sites. This results in substitution of the lacZ coding 
sequence against the PrP
D coding sequence. The newly generated plasmids bear the capacity of being packaged 
into lentiviral HIV-derived vectors and to become integrated into target cell genomes. 
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A stop-codon was added to the 3´end of the parental transferred PrP
D coding 
sequence, so that the available V5 epitope present in the parental pLenti6/V5-
GW-LacZ plasmid was not included in the reading frame. The expression remains 
under control of the CMV promoter, which is included in the expression plasmid 
plenti6/V5-GW-LacZ. 
 
IV.1.1.3.2  Packaging 
The newly generated plasmids pLenti6-DPrP111 and pLenti6-DPrP142 were 
cotransfected with the ViraPower packaging mix (Invitrogen), which consists of a 
mixture of plasmids needed for production of lentiviral vector particles. This 
mixture includes pLP1 and pLP2 coding for the HIV gag/pol genes and the HIV 
accessory Rev gene, respectively. The Rev protein interacts with the Rev 
response element (RRE) on pLP1 to enhance Gag and Pol expression as well as 
with the pLenti6/V5 expression vector to promote the nuclear export of the 
unspliced viral RNA for packaging into viral particles. The pLP/VSVG plasmid 
encodes the envelope G glycoprotein of the Vesicular Stomatitis Virus (VSV) to 
allow production of pseudotyped particles with a broad host range (Emi, N et al. 
1991). The cotransfection of HEK-293FT producer cells was performed according 
to the ViraPower manual (Invitrogen) followed by the collection of supernatants 
containing the vector particles.  
To assure the packaging of the pLenti-DPrP encoded genes, the supernatants 
were subjected to RNA isolation. Subsequently the RNA preparations were 
reverse transcribed using the V5 reverse primer (Table 3). PCR fragments of 889 
bp for pLenti-DPrP111 derived RNA and 982 bp for pLenti-DPrP142 derived RNA 
were the generated using the primer pair CMV forward and V5 reverse.  
The cDNA samples were analyzed by gel electrophoresis in comparison to RNA 
samples, which served as negative controls (Figure 28, lane 2, 5), because the RNA 
itself cannot act as template in PCR reactions. This control excludes the 
possibility that signals arose from residual plasmid DNA of the transfection of 
producer cells. The RNA sample of pLenti-DPrP111 did not give rise to any PCR 
signal, demonstrating that the RNA sample was free of DNA (Figure 28, lane 2). In 
contrast to that, the pLenti-DPrP142 sample resulted in a faint RNA signal (Figure 
28, lane 5), suggesting that residual DNA was present in this sample. 
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Figure 28  The pLenti-DPrP111 and pLenti-DPrP142-derived coding sequences were packaged 
into lentiviral vector particles. Vector containing supernatants were subjected to RNA isolation and 
subsequently reverse transcribed into cDNA. This cDNA was used as a template in analytical PCR analysis with 
CMVforward and V5reverse oligonucleotides. Besides the two constructs pLenti-DPrP111 (lane 1) and pLenti-
DPrP142 (lane 4), also RNA negative controls (lanes 2 and 5, respectively) and plasmid positive controls (lanes 
3 and 6) were included. For comparison the parental pLenti6/V5-lacZ plasmid (lane 7) was used as template. 
As positive controls the plasmids pLenti-DPrP142 and pLenti-DPrP111 were 
included as well as the parental plasmid pLenti/V5-lacZ (3393 bp signal), which 
indicated the expected size of the amplified fragments. 
pLenti-DPrP142-derived and pLenti-DPrP111-derived cDNA revealed the expected 
signals compared to plasmid DNA (Figure 28, lane 1, 3), although an unexpected 
second higher band was present for pLenti-DPrP142 possibly due to unspecific 
primer binding in the cDNA sample.  
Thus, the coding sequences for the PrP
D111 and PrP
D142 fusion proteins were 
sucessfully packaged into lentiviral vectors, which can be used for transfer into 
target cells. Furthermore, such particles may be useful to enhance immune 
responses against virus-derived display particles and to establish immunization 
protocols. 
IV.1.1.3.3  Transduction and stable cell lines 
The vector containing supernatants were subsequently used for transduction of 
the target cell lines N2a and 293 STAR. The neuroblastoma cell line will then 
stably express PrP
D on the surface, thus providing the basis for experiments with 
the scrapie-infected subclone PK1 available from this cell line. 293 STAR stably 
produce HIV-derived virus-like particles (Ikeda, Y, Takeuchi, Y et al. 2003) and 
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should therefore be convertable into a stable PrP
D-vector particle producer cell 
line upon transduction with PrP
D-(VSV-G)-lentivectors, as it is shown in Figure 26.  
The PrP
D-(VSV-G)-lentivectors provide a Blasticidin resistance marker enabling 
the selection of transduced cells after transduction events. As a prerequisite for 
successful blasticidin selection, the optimal blasticidin concentration for N2a and 
293 STAR cells was determined. For this purpose, cells were exposed to various 
concentrations of blasticidin ranging from 2 to 10 µg/ml. While for N2a cells 8 
µg/ml were sufficient to kill all cells after 10 days of incubation with blasticidin, 
for the 293 Star cell line 4 µg/ml blasticidin were sufficient. 
The cell lines were then transduced with vector stocks of both, pLenti-DPrP111-
derived vectors and pLenti-DPrP142-derived vectors, and incubated with the 
corresponding amounts of blasticidin for 7 days starting from day 2 after 
transduction. Cells were expanded and used for further analysis. For this, the 
genomic DNA was isolated from about 3 × 10
6 cells and subjected to PCR 
analysis (Figure 29) with the CMVforward/V5reverse primer pair as described for 
cDNA analysis above. 
 
Figure  29  Transduced cell lines integrate Lenti-PrP
D genetic information into their genome. 
Vector particles were used for the transduction of N2a and HEK 293 Star cells to achieve stable integration of 
the packaged pLenti-PrP
D coding sequences.  Upon isolation of genomic DNA and subsequent analytical PCR 
using  CMVforward/V5reverse primers, cells were tested for the integration of the virally packaged genes.   
pLenti-DPrP111 vectors (lane 3, 5) and pLenti-DPrP142 vectors (lane 2 and 6) were compared to genomic DNA 
of untransduced N2a (lane 1) and 293 STAR (lane 4) cells. 
 
While the control from untransduced cells remained without signal for both cell 
lines (Figure 29, lanes 1 and 4), specific bands for pLenti-DPrP111 and pLenti-
DPrP142 vector transduced cells appeared at the expected positions (889 bp and 
982 bp, respectively) for both cell lines (Figure 29).  
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Thus, the transduced and blasticidin-selected cell lines N2a and 293 STAR 
contained integrated PrP
D coding sequences and are available for production of 
the PrP
D fusion proteins (N2a) or as PrP
D lentivector producer cell line (293 
STAR). 
 
So far, display of monomeric PrP
D on the surface of retroparticles and 
lentiparticles has been achieved.  
However, oligo- or multimeric display of PrP may be advantageous for 
immunization. Attempts in this direction are addressed in the next chapter. 
 
IV.1.1.4  Display of PrP
c on the Env protein 
 
 
Figure 30  Schematic representation of PrP
E-retroparticles. PrP
c is presented in context of the MLV-
derived amphotropic Env protein. The coding sequence was fused to the N-terminal end of the trimeric Env 
protein (N-terminal display). Cotransfection with either MLV or HIV Gag and Pol genes results in production of 
corresponding retro- or lentiparticles, respectively.  
 
The display of PrP
c in an oligomeric system offers a distinct way of presenting the 
protein, because the single PrP molecules are believed to come into close 
proximity. Here, the amphotropic MLV (aMLV)-derived viral envelope protein 
(Env), which forms a trimer (Kamps, C A et al. 1991), is utilized as scaffold for 
the display of N-terminally fused cellular PrP. The N-terminus has previously 
been shown to tolerate insertions largely without affecting the Env functions 
(Russell, S J et al. 1993; Cosset, F L, Morling, F J et al. 1995; Finger, C et al. 
2005). The aMLV Env protein (includes human cell tropism) was used, because 
the presentation should be carried out in a trimeric but nonreplicative context. 
Utilization of the amphotropic instead of the ecotropic Env, which enters murine 
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cells only, was not relevant in terms of safety aspects (because retroparticle 
would not mediate infectivity) and was simply due to availability of the 
corresponding plasmid coding for the amphotropic variant.  
Upon cotransfection with MLV structural genes gag/pol, the production of VLPs 
incorporating the altered viral envelope can be achieved. The resulting particles 
were named PrP
E-retroparticles (MLV-derived VLPs) or PrP
E-lentiparticles (HIV-
derived particles), respectively. 
 
IV.1.1.4.1  Strategy 
The fusion proteins of mPrP with the aMLV Env were produced using the parental 
plasmid pFB-EASALF (Appendix, VI.1.5), coding for aMLV Env, cleaved by the 
restriction enzymes SfiI and NotI. The mPrP gene fragments coding for the aa23-
231 (mPrP209) and 121-231 (mPrP111) were inserted by use of NotI-containing 
reverse primers and subsequent PCR with PrP121Sfi+ forward and PrPNot- 
reverse primers (Table 3). 
For both constructed plasmids, one positive candidate was selected and insertion 
of the correct insert was verified by restriction analysis and DNA sequencing 
(Appendix, VI.5). Resulting expression plasmids (Figure 31) code the PrP-Env 
fusion protein PrP
E. 
 
 
Figure  31  Schematic representation of the pFB-EASALF derived mPrP expression plasmids 
pSALF-PrP209 and pSALF-PrP111. PrP111 and PrP 209 were inserted at the N-terminal end of the MLV 
amphotropic envelope gene, which stays under control of the viral promotor (LTR). The signal sequence 
remains N-terminally to target the protein to the plasma membrane. A factor Xa cleavage site was inserted 
between the PrP and the Env genes. The MLV packaging signal was deleted previously to reveal an 
unpackagable construct. 
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The factor Xa cleavage site was included between the aMLV Env and PrP 
sequence. At this. it is possible to specifically release PrP from the surface of the 
produced viral particles. 
IV.1.1.4.2  Incorporation into MLV-derived retroparticles 
Plasmids pSALF-PrP111 and pSALF-PrP209 were cotransfected with pHit60 
(Appendix, VI.1.7) to generate MLV-derived retroparticles bearing the Env-PrP 
fusion proteins PrP
E111 and PrP
E209, respectively, on their surface. The expression 
was addressed using Western Blot analysis (Figure 32). After cotransfection of HEK-
293FT producer cells with either wild-type Env (wt aMLV Env) (68.1 kD), PrP
E209 
(92.1 kD) or the PrP
E111 fusion envelope protein (82.3 kD), cell culture 
supernatants were filtered and concentrated by ultracentrifugation through 
sucrose cushion or low-speed centrifugation and subsequently analyzed by 
western Blot. As a control the wt aMLV Env was included in the analysis 
[pHit456/pHit60] (Figure 32, lanes 1, 2).  
 
Figure  32  The envelope fusion protein PrP
E111 is expressed and incorporated into 
retroparticles. Cell culture supernatants of HEK-293FT cells cotransfected with pSALF-PrP111/pHit60 (lanes 3-
6) were separated on 10% SDS polyacrylamide gel and compared to the wild-type Env coded by pHit456 in 
cotransfection with pHit60 (lanes 1, 2). Samples were incubated with PNGaseF to remove glycosylation (lanes 
2, 5-6). The PrP
E111 samples were treated with factor Xa (lanes 4, 6). Upper panel was stained with an anti-
MLV-SU antibody; lower panel was stained with the anti-p30 serum. The amount of supernatants corresponds 
to either 3 ml for the wild-type Env (lanes 1, 2) or 7.5 ml for the PrP
E111 protein (lanes 3-6).  
PrP
E111 is incorporated into retroparticles but incorporation rate showed lower 
efficiencies when p30/Env ratios were compared. The cleavage by factor Xa 
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protease is functional but a second cleavage site might be present in the PrP
E111 
sequence, as it is indicated by a second band with lower mobility shift compared 
to single-cleaved protein. The deglycosylation of PrP
E111 works well, but Env and 
PrP-glycosylation can not be distinguished.  
The PrP
E209 was analyzed in the same way but revealed no signal upon staining 
with the MLV-SU reactive antibody. 
These results indicated successful incorporation of PrP
E111 into MLV-derived 
retroparticles. 
IV.1.1.4.3  Incorporation into HIV-derived lentiparticles 
Furthermore, the question, whether PrP
E111 can also be incorporated into HIV-
derived particles, was addressed. HIV particles are known to be pseudotyped by 
the aMLV Env, although the incorporation efficiency is lower than that of wt HIV 
Env protein (Reiser, J et al. 1996). Therefore the pSALF-PrP111 plasmid was 
cotransfected with pCMV∆R8.2 (Appendix, VI.1.7) coding for the HIV-derived 
structural proteins resulting in the production of PrP
E111-lentiparticles (Figure 33).  
There were no signals obtained in the negative control, i.e. untransfected cells 
neither when stained with the anti-MLV-SU reactive antibody, the anti-capsid 
antibodies (p24 and p30) nor with the anti-PrP6H4 antibody (Figure 33, lane 1). 
PrP
E111-retroparticles served as positive controls and resulted in the expected 
signals (Figure 33, lane 2). 
In contrast to the MLV-derived particles, PrP
E111-lentiparticles were specifically 
stained by the p24 antibody but revealed no signal when stained by anti-p30 
(Figure 33, lane 3).  
For both MLV- and HIV particles, staining against the soluble unit (SU) of the Env 
resulted in two bands (Figure 33 A , lanes 2, 3). However, only when high amounts 
were loaded on the gel, the second band appeared (compare to Figure 32, lane 3). 
As explained before (IV.1.1.4.2), due to cleavage at the factor Xa cleavage site, 
the lower one most likely represents the SU protein. The PrP
E111 protein could 
additionally be stained with the anti-PrP 6H4 antibody, although the signal 
intensity was weak (Figure 33 D). The band was present only for PrP
E111-
retroparticles and not for PrP
E111-lentiparticles, in which lower incorporation 
efficiencies might contribute. Incorporation rates for PrP
E111-lentiparticles were 
twofold decreased compared to PrP
E111-retroparticles, as it was roughly estimated 
from Western Blot analysis. 
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Figure 33  PrP
E111 protein is present in HIV-derived lentiparticles. Cell culture supernatants from 
both pSALF-PrP111/pHit60 (lane 2) and pSALF-PrP111/pCMV∆R8.2 (lane 3) cotransfection were subjected to 
Western Blot analyses on 10% SDS gels in comparison to supernatants of untransfected cells (lane 1). Samples 
were stained with anti-MLV-SU reactive antibody (A), with the monoclonal anti-p24 antibody (B), with the anti-
p30 serum (C) or with the anti-PrP 6H4 antibody (D), respectively. Loaded amounts correspond to 10 ml (A-C) 
or 15 ml (D) cell culture supernatants.  PrP
E111-lentiparticles signal intensities were compared to PrP
E111-
retroparticles by estimating peak density using Adobe Photoshop Software. 
Taken together, the PrP
E111 protein was expressed and incorporated upon 
cotransfection with MLV- and HIV-derived structural proteins to result in the 
characterized PrP
E111-retro- and lentiparticles, respectively, whereas the full 
length PrP form could not be detected. Western Blot analysis of producer cell 
supernatants indicated the incorporation of PrP
E111 into MLV and HIV, a result 
which was further addressed by electron microscopy as described in the next 
chapter. 
IV.1.1.4.4  Characterization by electron microscopy 
Characterization by electron microscopy of immunogold labelled samples was 
done to verify, that PrP
E proteins were displayed on the surface of retro- or 
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lentiparticles, respectively. Either pSALF-PrP111/pHit60- or pSALF-
PrP111/pCMV∆R8.2-cotransfected HEK-293FT cell supernatants were therefore 
stained by the anti-PrP 6H4 antibody.  
The aMLV Env-bearing retroparticles were not stained by the anti-PrP 6H4 
antibody. On the contrary, both PrP
E111-retro- and lentiparticles show PrP-specific 
staining (Figure 34 D-F). In line with the Western Blot data, for PrP
E111-
lentiparticles, much lower numbers of stained particles were found, compared to 
PrP
E111-retroparticles. 
 
This result demonstrates that PrP
E111 was effectively incorporated into retro-and 
lentiparticles. These particles are available for immunization studies possibly 
resulting in enhanced antibody titers. 
 
 
 
Figure 34  MLV- and HIV- derived particles incorporate the PrP
E111 fusion protein. Supernatants 
of cotransfected HEK-293FT producer cells were analyzed by immunogold stains using the anti-PrP 6H4 and an 
anti-mouse gold-conjugated secondary antibody. Plasmids pHit456/pHit60 (A, D), pSALF-PrP111/pHit60 (B, E) 
and pSALF-PrP111/pCMV∆R8.2 (C, F) were cotransfected to reveal MLV-derived (A, B, D, E) or HIV-derived (C, 
F) retro- or lentiparticles, respectively. Upper panels show an overview, whereas magnified particles are shown 
in the lower panels. Groups of typical retrovirus-derived particles are marked by arrowheads. Gold labelling is 
marked by arrows. 
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IV.1.2  Nucleocapsid-like particles 
An alternative approach to present oligomeric PrP
c was followed by using the 
Sendai virus nucleocapsid protein NP as scaffold. Upon expression of NP in 
eukaryotic cells, the protein self-assembles into dense RNA-protein particles 
remaining in the cytoplasm of the cell when the other viral proteins are absent. 
In this case the NP assembles around cellular RNA. The resulting particles can be 
harvested through cell lysis and subsequent purification of the particles via 
ultracentrifugation in caesium chloride gradients. The assembly of such NP 
particles has been examined in detail for the wild-type NP protein (Finch, J T and 
Gibbs, A J 1970; Lamb, R A, Mahy, B W et al. 1976) and various deletion 
mutants (Buchholz, C J, Spehner, D et al. 1993; Curran, J, Homann, H et al. 
1993). Whereas the N-terminal part of the protein is responsible for RNA binding, 
the C-terminal part is located at the particle surface, and therefore seems to be 
optimal for presentation of foreign amino acid sequences.  
To investigate the suitability of NP for PrP display, insertion of the Prnp gene at 
the C-terminal end of NP and subsequent expression analysis had to be carried 
out. Upon this, it had to be investigated, whether the newly generated fusion-
proteins maintained the ability to self-assemble around RNA molecules. 
 
IV.1.2.1.1  Construction 
The NP fusion protein expression plasmids were produced starting from plasmid 
pGem-NP (Appendix, VI.1.6). This plasmid encodes the NP protein under control 
of the T7 promotor. The PrP
111 protein had to be fused to either amino acids (aa) 
425 or 456 of NP. This was achieved by making use of the restriction sites MscI 
and  EcoRI or EcoRV and EcoRI, respectively. The resulting plasmids were 
referred to as pGem-NP425-PrP
111 and pGem-NP456-PrP
111 (Appendix, VI.7) 
corresponding to the number of NP aa present in the constructs (Figure 35).  
To further examine the influence of the addition of foreign peptides to NP at the 
C-terminus, an immunological tag, derived from the hemagglutinine A (HA) was 
fused to the original C-terminus of NP (Figure 35) resulting in the plasmid pGem-
NP523-HA (Appendix, VI.7). Thus, a possibility to insert foreign genes via XhoI 
and NdeI restriction and render the HA-tag intact at the C-terminal end is 
offered.  
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Figure  35  Schematic representation of the NP fusion protein expression plasmids. Either the 
PrP
111 coding sequence or the HA-tag gene was fused to the C-terminal part of the Sendai virus NP protein. NP 
was thereby C-terminally truncated to 425 or 456 aa or left complete (523 aa). The NP gene expression is 
controlled by the phage-derived T7 promotor. 
IV.1.2.1.2  Expression 
Expression of the NP fusion proteins was investigated using the vaccinia virus T7 
expression system (Fuerst, T R et al. 1986). HEK-293FT producer cells were at 
first infected by the recombinant vaccinia virus modified vaccinia Ankara (MVA)-
T7 providing the T7 RNA polymerase. This phage-derived polymerase is widely 
used to enable overexpression of recombinant proteins in target cells. The 
corresponding T7 promotor is highly active and results in huge amounts of 
proteins, when the polymerase, which is absent in eukaryotic cells, is provided in 
trans. After infection with MVA-T7, the producer cells were transfected with the 
target plasmids and lysed after 24 hours. For comparison, instead of utilization of 
the MVA-T7 system, cells were cotransfected by the NP fusion protein plasmids 
and a T7 polymerase-coding plasmid, namely pScT7 (Appendix
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Appendix, VI.1.6). Cell Lysates of both systems were then examined by Western 
Blot analysis (Figure 36). The molecular weights of NP fusion proteins were 
calculated as 61.3 kD (NP425-PrP
111), 64.7 kD (NP456-PrP
111) and 58.5 kD 
(NP523-HA) compared to 56.8 kD for the wt NP protein. To compare the protein 
expression levels, wt NP protein is included in the analysis.  
 
 
Figure 36  Expression of the NP fusion proteins using MVA-T7. MVA-T7-infected HEK-293FT cells 
were transfected with the pGem-NP-derived plasmids. The resulting proteins NP425-PrP
111  (A, lanes 4, 8), 
NP456-PrP
111 (A, lanes 5, 9) as well as NP523-HA (B, lanes 4, 8) were detected 24 h post transfection in cell 
lysates by either anti-NP sera (A and B, left panels), the anti-PrP 6H4 antibody (A, right panel) or the anti-HA 
tag antibody (B, right panel). The wt protein, which was included as a control, was expressed via cotransfection 
with the T7 polymerase expression plasmid pScT7 (A, lane 2) or via the MVA-T7 system (A, lanes 3, 7; B, lanes 
3, 7). As negative controls untreated HEK-293FT cell lysates (A, lanes 1, 6; B, lane 1) and untransfected, MVA-
T7 infected cell lysates (B, lane 2) were applied. 
No signal was obtained for the wild-type protein when stained by anti-PrP 6H4 or 
anti-HA tag antibodies (Figure 36).´The PrP fusion proteins NP425-PrP
111 and 
NP456-PrP
111 (Figure 36 A, lanes 4-9) were detectable by both, the anti-NP serum 
and the anti-PrP 6H4 antibody. The anti-PrP signal is present only in the PrP 
fusion proteins, demonstrating successful fusion of NP and PrP proteins as well as 
the retained antigenicity of PrP. Also NP523-HA was detected by both specific 
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antibodies, namely the anti-NP or the anti-HA antibody (Figure 36 B, lanes 4, 8). As 
expected from its molecular weight, the NP523-HA showed a reduced 
electrophoretic mobility when compared to wt NP protein.  
In summary, the expression of the different NP fusion proteins was successful in 
HEK-293FT producer cells, as detected in cell lysates 24 h post transfection. It 
remained to be detected whether these proteins retained the capability to 
assemble into nucleocapsid-like particles. 
 
IV.1.2.1.3  Assembly analysis by gradient purification 
Next, the assembly of the NP fusion proteins had to be examined. Therefore the 
cell lysates were purified via ultracentrifugation in a caesium chloride gradient. 
Due to their RNA content, nucleocapsids reveal a high density of about 1.31 
g/cm
3. CsCl density gradients were therefore the method of choice to determine 
the density of the NP-PrP fusion proteins. Whereas non-assembled proteins are 
unable to migrate into high density fractions of the gradient, assembled NP/RNA 
particles are present in the 30-40% Caesium chloride layer (Buchholz, C J, 
Spehner, D et al. 1993). The gradient was established as a step gradient 
including 40%, 30% and 20% CsCl-solution from bottom to top of the tube. After 
centrifugation, fractions were collected from the bottom of the tube and 
individually analyzed for the presence of the NP-PrP proteins via Western Blot 
analysis.  
For the wt NP protein included for comparison, the vast majority of protein 
accumulated in fractions 1-3. Only faint bands were present in the other fractions 
(Figure 37 D). For the proteins NP456-PrP
111 and NP425-PrP
111, signals were found 
in fractions number 3 and 4 corresponding to 30-40 % CsCl (Figure 37 B). 
Additionally, signals were present in the upper fractions arising from 
unassembled monomeric proteins (Figure 37 A and B, fractions 7-10). The same 
result was observed for the HA-tag fusion protein NP523-HA, for which 
assembled proteins are present in fraction 4 (Figure 37 C). 
 
This result indicated that the NP fusion proteins must have been assembled into 
dense particles. However, the assembly efficiency was much reduced compared 
to the wt protein. Overall, only about 5-10% of NP4456-PrP
111, 10% of NP523-
HA and 20-30% of NP425-PrP
111 appeared in high density fractions. 
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Thus it remained to be further analyzed, to what extend the NP/RNA 
nucleocapsid-like particles were build. Therefore the proteins were subsequently 
examined by electron microscopy. 
 
 
Figure 37  NP fusion proteins were present in high density fractions. The NP fusion proteins were 
subjected to ultracentrifugation in a CsCl step gradient ranging from 20-40%. Low fraction numbers contain 
highest density. NP456-PrP
111 (A) and NP425-PrP
111 (B) as well as the wt NP (D) were stained by the anti-NP 
serum. NP523-HA (C) was stained by ant-HA. CL cell lysate before ultracentrifugation. 
IV.1.2.1.4  Detection of nucleocapsid-like particles by electron microscopy 
To further analyze the assembly, the fusion proteins were subjected to electron 
microscopy immunogold labellingFigure 38. For this purpose, cell lysates were 
utilized, as CsCl present in the purified gradient samples led to reduced detection 
efficiency.  
Nucleocapsid-like particles could be visualized for the wt NP samples (Figure 38 A), 
which was stained by anti-NP serum. On the contrary, staining of NP425-PrP
111 
with the anti-PrP 6H4 antibody was negative (Figure 38 B). For both PrP
111 fusion 
proteins, only low amounts of nucleocapsid-like particles were detected in 
comparison to wt samples. Only some multimeric complexes were observed, 
which could not specifically be stained by the anti-NP (not shown) or the anti-PrP 
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6H4 antibody. The same was true for NP523-HA, which also revealed low 
amounts of nucleocapsid-like particles, only. Nevertheless, some huge complexes 
were found in the latter case, which could be slightly marked by the anti-HA tag 
antibody (Figure 38 C). 
 
 
 
Figure  38  Formation of nucleocapsid-like particles was affected by the insertion of foreign 
peptides. The assembly of NP fusion proteins was addressed by electron microscopy immunogold labelling 
using different specific antibodies. The wt NP was stained with the NP-specific serum (A), NP425-PrP
111 was 
stained using anti-PrP 6H4 antibody (B) and NP523-HA was stained with the anti-HA-tag antibody (C). 
Nucleocapsid-like particles are marked by arrowheads; gold-labelling is marked by arrows. Bars represent 100 
nm.  
 
This result showed that the insertion of foreign polypeptides and proteins 
impaired the formation of nucleocapsid-like particles. The suitability of this 
approach for the generation of PrP particle vaccines therefore remained 
questionable. 
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IV.2  Display of prions 
The second part of this thesis attempted the display of the pathogenic isoform of 
PrP (PrP
Sc or prion) on the surface of retroparticles. This goal was addressed on 
one hand via conversion of the PrP
c, displayed on retroparticles as described in 
chapter IV.1.1.1. On the other hand the production of replication-competent MLV 
variants in scrapie-infected cells was pursued. 
IV.2.1  Conversion of PrP
D-retroparticles 
The conversion was examined for the PrP
D142-retroparticles (IV.1.1.1). These 
particles offer the opportunity to work with high amounts of PrP
c. Secondly, the 
PrP protein variant bearing 142 aa has previously been shown to be sufficient to 
propagate prion infection, while this was not the case for a truncated form of PrP 
containing only 111 aa (Flechsig, E et al. 2000).  
In vitro conversion assays have been carried out extensively as reviewed in 
(Caughey, B 2003). Upon incubation with PrP
Sc or other types of proteinase K 
(PK) resistant PrP (PrP-res), the PK-sensitive PrP
c tends to bind to PrP-res and 
then slowly converts to a protease-resistant state like that of the original PrP-res. 
This reaction has been shown to occur under a variety of conditions. The 
simplest, most biochemically defined reactions contain mixtures of largely 
purified PrP
c and PrP-res preparations and can be stimulated by chaotropes, 
detergents and/or chaperone proteins. In an effort to amplify PrP-res 
substantially in an in vitro conversion reaction, the protein misfolding cyclic 
amplification (PMCA) system has been developed (Saborio, G P et al. 2001). In 
this system, detergent extracts of TSE-infected brain homogenate are mixed with 
vast excesses of similar extracts of PrP
c-containing normal brain tissue and 
subjected to repeated cycles of sonication and incubation. More than 30-fold 
increases in the amount of PrP-res over that provided in the infected brain 
extract were reported. 
To achieve the conversion of the PrP
D142-retroparticles, the particles were 
incubated with the scrapie-infectious agent in form of brain homogenates from 
scrapie-infected mice (Chandler strain). Particles were incubated overnight at 
physiological conditions. This setting is achieved by addition of brain 
homogenates of either infected mouse brain (Ch) to the particles or by addition 
of brain homogenate from an untreated mouse (HG) as a control. The amounts 
of brain homogenates were determined by Bradford assay (Biorad). For the 
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detection of coverted PrP in the retroparticles, PK digestion assays were 
performed. PK cleaves the pathogenic form of PrP with lower kinetics than the 
cellular PrP. An important prerequisite for this assay is to apply absolute similar 
amounts of total protein present in the infectious brain homogenates compared 
to the solely PrP
c-bearing control homogenates. Only when overall amounts of 
protein are identical, the kinetic of PK is exclusively dependent on the two 
different PrP forms.  
The samples were digested with different concentrations of PK ranging from 1 to 
5 µg/ml and then subjected to Western Blot analysis. 
 
Figure 39  Western Blot analysisof conversion assay. PrP
D142–retroparticles particles were incubated 
with either infected brain homogenates (Ch) (lanes 1-4) to convert PrP content into PrP
Sc or uninfected brain 
homogenates (HG) as a control (lanes 6-9). An additional control, in which Ch was added but particles were 
absent was included (lane 5). Incubation with 1 µg/ml PK (lanes 2, 7), 2 µg/ml PK (lanes 3, 8), 5 µg/ml PK 
(lanes 4, 9) or left untreated (lanes 1, 5 and 6) was carried out. Samples were stained by anti-PrP 6H4 (A), 
anti-HA (B), anti-p30 MLV capsid (C) and anti-β-actin (D).  
The differently incubated particles showed distinct titration behaviours. 
Unexpectedly, the PrP
D142-retroparticle sample containing HG was cleaved with a 
lower kinetic (Figure 39). Therefore staining against the viral capsid was included, 
to verify that similar amounts of particles were present. This was true for both 
samples as shown by the presence of equal amounts of the viral capsid protein 
p30 in the absence of PK (Figure 39 C, compare lanes 1 and 6). Nevertheless, again 
about half the amounts of PK were sufficient to digest p30 for the HG 
homogenate than for the Ch homogenate (Figure 39 C, lanes 1-4 to lanes 6-9). This 
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different titration behaviour was unexpected for p30, which was thought to show 
equal titration in both samples, when similar amounts of protein are present. 
Thus, this finding might be explained by different overall protein amounts and 
led to the assumption that the detection by the Bradford assay revealing 10 
µg/ml for both Ch and HG was inappropriate. Therefore, the amounts of brain 
homogenate proteins were further analyzed by Western Blot analysis using an 
anti-β-actin antibody (Figure 39 D). The brain homogenate of untreated mouse HG 
could be stained by anti-β-actin antibody, whereas this band was absent for 
scrapie-infected mouse brain Ch (Figure 39 D). Thus, the staining revealed that 
more actin was present in HG homogenate.  
As a consequence, the amounts of both homogenates, had to be reevaluated 
more exactly by further experiments. A Western Blot analysis using anti-β-actin 
was carried out for various volumes of the homogenate (Figure 40). Densitometric 
analysis revealed that roughly equal quantities of β-actin were present in 5 µl 
(lane 4, 6401 pixel) of Ch and 1.5 µl of HG (lane 7, 6344 pixel), indicating a 
more than twofold difference in the total protein amounts. 
 
Figure 40  Detection  of  β-actin in the brain homogenates. Chandler-infected mouse brain 
homogenate and uninfected mouse brain homogenate was stained by anti-β-actin antibody. Different volumes 
were loaded ranging from 2-5 µl Ch and 0.5 to 2.5 µl HG. Densities were compared using black tone pixel 
values (Adobe, Photoshop Software). 
 
However, it has to be considered that in Chandler infected mouse brain, the 
amount of PrP in the total protein content is higher than in HG, because PrP
Sc 
accumulates in these brains (Brandner, S 2003). Therefore, the determination of 
β-actin might be inappropriate, as PrP
Sc accumulation then influences the 
percentage of actin in the total protein amount. 
Thus, the highly sensitive BCA protein assay (Pierce) was carried out for protein 
quantification. 
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Figure 41  Quantification of total protein amounts in Ch and HG homogenates. Chandler-infected 
mouse brain (Ch) and uninfected brain homogenate (HG) were measured by the BCA-assay (Pierce) in three 
different dilutions (1:20, 1:40 and 1:60). BSA-solution (0.025-2µg/ml) was included as a standard. Extinction 
at 570 nm was measured. Mean values of total nine measurements and the corresponding error bars were 
determined.  
The BCA assay revealed almost equal amounts of total protein present in both 
homogenates (Figure 41). There was no indication for higher protein levels in the 
HG homogenate. If at all, a 1.2fold higher amount in Ch was observed. This 
result was thus in line with previous the Bradford assay measurements.  
Thus, these findings indicate that the conversion of PrP
D142-retroparticles did not 
result in altered PK digestion behaviour of PrP in the samples under the chosen 
conditions. Since in vitro conversions have been carried out under various 
conditions, as e.g. low pH and addition of detergents, the conversion process 
might be further adapted. Also, prolonging the incubation times might help to 
overcome a potentially slower kinetic for conversion of retroparticle-displayed 
PrP.  
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IV.2.2  Retroviral infection of scrapie-infected cells 
Alternatively to the in vitro conversion of PrP
c displayed on the surface of 
retroparticles, the production of virus particles in scrapie-infected neuroblastoma 
cells (Race, R E et al. 1987) was considered. Virus particles displaying PrP
c and 
being released from such cells could present PrP
Sc either because of in vivo 
conversion of PrP
c or because of the incorporation of PrP
Sc, present on the cell 
surface, into their envelopes (Figure 42).  
 
Figure 42  Schematic representation of the infection of scrapie-infected neuroblastoma cells by 
PrPMo.  The replication competent PrPMo
111 is utilized to infect scrapie-infected PK1 cells. Virus particles 
produced in this cell line might bear the pathogenig form of PrP on the surface either as incorporated PrP
Sc or as 
PrP-Env fusion protein. PrP
c is indicated by green squares. PrP
Sc is represented by red triangles. The ecotropic 
Env protein is represented as blue trimers. 
 
For the infection of scrapie-infected cells an ecotropic Moloney murine leukaemia 
virus variant (eMLV) had to be used. The ecotropic variant infects mouse cells, 
only (Kozak, C A et al. 1990). Due to lack of its receptor on the cell surface eMLV 
can not enter human cells. The ecotropic variants were chosen because of safety 
aspects of this type of virus. Transfer of this virus to the human population was 
therefore excluded. 
The Prnp gene, or parts thereof, was inserted into the eMLV. For this, the 
envelope gene, which was proven successful in non-replicative retroparticle 
display (IV.1.1.4), was chosen. The insertion of Prnp was implemented in order 
to incorporate PrP into the newly synthesized viruses. Upon replication of such 
viruses in scrapie-infected cells, the PrP
c fused to viral Env would eventually be 
converted into the pathogenic form (Figure 42). At least an equilibrium state of the 
two forms of PrP can be expected for particles which are generated in the 
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scrapie-infected cell line. In this way, particles containing PrP
Sc on top of the viral 
Env would be harvested from retrovirus- and scrapie-infected cells. 
 
IV.2.2.1.1  Construction 
As it was the case for PrP
E fusion proteins in the pSALF backbone (IV.1.1.4), the 
PrP was inserted into the viral Env gene between the virally derived signal 
peptide and the env coding region (Figure 43). For this purpose, PrP coding 
sequences for PrP
209 or PrP
111 were inserted using SfiI- and NotI-containing 
oligonucleotides (Table 3) as described previously (IV.1.1.4). As parental plasmid 
pEMo (Appendix, VI.1.9) was used. The generated plasmids were named 
pPrPMo209 and pPrPMo111, respectively. The corresponding viruses are referred 
to as PrPMo
209 and PrPMo
111. 
 
 
Figure 43   Schematic  representation of the viral expression plasmids. The wt eMLV bearing 
expression plasmid pNCA is shown in the upper panel.  The PrP-bearing pPrPMo plasmids are seen in the lower 
panel. Both constructs consist of the full viral genome. The PrP coding sequences are inserted into the viral env 
gene. A factor Xa cleavage site is included in the construct. 
 
IV.2.2.1.2  Generation of PrPMo virus stocks 
For production of the virus stocks, HEK-293FT producer cells were transfected 
with the generated plasmids pPrPMo209 and pPrPMo111 as well as with the wild-
type eMLV coding plasmid pNCA (VI.1.8). The virus-containing cell culture 
supernatants were harvested and analysed by Western Blot for the presence of 
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the viral Env proteins. The molecular weight of PrPMo
209 Env was 93.7 kD 
compared to 83.9 kD of PrPMo
111 Env and 74.1 kD of wt eEnv. 
 
 
Figure 44  Western Blot analysis of PrPMo virus stocks. HEK-293FT producer cells were transfected 
with the virus-coding plasmid pNCA (lane 1, 7), PrPMo209 (lane 2) or pPrPMo111 (lanes 3-6, 8), respectively. 
Supernatants were harvested 2 days post transfection, filtered (0.45 µm filter) and subjected to centrifugation 
at 13.000 rpm (Eppifuge, Haraeus) for two hours. Loaded volumes corresponded to 0.75 ml (pNCA, lane 1, 7), 
6 ml pPrPMo209 (lane 2) and 1 ml pPrPMo111 (lanes 3-6, 8). PrPMo
111 Env was subjected to factor Xa cleavage 
(lanes 4, 6) and PNGaseF treatment (lanes 5, 6). Blots were stained by either anti-MLV-SU reactive serum (left 
panel) or anti-PrP6H4 (right panel). 
Virus particles harvested from pNCA-transfected cells were included as a control 
and contained wt eMLV Env protein, as shown by staining with the anti-MLV-SU 
reacting antibody (Figure 44, lane 1). No signal was detected, when these particles 
were stained by anti-PrP 6H4. PrPMo
111 Env migrated at the expected molecular 
weight. This protein was either detected by the anti-MLV-SU reacting serum or 
by the anti-PrP 6H4 antibody (Figure 44, lanes 3, 8). A signal for PrPMo
209 Env 
could not be detected, although particles were pelleted from about six times 
more cell culture supernatants (Figure 44, lane 2). 
Upon treatment with factor Xa, PrPMo
111 Env was cleaved into its PrP and Env 
part, as confirmed by the appearance of the wt Env band (Figure 44, lane 4). 
Incubation with a Peptide:N-GlycosidaseF (PNGaseF) led to deglycosylation of 
PrPMo
111 Env (Figure 44, lane 5). When both enzymes were added, cleavage and 
deglycosylation occurred (Figure 44, lane 6). 
 
Thus, this result demonstrated successful production of PrPMo
111 in transfected 
HEK-293FT producer cells which was not the case for PrPMo
209. Next, the titration 
of PrPMo
111 stocks was carried out. 
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IV.2.2.1.3  Titration of PrPMo 
The produced virus stocks were titrated on NIH-3T3 cells using the immune 
peroxidase assay (IPA) as described in detail in chapter III.3.4. The 
determination resulted in different titers of the three virus stocks (Table 6). 
Table 6     Titration of virus stocks PrPMo 
virus  wt eMLV  PrPMo111 
Positive cells  141  263 
positive cells per well  423  789 
dilution factor  2 × 10
4 2 × 10
2
titer  8.4 × 10
6 2.3 × 10
5
 
The resulting volume used for subsequent experiments varied between 108 µl for 
PrPMo
111 and 298 µl for 100fold prediluted wt eMLV to result in a moi of 0.1. In 
case of PrPMo
209 revealing no positive infection event even in lowest dilution, the 
highest possible volume was added to the cells (500 µl). 
IV.2.2.1.4  Expression of PrPMo Env post infection  
Furthermore the expression of the PrPMo
111 Env was examined post infection of 
NIH-3T3 cells carried out by immune fluorescence analysis (Figure 45). The 
analysis was done by staining with the specific anti-PrP 6H4 antibody and a 
second antibody labelled with FITC, which was directed against murine IgGs. 
 
Figure 45  Cell surface expression of the modified viral envelope protein on NIH-3T3 cells. NIH-
3T3 cells were infected with the modified ecotropic MLV PrPMo111 (A, C) at a moi of 0.1. Cells were analyzed 
48h after infection and stained by the anti-PrP 6H4 and a FITC-labelled anti-mouse antibody (A) or by the 
second antibody, only (C). Uninfected cells (B) were stained in the same way described for (A). 
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NIH-3T3 cells have a low background level of endogenously expressed PrP
c as 
confirmed by staining of the cells by the ant-PrP 6H4 antibody i(Figure 45 B). 
Background binding of the secondary antibody, was rather low (Figure 45 C). 
PrPMo
111 Env was detectable in infected NIH-3T3 cells at a moi of 0.1 using anti-
PrP 6H4 antibody (Figure 45 A). Compared to endogenous PrP
c level the signal was 
slightly increased when cells were infected by PrPMo
111 (compare Figure 45 A and 
B).  
This result indicated the presence of PrPMo
111 Env also in virally infected NIH-3T3 
cells. 
 
IV.2.2.1.5  Morphology analysis by electron microscopy 
To exclude alterations in the morphology of PrPMo
111 compared to eMLV electron 
microscopy analysis including immunogold labelling was performed. Transiently 
transfected HEK-293FT producer cells were therefore examined using ultrathin 
sections to detect C-type MLV particles. The cell culture supernatants derived 
from these cells were examined via negative contrast. Subsequently they were 
stained with the anti-PrP 6H4 antibody and a secondary, gold-labelled antibody.  
Virus particles were found in different budding states for wt eMLV (Figure 46 A, B). 
Furthermore, supernatants contained C-type retrovirus particles in case of wt 
eMLV (Figure 46 C), which were not stained by the anti-PrP 6H4 antibody (Figure 46 
G). For PrPMo
111, budding particles were also found in cell sections to similar 
extent (Figure 46 D, E) and the supernatants of these producer cells also revealed 
C-type MLV particles. The latter contained PrP on their surface as shown by anti-
PrP 6H4 specific stain (Figure 46 F). 
Thus, electron microscopy experiments confirmed the successful production of 
PrPMo
111 in HEK-293FT producer cells. The virus variant presents PrP on the viral 
surface without being altered in morphology and shape. Based on this result the 
question, whether PrPMo
111 can replicate to same extent as wt eMLV, was 
adressed next. 
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Figure  46  Electron microscopic analysis of PrPMo
111. Cell sections of transfected HEK-293FT are 
shown for both wt eMLV (A, B) and PrPMo
111 (D, E). Cell culture supernatants are shown for wt eMLV (C, G) and 
PrPMo111 (F, H). Samples were labelled by anti-PrP 6H4 and immunogold-labelled secondary antibody. Typical 
C-type retroviruses in budding states are indicates by open arrowheads. Virus particles are indicated by filled 
arrowheads. Gold particles are indicated by arrows.  
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IV.2.2.1.6  Replication kinetic of PrPMo 
PrPMo
111 was next tested for its replication kinetics in cell culture. Thus, the 
kinetic experiment was carried out on NIH-3T3 cells at an moi of 0.1 for both, 
PrPMo
111 and wt eMLV. PrPMo
209 was included in the kinetic study, although due 
to results from the titration experiment (IV.2.2.1.3) the highest possible volume 
of this variant was added (500 µl) RT activity (III.4.2) was monitored on day 1, 
2, 4, 5, 7 and 8 post infection. Upon this, values were determined in triplica for 
each sample. Simultaneously, supernatants were subjected to RNA preparation 
followed by reverse transcription with the EMoseq primer (Table 3). Afterwards, 
cDNA was analyzed by PCR using the CB6/EMoSeq2 primer pair (Table 3),  
ensuring that the Prnp gene insertions had not been deleted during viral 
replication. Expected molecular weights of the PCR fragments were 743 bp of 
PrPMo
209 and 446 bp of PrPMo
111 compared to 98 bp of wt eMLV. 
 
 
Figure  47    PrPMo growth kinetics on murine NIH-3T3. Titrated virus stocks PrPMo
111 (orange 
triangles), PrPMo
209 (blue squares) and wt eMLV (red diamonds) were used for infection of NIH-3T3 cells (A).  
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Supernatants were tested 1, 2, 4, 5, 7 and 8 days post infection in RT assay to quantify virus. At the same 
time, samples were subjected to RNA isolation (B) and subsequent reverse transcription/PCR assay using CB6 
and EMoSeq2 primers. Non reverse-transcribed RNA samples were included as negative controls (-), pPrPMo209 
plasmid (pl) served as positive control. dpi days post infection. 
The replication kinetic of PrPMo
209 and PrPMo
111 showed distinct results. Whereas 
PrPMo
111 replicated similar to the wt eMLV, PrPMo
209 did not replicate. Both 
PrPMo
111 and wt eMLV reached high particle numbers on day two post infection 
and retained constant levels during one week as monitored for 8 days post 
infection. PrPMo
209 virus was not detected in NIH-3T3 cell culture supernatants. 
Amplification of the corresponding viral env genes showed the expected 
electrophoretic mobility shifts for PrPMo
111 and wt eMLV for all time points. In 
contrast, PrPMo
209 signals were lost on day two post infection.  
These findings indicated that PrPMo
111 was able to replicate in NIH-3T3 cells 
roughly to the same extend as wt eMLV. However, PrPMo
209 was not able to 
infect and replicate to NIH-3T3 cells. Next it remained to be determined how 
stable PrPMo
111 was upon passaging the virus in cell culture. This question was 
addressed in the following chapter. 
 
IV.2.2.1.7  Genetic stability of PrPMo
111 
The genetic stability of PrPMo
111 was addressed via passaging of the virus on 
NIH-3T3 cells (Figure 48). For this purpose, cells were infected with a moi of 0.01 
and passaged for 7 days post infection. Supernatants were harvested, 100fold 
diluted and transferred to naïve NIH-3T3 cells in. Six rounds of passaging were 
implemented and analysis was done by IPA on day 3 and viral RNA isolation on 
day 6 post infection of each cycle. Both analysis were done in triplica. For RNA 
isolation and subsequent PCR analysis the expected molecular weights were 446 
bp for PrPMo
111 and 98 bp for wt eMLV. 
For all six passages approximately the same values of virus-infected cells were 
obtained. Percentage of red stained cells thereby varied from 14-18 % (Figure 48 
A-F). 
RNA preparations obtained from passage one were free of a PCR signal ensuring 
lack of plasmid DNA in the virus stock. The PCR analysis performed on plasmid 
DNA from either pPrPMo111 or pNCA revealed the expected mobility shifts for 
the amplified sequences.  
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Signals of all passages of PrPMo
111 showed intact env sequences including the 
PrP
111 insertion (Figure 48 G, lanes 5-22) , which was further verified by sequencing 
analysis of the amplified sequences (not shown). 
 
 
 
Figure 48  Genetic stability of PrPMo
111. The PrPMo
111 virus stock was used for infection of NIH-3T3 
cells at a moi of 0.01. Cells were cultivated for 6 days; supernatants were then diluted 100fold and were 
subsequently used for the next infection cycle. Immune peroxidase assays were carried out at day 3 post 
infection of each cycle for passages 1-6 (A-F). Percentage of infected cells is shown as values in the images. 
Viral supernatants were subjected to RNA preparation at day six post infection of each cycle and subsequent 
reverse transcription followed by PCR analysis with CB6 and EMoSeq2 primer pair (G) was carried out. PCR 
control without template (lane 1) and non-reverse-transcribed RNA sample from passage 1 (lane 2) were 
included during PCR reaction. Plasmids pNCA coding wt eMLV (lane 3) and pPrPMo111 (lane 4) served as 
positive controls. Each passage was carried out in triplica. Passage 1 (lanes 5-6), passage 2 (lanes 8-10), 
passage 3 (lanes 11-13), passage 4 (lanes 14-16), passage 5 (lanes 17-19), passage 6 (lanes 20-22).  
Thus, PrPMo
111 remained genetically stable during six passages on NIH-3T3 cells, 
no deletions occured upon replication in these cells throughout the experiment. 
IV.2.2.1.8  Host range of PrPMo
111 
Insertions of foreign proteins have previously been shown to alter the host range 
of MLV (Cosset, F L, Morling, F J et al. 1995). To exclude, that the Prnp gene 
  105ResultsT 
influences the host range of PrPMo
111, different target cells were tested for virus 
integration (Figure 49). After infection with a moi of 0.5, the murine cell lines N2a 
and NIH-3T3 as well as the human cell lines HEK-293FT and A3.01 were 
examined by PCR analysis using genomic DNA one day post infection.  
The cell line A3.01 was especially chosen as a T cell line expressing endogenous 
human PrP, in contrast to HEK-293FT, which show very low levels of cellular PrP 
expression. Therewith, the influence of the expression of PrP
c on the surface of 
target cells was considered. 
Besides PrPMo
111 and the wt eMLV infection, also a VSV-G pseudotyped PrPMo
111 
was included in the experiment. This virus was produced by cotransfection of the 
VSV-G encoding plasmid pM.DG (Appendix, VI.1.10) with pPrPMo111 resulting in 
production of the virus stock PrPMo
111(VSV-G). The stock was titrated on NIH-
3T3 cells revealing a titer of 1.3 × 10
5 IU/ml. VSV-G generally enables cell entry 
into all tested cells and served as a positive control during the experiment. 
A3.01 cells were further subjected to analysis of genomic DNA and cellular RNA 
on day 2, 4, 6 and 8 post infection to follow-up viral transcription. 
The tested cell lines were free of endogenous signals upon analysis of genomic 
DNA by PCR with the primer pair CB6/EMoSeq2 amplifying the env gene of the 
eMLV (Figure 49). The PCR analysis was expected to yield a 446 bp signal for 
PrPMo
111 as it was observed for the plasmid control (Figure 49 B, upper left panel, 
lane 2) and a 98 bp signal for wt eMLV. The wt eMLV was restricted to mouse cell 
lines and showed no integration into human cells when genomic DNA was 
examined. Genomic DNA of NIH-3T3 cells showed integration of PrPMo
111 and 
PrPMo
111(VSV-G) viruses. The same result was observed for N2a cells; although 
the efficiency of infection was reduced compared to NIH-3T3 cells (Figure 49 A, left 
panel, lanes 3 and 4, respectively). In contrast to that the human cell lines HEK-
293FT and A3.01 showed integration of PrPMo
111(VSV-G), only. A faint band was 
also observed for PrPMo
111 on A3.01 genomic DNA (Figure 49 A, right panel).  
This finding indicated, that PrPMo
111(VSV-G) and to a minor extend PrPMo
111 
were present in A3.01 cells one day post infection, which was not observed for 
wt eMLV. However, further analysis showed, that these signals from genomic 
DNA disappeared from day 2 to day 8 post infection, although the loading control 
of human glycerolaldehydphosphat dehydrogenase (hGAPDH) confirmed that 
equal amounts of DNA had been used in the samples (Figure 49, upper left panel, 
lanes 3-6).  
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Figure 49  Analysis of the tropism of PrPMo
111. A) Cell lines NIH-3T3, N2a, HEK-293FT and A3.01 
were infected by either wt eMLV (lane 2), PrPMo111 (lane 3), PrPMo
111(VSV-G) (lane 4) or left uninfected (lane 
1). PCR analysis was carried out using CB6/EMoSeq2 primer pair detecting viral env genes on genomic DNA 
prepared on day one post infection. B) PrPMo
111-infected cell line A3.01 was analyzed on day 2, 4, 6 and 8 post 
infection using either genomic DNA (left panels, lanes 3-6) or reverse transcribed cellular RNA (right panel, 
lanes 4-7). As a comparison wt eMLV-infected genomic DNA (left panels, lanes 7, 8) or RNA (right panel, lanes 
8, 9) of A3.01 cells was analyzed on day 2 and 4 post-infection. PCR-samples without template (lane 1, each 
panel), pPrPMo111 plasmid (upper left panel, lane 2), DNA from uninfected A3.01 (lower left panel, lane 2) and 
non-reverse transcribed RNA of wt eMLV (right panel, lane 2) or PrPMo111 (right panel, lane 3) served as 
controls. PCR was carried out using CB6/EMoSeq2 primer pair amplifying the viral env gene (upper panels) or 
hGAPDHforw/rev primer pair detecting the human glycerolealdehydphosphat dehydrogenase (lower panel) as 
loading control. 
In addition to the analysis of genomic DNA, also RNA was isolated from human 
A3.01 cells. Upon this, RNA isolations of wt eMLV-infected cells showed the 
corresponding env gene signal, when non-reverse transcribed RNA was loaded 
(Figure 49 B, right panel lane 2) indicating that the RNA preparation was not 
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completely free of DNA. Subsequently, reverse transcribed samples showed 
signals for wt eMLV env as well (Figure 49 B, right panel lane 8). This finding led to 
the assumption that low levels of pNCA wt eMLV plasmid, present in virus stocks, 
possibly entered the cells causing background signals of RNA isolates. 
Nevertheless, this was not the case for PrPMo
111 virus stocks (Figure 49 B, right 
panel lane 3).  In this case transcribed RNA was detected in the cells on day 2 
post infection, only (Figure 49 B, right panel, lanes 4-7). 
 
Taken together, the results suggested, that PrPMo
111 did not stably integrate into 
A3.01 cells. The insertion of the Prnp gene into eMLV thus did not extend the 
tropism of this virus variant to human cells.  
 
IV.2.2.1.9  Infection of scrapie-infected PK1 cells 
The scrapie-infected cell line PK1 was infected by either the wt eMLV or PrPMo
111. 
To determine whether these two viruses can enter PK1 cells, genomic DNA and 
cellular RNA were isolated one day after infection and subsequently analyzed by 
PCR with the primer pair CB6/EMoSeq2. As a prerequisite for further infection 
analysis the RT activity of the PK1 cell line in comparison to N2a cells was 
monitored for 8 days to reveal the presence of endogenous MLV. The RT values 
were determined in triplica.  
For PK1 infection, different moi including 2, 4, 8, 10 and 20 for wt virus and 2, 4, 
10 for PrPMo
111 were chosen. The infected cells were cultivated for 9 days and 
viral production was followed by RT activity assay in triplica for each value. 
For wt eMLV at an moi of 20, cells were (after one freeze and thaw event) 
recultivated and monitored for additional 20 days.  
Analysis of DNA revealed signals for both wt eMLV and PrPMo
111 in PK1 cells, 
whereas no endogenous signal was present (Figure 50 A). Also in isolated RNA, 
presence of PrPMo
111-derived RNA was detected (Figure 50 A). PK1 cells lack 
endogenous MLV in contrast to N2a cells, as shown via RT activity assay (Figure 50 
B). The N2a cell line showed constantly low levels of MLV particles present in 
supernatants about 20 mU/ml. This RT activity number corresponds to 6 × 10
7 
virus particles using the equation nCP = 3 × 10
9 [p/units] × RT-value [units] 
(Pyra, H, Boni, J et al. 1994). 
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Figure 50  Infection of PK1 cells with wt eMLV and PrPMo
111. Scrapie-infected PK1 cells were infected 
with wt eMLV or PrPMo
111. A) PCR analysis using CB6/EMoSeq2 was carried out on genomic DNA and cellular 
RNA isolated one day post infection (moi of 0.4). c uninfected cells wt eMLV PrP PrPMo111 B) RT activity test 
of either uninfected N2a or PK1 cells C) RT activity test of PrPMo
111 or wt eMLV infected PK1 cells using different 
moi (2, 4, 8, 10, 20). D) RT activity test of recultivated wt eMLV-infected PK1 cells (moi 20). 
The infection of PK1 cells with PrPMo
111 did not lead to production of detectable 
titers independent from the chosen moi (Figure 50 C, orange lines). In contrast to 
that, infection with wt eMLV resulted in low level particle production. The amount 
of produced particles correlated well with the corresponding moi (Figure 50 B, red 
lines). Further analysis of the infected PK1 cells (moi 20) showed that the 
numbers remained at a low level. Released RT values did not exceed 20 mU/ml 
and stayed constant for over 20 days (Figure 50 D). As for N2a cells, the particle 
numbers produced from infected PK1 cells mounted up to 6 × 10
7.  
Taken together, it was not possible to infect PK1 cells with PrPMo
111, although the 
infection with wt eMLV at high mois resulted in low titer production of virus in 
PK1 cells. Nevertheless, the amount was too low to subsequently analyze the 
particles for PrP incorporation. 
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V  Discussion 
Basically, this thesis has provided insights into the incorporation of the prion 
protein (PrP) into retroparticles and the connection between prions and 
retroviruses. A novel vaccine candidate against prion disease has been developed 
and implications on further improvement are being made as it will be discussed 
in the last part of this chapter. 
V.1  Incorporation into retroviral particles 
Retroviral particles were selected as display vehicles based on their known ability 
to accommodate foreign transmembrane proteins in their envelope membrane. 
An important prerequisite for incorporation is an efficient cell surface expression 
thus increasing the likelihood of foreign transmembrane proteins to be present at 
sites of viral budding.  
A system, previously used for cell surface targeting of proteins, consisting of a 
signal peptide derived from the κ light chain and the platelet derived growth 
factor receptor (PDGFR) transmembrane domain (Chesnut, J D, Baytan, A R et 
al. 1996; Douglas, J T, Miller, C R et al. 1999) was used. This approach resulted 
in efficient cell surface expression of the epidermal growth factor receptor (EGF) 
molecule (Merten and Buchholz, unpublished) as well as of the C-terminal prion 
protein (PrP) domains (PrP
111 consisting of aa 121-231 and PrP
142, aa 90-231), 
and consequently in highly efficient particle incorporation.  
The incorporation of cellular proteins into retroviruses has previously been shown 
for human immunodeficiency virus (HIV) and murine leukemia virus (MLV). It 
was demonstrated that budding by the HIV-derived Gag protein proceeds without 
significant alteration of the original host protein composition at the cell 
membrane (Hammarstedt, M and Garoff, H 2004). Upon this, the observation, 
that the bulk of the host proteins, e.g. actin and clathrin, were passively included 
into the virus-like
 Gag particles was made. This result suggested that budding by 
HIV Gag
  proceeds without significant alteration of the original host
  protein 
composition at the cell membrane. Nevertheless, some
  proteins were 
concentrated in the particles, and a few were
  excluded (the latter were not 
further identified). The concentrated proteins included cyclophilin A (a peptidyl-
prolyl cis-trans
 isomerase, shown to be required for efficient HIV-1 infection) and
 
Tsg-101 (a host protein required for HIV-1 budding, in its absence HIV is 
arrested at a late stage of its budding process). These were recruited to the 
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plasma membrane by HIV Gag.
  The membrane-bound cyclophilin A was 
concentrated into particles
  as efficiently as Gag itself, whereas Tsg-101 was 
concentrated
 more efficiently. The latter finding is consistent with a role
 for Tsg-
101 in Gag particle release (Hammarstedt, M and Garoff, H 2004).  
Also for MLV it was found that most plasma membrane proteins become 
incorporated into the retrovirus envelope without significant sorting of host 
proteins (Hammarstedt, M, Wallengren, K et al. 2000). Interestingly, it was 
furthermore demonstrated that interactions between virion-anchored host 
molecules and their cognate ligands take place. Such an enhancement of the 
viral attachment process was found to result in an increase of infectivity of HIV-
1. The incorporation of e.g. CD28 and the acquisition of this specific host surface 
glycoprotein e.g. modulates the virus life cycle (Giguere, J F et al. 2002).  
The incorporation of the retroviral Env protein is, in contrast to passively included 
plasma membrane proteins, a more specific process. At this, the interaction with 
the retroviral matrix protein MA seems to play a role (Yu, X et al. 1992). For γ-
type retroviral Env proteins, an approach using directed evolution implies a role 
of the so-called R peptide. The corresponding R-peptide cleavage site is 
processed by the viral protease and seems to be important for the Env 
incorporation and pseudotyping mechanism (Merten, C A et al. 2005).  
Thus, the incorporation of PrP
c displayed on either transmembrane domains or on 
viral Env proteins may also be influenced by such regimens. Similarly to the 
above mentioned inclusion of cellular proteins, the incorporation of PrP
D111 and 
PrP
D142 into retroviral particles most likely reflected the composition of the 
producer cell membranes. In comparison to that, the incorporation of the PrP
c-
carrying Env protein (PrP
E111) into particles was found to be substantially lower. 
Assuming equal well detection with the anti-PrP 6H4 antibody, incorporation 
rates of of PrP
E111 were generally lower than those of PrP
D111 (Figure 51). However, 
when expressed in context of the replication competent ecotropic MLV (eMLV), 
PrP Env proteins where more efficiently incorporated, suggesting that the Env 
protein of ecotropic MLV is more suitable for PrP display than that of amphotropic 
MLV. Furthermore, incorporation into HIV-derived VLPs with both, PrP
E111 or 
PrP
D111 was about twofold less efficient than for the corresponding MLV-derived 
VLPs. 
The incorporation values in percent were roughly calculated from anti-PrP signals 
in separate Western Blot analyses.  
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Figure 51  Comparison of the generated particles. Display- and Env-based particles are shown from 
left to right according to their PrP-incorporation capacity. Incorporation rate was roughly calculated from PrP
c 
signal in Western Blot analysis. Upon this, the amount of particles present was not taken into account and 
would eventually redirect the resulting efficiencies. However, since all particles were prepared according to the 
same protocol, the amount of PrP
c present in the particle stocks may be compared without using equal particle 
amounts as basis. Highest capacity (left hand side), lowest capacity (right hand side). PrP
c is shown as green 
cubes; different capsids are shown as octagons, HIV  red octagons, MLV blue octagons. Ecotropic MLV Env 
molecules are shown in black, amphotropic MLV Env molecules are shown in blue.  
The incorporation rates for PrP
D142 retroparticles even exceeded those of PrP
D111 
retroparticles (130%), thus demonstrating that amino acids 90-120 did not 
interfere with incorporation into retroparticles. However, in all settings the 
complete PrP molecule (PrP
209, aa 23-231) showed strongly impaired expression 
and drastically reduced incorporation efficiencies.   
 
 
Figure 52  Hypothesis for incorporation of truncated PrP
c into VLPs. Truncated PrP forms bearing 
aa 90-231 or 121-231, respectively, might show reduced internalization and turnover rates compared to wt full-
length PrP
c and are therefore incorporated into VLPs with higher efficiency. PrP
c, bearing aa 23-231, contains 
the flexible N-terminus (triangle) which  might contribute to quick internalization and turnover. 
This observation might be explained by reduced internalization rates and 
increased half-life of PrP-truncation mutants (Nunziante, M et al. 2003), in which 
amino acids 23 to 90 were deleted, might facilitate the incorporation into VLPs. 
Therefore the hypothesis that the flexible N-terminal arm of PrP
c is responsible 
for quick internalization and turnover is postulated (Figure 52). 
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V.2  Prions and retroviruses 
V.2.1  PrP influence on cell entry 
PrPMo
111, displaying aa 121-231 of PrP
c on top of the ecotropic Env protein, 
represents a newly generated virus, that most interestingly propagates to a 
similar extend as wt eMLV. It was expected that the cell entry properties of MLV 
were altered upon PrP
c display. In very few cases host range extension of 
ecotropic MLV to human cells was described, as e.g. the display of a human MHC 
class I specific single chain variable fragment (scFv), which retargeted an 
ecotropic MLV to human MHC-positive cells thus extending its host range (Marin, 
M et al. 1996). Usually the display of foreign polypeptides resulted in host range 
restriction. Two types of host range restriction can be distinguished. The first one 
is represented by display of the epidermal growth factor (EGF). The resulting 
MLV variants replicated freely on EGF receptor-poor cells but did not propagate 
on EGF receptor-rich cells because they were sequestered by the EGF receptors 
(Buchholz, C J et al. 1998). As a second possible influence, trimerizing molecules 
like CD40 ligand have been shown to block retroviral infectivity in general 
(Morling, F J, Peng, K W et al. 1997).  
The insertion of PrP was therefore also expected to alter viral entry into cells. 
This entry might be abrogated or also facilitated by either PrP-PrP interaction or 
binding to a putative PrP receptor. Such a putative receptor has been postulated 
to be the 37-kDa/67-kDa laminin receptor (Gauczynski, S et al. 2001), Heparan 
sulphate proteoglycan (HSPG) (Horonchik, L et al. 2005) and a few other surface 
receptors (Lasmezas, C I 2003). Mapping analyses in the yeast two-hybrid 
system and cell-binding assays identified amino acids (aa) 144-179 as a direct 
and aa 53-93 as an indirect HSPG-dependent laminin receptor precursor (LRP)-
binding site on PrP (Hundt, C et al. 2001). Therefore PrP
111 would be sufficient at 
least to bind to the laminin receptor on the cell surface via its direct binding site. 
Although the laminin receptor is a ubiquitously expressed protein, the expression 
levels in the herein used cell lines have not been tested. However, PrP
111 did not 
show blocking potential, since PrPMo
111 was replication competent on NIH-3T3 
cells. NIH-3T3 cells have low level of PrP
c and might have also low levels of the 
putative PrP-receptor, so that an influence through receptor binding can not be 
observed. The human T cell line A3.01, which expresses PrP
c, was therefore also 
tested for PrPMo
111 replication capacity. The observation was that PrPMo
111 
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entered these cells with higher efficiencies than the wild-type eMLV, but was 
unable to replicate in these cells. However, MLV has generally a low replication 
capacity in human primary T cells (Ebeling, S B et al. 2003), so that the A3.01 
cell line was not chosen optimally to detect PrP-dependent entry and subsequent 
virus replication. Contrary, a chimeric eMLV consisting of the amphotropic Env 
protein has been shown to replicate in human T cell lines Jurkat and A3.01 (Hartl 
I, unpublished data). Nevertheless, there might be post-entry blocks as Trim5α 
or APOBEC3G present in A3.01 cells that inhibit ecotropic MLV before the virus 
integrates into the cellular genome (Bishop, K N et al. 2004; Yap, M W et al. 
2004).  
Thus, it remains unclear whether PrP
111 shows either no influence on the host 
range or can mediate a host range extension on PrP
c/PrP
c-receptor-positive cells 
(Figure 53). Further implications would be obtained by introducing the PrP coding 
sequence into HEK 293FT cells. This cell line was shown to be negative for 
PrPMo
111 replication and might show PrP-specific entry and subsequent 
replication. Upon this, PrP-dependent entry might be competed by use of PrP-
specific or PrP receptor blocking antibodies. 
 
 
Figure 53  Hypothesis for PrP-mediated cell entry of PrPMo
111 into human cells. In absence of the 
MoMLV receptor the generated virus bearing PrP may interact via i) a putative PrP-receptor ii) interaction with 
PrP
c located on the cell surface. Both interactions may lead to increased internalization of the virus and 
therefore enhanced cell entry events. 
 
V.2.2 PrP influence on replication 
In principal, concerning the replication of PrPMo and wild-type ecotropic MLV on 
different cell lines, the influences of endogenous and transgenic PrP have to be 
considered as well as the presence of endogenous MLV. The combinations used 
in this thesis are briefly summarized in Table 7. At this, it seems that both PrPMo
111 
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and eMLV does not or only slightly replicate on PrP-positive cells. As it was 
described in the previous chapter, this low capacity is not due to cell entry 
inhibition. A possible explanation includes an antiretroviral effect of PrP
c. Such an 
effect has been proposed for PrP itself as shown by interactions with HIV 
(Leblanc, P et al. 2004). According to this publication, PrP influences the 
expression of viral genes. PrP
c was thus shown to inhibit expression of the HIV 
Env protein and had also an influence on HIV Gag as well as some accessory 
proteins(Leblanc, P, Baas, D et al. 2004). 
Table 7   Influence of PrP on virus replication 
Cell line  origin  Endogenous 
PrP 
Endogenous 
MLV 
Virus production  
(after transfection) 
Replication 
of eMLV 
Replication 
of PrPMo
111
HEK-293FT  human  low levels  No 8  Yes 9  No 8  No 8 
NIH-3T3  murine  low levels  No 8  Not determined  Yes 9  Yes 9 
N2a  murine  moderate 
levels 
Yes 9  Not determined  Not above en-
dogenous MLV 
level  
Not above en-
dogenous MLV 
level  
PK1  murine  high levels  No 8  Not determined  Moderate ~  No 8 
  
The human HEK-293FT cell line expressing low levels of PrP allowed the efficient 
production of the eMLV and PrPMo
111 virus stocks after transfection. Spreading 
for both viruses was not possible, most likely due to their human origin and 
therefore lack of the receptor for ecotropic MLV. NIH-3T3, expressing low levels 
of endogenous PrP, showed equal well replication of both eMLV and PrPMo
111. For 
the N2a cell line a low levels of endogenous MLV were detectable (by RT assay 
and IPA) and result in down regulation of the MLV receptor; this represents the 
most likely explanation for the inability of both PrPMo
111 and eMLV to spread 
through this cell line. The PK1 is a subclone of N2a, which was infected with a 
scrapie strain. Interestingly, the subclone did not show endogenous levels of 
MLV, which is eventually due to the fact that it was selected to express high 
levels of PrP
c. Yet, PK1 cells were unable to propagate the infection PrPMo
111 and 
revealed only low-level replication of ecotropic wt MLV even, when high moi were 
used to infect the cells.  
In line with this, the expression of the viral Env protein in N2a- and PK1-derived 
cell lysates and supernatants was not detectable, suggesting that gene 
expression was impaired in these cells. Thus, these observations can be regarded 
as evidence for the interference of PrP with MLV-derived genes as it was also 
described for HIV derived genes. A similar mechanism might contribute to low-
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level replication of eMLV in PrP
c expressing cells by influencing the expression of 
MLV capsid and Env proteins (Figure 54). Whether this influence takes place on 
level of transcription, translation or assembly has not been determined. 
 
 
Figure 54  Postulated mechanism of PrP
c influence on the expression of MLV-derived genes. A) 
Replication of wt eMLV and PrPMo111 viruses might be inhibited by expression of cellular PrP.  Levels of viral 
capsid (octagon) and viral Env protein are reduced resulting in low virus production. B) Three topological forms 
of PrP present in PrP-expressing cells (Harris, D A 2003)  
Nevertheless, speculation about the compartment in which such an influence of 
PrP
c on expression of Env and Gag might take place, it was demonstrated that 
loss of the GPI anchor of PrP
c anchoring the protein into the membrane resulted 
in impaired inhibition of HIV (Leblanc, P, Baas, D et al. 2004). Thus, trafficking of 
PrP
c is critical for this inhibitory effect. Most PrP
c molecules are attached to the 
outer leaflet of the plasma membrane through a C-terminal glycosyl-
phosphatidylinositol anchor (this topology is designated 
SecPrP; see Figure 54). 
However, when PrP is synthesised in vitro, in transfected cells or in mouse brain, 
some of the molecules resume a transmembrane orientation (Harris, D A 2003). 
These species, designated 
NtmPrP and 
CtmPrP, span the lipid bilayer once via a 
highly conserved hydrophobic region in the centre of the molecule (amino acids 
111–134), with either the N-terminus or C-terminus, respectively, on the 
extracytoplasmic side of the membrane (Figure 54). 
NtmPrP and 
CtmPrP are 
generated in small amounts (<10% of the total) as part of the normal 
biosynthesis of wild-type PrP in the endoplasmic reticulum. Thus, an influence of 
PrPc on viral replication might principally take place through all of these PrP 
forms in various compartments. In this context, it is notable, that PrP
111 on top of 
the viral Env does not show any negative effect on replication, as assayed by 
replication in NIH-3T3 cells (Table 7). Therefore it can be concluded that the N-
terminal part including aa 23-120 is responsible for these properties. This 
conclusion is further verified by the finding that PrP
209 display resulted in 
inhibition of virus production in all tested settings as discussed above (V.1). 
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PrP
c has also been described to bind nucleic acids resembling the properties of a 
putative nucleic acid chaperone. Surprisingly, PrP
c possesses all nucleic acid 
chaperoning properties previously specific to retroviral nucleocapsid proteins, as 
it was found for NC p7, the nucleocapsid protein of HIV-1 (Derrington, E et al. 
2002). Thus PrP
c, like NC p7, chaperones the annealing of tRNA(Lys) to the HIV-
1 primer binding site, the initial step of retrovirus replication, the two DNA strand 
transfers required for production of a complete proviral DNA with LTRs as well as 
the dimerization of the HIV-1 genomic RNA. The same data were obtained for 
PrP
c in comparison to feline immunodeficiency virus (FIV) nucleocapsid protein 
(Moscardini, M et al. 2002). These findings point to a second possible interaction 
mechanism for PrP
c resulting in virus inhibition. However, the chaperoning 
property of PrP
c has not been mapped to specific parts of the protein, therefore it 
remains unclear whether displayed PrP
111 or PrP
142 may exhibit such interactions. 
Future experiments aiming at the production of MLV in scrapie-infected cells, 
could focus on NIH-3T3 cells, as recently the scrapie infection of these cells 
became possible (Vorberg, I et al. 2004). Since wt eMLV and also PrPMo
111 
replicate in these cells, inhibitory effects on virus replication by cellular factors or 
endogenous retrovirus can be excluded. Thus it should be possible to investigate 
the above mentioned PrP/MLV interactions directly.  
 
V.3  Towards a vaccine against TSEs 
Retroviral PrP-expressing particles represent a highly immunogenic PrP vaccine 
candidate, which, for the first time, is capable of inducing anti-native PrP
c 
antibody titers in wild-type mice. 
V.3.1 The immune response against VLPs 
Virus-like particles (VLPs) have been widely used to generate subunit vaccines 
(Noad, R and Roy, P 2003; Deml, L, Speth, C et al. 2005). At this, the capacity of 
VLPs derived from HIV to induce innate immunity by stimulating toll-like 
receptors (TLR) was shown and cytotoxic T lymphocyte (CTL) response was 
examined in detail. Since estimated 50-100 major histocompatibility complex 
(MHC) molecules on the surface of an antigen-presenting cell (APC) are sufficient 
to trigger CTL response, the uptake of only one VLP bearing 1500-2000 Gag 
precursor molecules is regarded as sufficient for induction. Moreover, VLPs are 
lipoprotein spheres and conjugation of proteins with lipids or liposomes has been 
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previously demonstrated to facilitate their access to the endogenous MHC class I 
processing pathway. This way of presentation might be further stimulated by 
viral fusion with APC target membranes. Processing by the MHC class II pathway 
takes place in addition. (Deml, L, Speth, C et al. 2005)  
Immune responses were not only observed for the HIV-derived Gag protein but 
also for foreign peptides presented in the retroviral context. So far HIV-derived 
and a few other virally derived genes have been inserted into HIV Gag particles. 
In all cases strong antibody titers and CTL responses were obtained (Deml, L, 
Speth, C et al. 2005).  The PrP-retroparticles described in this thesis are the first 
example for self-antigens presented in this system. 
 
V.3.2  Tolerance or auto-reactivity? 
In principle VLP vaccination using HIV Gag has extensively been done for virus-
derived genes thus presenting foreign protein sequences to the immune system. 
Contrary, the approach used in this thesis utilizes particles to display antigens of 
cellular origin and to induce auto-reactive antibody responses for the first time.  
Remarkably, a single intravenously (i.v.) immunization with PrP-retroparticles 
was sufficient to induce native PrP
c binding serum immune globulin (Ig) M and 
IgG antibodies in Prnp
o/o mice (PrP gene deficient mice), the latter of which 
showed at least as strong binding as the monoclonal anti-PrP IgG antibody 6H4. 
The induction of native PrP
c-specific IgM and IgG upon i.v. immunization with 
PrP-retroparticles of wild-type mice is remarkable and has not been accomplished 
in a flurry of previous immunization studies (Hanan, E et al. 2001; Hanan, E, 
Priola, S A et al. 2001; Souan, L, Tal, Y et al. 2001; Koller, M F, Grau, T et al. 
2002; Arbel, M, Lavie, V et al. 2003; Gilch, S, Wopfner, F et al. 2003; Schwarz, 
A, Kratke, O et al. 2003; Sigurdsson, E M et al. 2003; Rosset, M B, Ballerini, C et 
al. 2004).  
In a recent report, immunization with bacterially expressed recombinant full-
length PrP emulsified in complete Freund´s adjuvants (CFA) resulted in the 
induction of antibodies directed against native PrP
c, only in mice aberrantly 
expressing transgenic PrP under the control of an oligodendrocyte and Schwann 
cell specific promoter, whereas wild-type controls and all other PrP transgenic 
mice tested showed at best serum binding to recombinant PrP coated to plastic 
(Polymenidou, M, Heppner, F L et al. 2004). The authors concluded that the 
expression of PrP
c in other than these organs leads to impaired antibody titers 
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due to tolerance induction. Given the antibody response using PrP-retroparticles 
in wild-type mice observed in this thesis, this conclusion has to be reconsidered. 
It is rather likely, that the immunization using bacterially expressed PrP
c is the 
main determinant for the observed antibody titers and that the use of eukaryotic 
expressed PrP
c in the context of highly immunogenic retroparticles may 
circumvent these limitations.  
The magnitude of PrP-specific IgG responses upon i.v. PrP-retroparticle 
immunization inversely correlated with the number of Prnp alleles expressed, i.e. 
highest PrP-specific IgG was induced in Prnp
o/o mice, whereas intermediate and 
lower levels were detected in Prnp
o/+ (heterozygous) and Prnp
+/+ (wild-type) 
mice, respectively. Nevertheless, it is remarkable, that overall similar IgM levels 
were induced in mice of all three genotypes, especially at early time points. The 
switch from the IgM to the IgG isotype of PrP
c-specific antibodies is less 
pronounced in wild type animals when compared to Prnp
0/0  mice (Nikles, D, 
Bach, P et al. 2005). 
An explanation for the observations from this and other studies would be that 
immunologic host tolerance is manifested on the T cell level and that T helper 
determinants may be provided by MLV-derived VLP related antigens. IgM 
responses of B cells do not depend on T cell help and would therefore remain 
more or less unaffected (Adelstein, S et al. 1991). On the contrary, the IgG 
switch takes place in Prnp
0/0 mice but it is impaired upon introduction of the Prnp 
gene.  Nevertheless, PrP-retroparticles seemed to be capable of inducing MLV-
specific T cell help accounting for PrP
c-specific IgG production with low affinity in 
20-25% of the immunized wt animals (Nikles, D, Bach, P et al. 2005).  
 
Figure 55  Immune response against PrP
c-displaying VLPs. The antigen is processed by antigen-
presenting cells (APC) upon presentation via MHC class I or class II pathways. A fast IgM response takes place 
without T cell help, whereas the switch to specific IgG response needs the activation of CD4
+ T cells. PrP
c-
specific IgGs might be generated with MLV capsid-specific T cell help rather than with PrP
c-specific help due to 
tolerance mechanisms. 
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In conclusion, it is remarkable that host tolerance left enough room for the 
induction of potentially auto-reactive PrP-specific antibodies. However, this 
finding is in line with previous observations that PrP-specific B cells can develop 
in the presence of endogenously expressed PrP in transgenic mice expressing the 
antibody chain 6H4µ derived from a monoclonal anti-PrP antibody (Heppner, F L, 
Musahl, C et al. 2001). It remains to be determined whether the induced 
antibodies belong to weak or efficiently opsonizing (and therefore stable and 
persistent) antibody titers and whether they have prionostatic potential (Figure 55). 
V.3.3  Outlook: Improving the antigen 
Two further vaccine candidates were generated in this thesis which might further 
improve quality and quantity of the immune responses generated so far. Firstly, 
HIV-derived VLPs are available, for which the induction of strong antibody 
responses against presented foreign polypeptides in BALB/c mice has been 
shown (Osterrieder, N et al. 1995; Deml, L et al. 1997). Especially prime/boost 
experiments will be attractive to maximize the PrP
c response. Secondly, a 
lentiviral vector packaging the Prnp gene was produced to combine protein- and 
nucleic acid-based vaccination strategies. The potential of such combination-
based immunization strategies has not been tested before and remains to be 
determined.  
Furthermore, VLPs presenting PrP as an Env fusion protein have been generated. 
The viral envelope protein has previously been shown to be highly immunogenic 
but suffers from the presence of low numbers of molecules on the surface of viral 
particles with a Gag:Env ratio of approximately 60:1 (Chertova, E et al. 2002).  
The Env display might facilitate the development of an oligomeric PrP status, 
believed to be present in equilibrium with the monomeric form of cellular PrP 
(Weissmann, C 2004), may be enhanced. The oligomeric or multimeric forms of 
PrP, resembling the infectious so-called “scrapie isoform” of the protein (PrP
Sc), 
might be an improved tool for immunization approaches representing the more 
adequate targets in terms of antibody production.  
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Figure 56  Combination of Env- and Display-system might yield improved immune responses. 
The cellular form of PrP is either presented on top of the viral Env protein (PrP
E) to generate oligomeric PrP or 
as fusion to PDGFR-TM (PrP
D) to obtain high amounts of PrP in the retroparticles. The combined approach may 
enhance immune response against cellular PrP.  
However, since both number and structure play a role in presenting the antigen, 
a combination of monomeric and multimeric PrP
c display might give rise to 
highest possible titers (Figure 56). 
 
A hallmark of propagation of the infectious agent of TSEs is the conversion of the 
cellular form of PrP into the pathogenic form PrP
Sc. So far, approaches to isolate 
prion infectivity in vitro are limited to the stable infection of cell cultures. Only 
recently, the de novo synthesis of prions was achieved via conversion of 
recombinant PrP (Legname, G et al. 2004).  
In terms of a more specific immune response, the generation of VLPs displaying 
the pathogenic isoform of PrP (PrP
Sc) will offer advantages. The organism would 
then directly respond against the pathogen, thus avoiding potential severe side-
effects upon an response against cellular PrP. However, the generation of VLPs 
containing PrP
Sc has been and remains an ambitious target.  
In this thesis the conversion of PrP
c displayed on the surface of viral particles was 
tempted with a truncated PrP consisting of amino acids 90-231. This shortened 
form was previously shown to support prion propagation and thus to be sufficient 
for the conversion of PrP
c into PrP
Sc (Flechsig, E, Shmerling, D et al. 2000). Thus, 
the PrP
D142 particle was in principle thought to be amenable to conversion into 
PrP
Sc, although there might be a negative impact of the altered transmembrane 
domain. However, difficulties also arise from the fact that the only assay 
differentiating between the two PrP forms is the proteinase K (PK) digestion 
assay. The titration of PrP with the enzyme critically depends on the amount of 
total protein. Since there is only a relative difference between PrP
c and PrP
Sc 
upon titration with PK, the conditions for titration are highly sensitive to slight 
changes. Under the conditions applied here it seems that PrP
D142 particles were 
not converted, when they were incubated for 1d at 37°C. However it may well be 
  122Discussion 
possible to identify conditions that will allow the conversion of PrP
c displayed on 
retrovirus particles. 
 
Taken together, the PrP-vaccination approach described in this work represents 
the first successful system inducing PrP-specific antibody responses in wt mice 
against the native form of the prion protein.  
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VI Appendix 
VI.1  Parental plasmids  
VI.1.1  phgPrP 
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VI.1.2   pDisplay 
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VI.1.3  pD-EGF 
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VI.1.4  pLenti6/V5-lacZ 
 
 
 
Feature   Benefit  
HIV-1 truncated 5′LTR   Permits viral packaging and reverse transcription of the viral mRNA 
(Luciw, 1996).  
HIV-1 psi (ψ) packaging 
signal  
Allows viral packaging (Luciw, 1996).  
HIV-1 Rev response 
element (RRE) 
Permits Rev-dependent nuclear export of unspliced viral mRNA (Kjems 
et al., 1991; Malim et al., 1989).  
Human CMV promoter   Permits high-level expression of the gene of interest (Andersson et al., 
1989; Boshart et al., 1985; Nelson et al., 1987).  
CMV forward priming site   Permits sequencing of the insert.  
V5 epitope  
(Gly-Lys-Pro-Ile-Pro-Asn-
Pro-Leu-Leu-Gly-Leu-
Asp-Ser-Thr)  
Allows detection of your recombinant protein with the Anti-V5 
antibodies (Southern et al., 1991).  
V5(C-term) reverse 
priming site  
Allows sequencing of the insert.  
SV40 early promoter and 
origin  
Allows efficient, high-level expression of the blasticidin resistance gene 
and episomal replication in cells expressing the SV40 large T antigen.  
Blasticidin (bsd) 
resistance gene  
Permits selection of stably transduced mammalian cell lines (Kimura et 
al., 1994).  
∆U3/HIV-1 truncated 
3′LTR  
Modified 3′LTR that allows viral packaging but self-inactivates the 5′LTR 
for biosafety purposes (Dull et al., 1998). The element also contains a 
polyadenylation signal for efficient transcription termination and 
polyadenylation of mRNA in transduced cells.  
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VI.1.5   pFB-EASALF 
 
translated sequence 
         aMLV env 
1620  cctctagact gacatggcgc gttcaacgct ctcaaaaccc cttaaaaata aggttaaccc gcgaggcccc   
      i  l  -  t   d  m  a   r  s  t   l  s  k  p   l  k  n   k  v  n   p  r  g  p   
                SfiI 
1690  ctaatcccct taattcttct gatgctcaga ggggtcagta ctgcttcgcc cggctccagt gcggcccagc   
        l  i  p   l  i  l   l  m  l  r   g  v  s   t  a  s   p  g  s  s   a  a  q   
  hEGF 
1760  cggccatggc caatagtgac tctgaatgtc ccctgtccca cgatgggtac tgcctccatg atggtgtgtg   
       p  a  m   a  n  s  d   s  e  c   p  l  s   h  d  g  y   c  l  h   d  g  v   
 
1830  catgtatatt gaagcattgg acaagtatgc atgcaactgt gttgttggct acatcgggga gcgatgtcag   
      c  m  y  i   e  a  l   d  k  y   a  c  n  c   v  v  g   y  i  g   e  r  c  q   
NotI 
1900  taccgagacc tgaagtggtg ggaactgcgc gcggccgca…  aMLV-Env 
        y  r  d   l  k  w   w  e  l  r   a  a  a 
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VI.1.6  pGem-NP and pSCT7 
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VI.1.7  pHit60 and pCMV∆R8.2 
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VI.1.8   pNCA 
 
 
 
VI.1.9  pEMo 
 
pEMo
11623 bps
2000
4000
6000
8000
10000
EcoRI
BsrGI
XhoI
NruI
BclI
MunI
BsgI
SalI
Bpu1102I
HindIII
SacII PmlI
SfiI
NaeI
NgoMIV
NotI
SgrAI
SspI
FspI
AflIII
PciI
gag
pol
env
CB6 primer (+)
EMoSeq2 primer (-)
EMoSeq primer (-)
amp
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VI.1.10   pm.DG 
 
 
VI.1.11  Lentipower packaging mix 
VI.1.11.1  pLP1 
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VI.1.11.2  pLP2 
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VI.1.11.3  pLP-VSV 
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VI.2 Constructed plasmids 
VI.2.1  pD-PrP209 
 
translated sequence 
      HA-Tag           SfiI           PrP-208 
 800  tatccatatg atgttccaga ttatgctggg gcccagccgg ccaaaaagcg gccaaagcct ggagggtgga   
        y  p  y   d  v  p   d  y  a  g   a  q  p   a  k  k   r  p  k  p   g  g  w   
 
 870  acaccggtgg aagccggtat cccgggcagg gaagccctgg aggcaaccgt tacccacctc agggtggcac   
       n  t  g   g  s  r  y   p  g  q   g  s  p   g  g  n  r   y  p  p   q  g  g   
 
 940  ctgggggcag ccccacggtg gtggctgggg acaaccccat gggggcagct ggggacaacc tcatggtggt   
      t  w  g  q   p  h  g   g  g  w   g  q  p  h   g  g  s   w  g  q   p  h  g  g   
 
1010  agttggggtc agccccatgg cggtggatgg ggccaaggag ggggtaccca taatcagtgg aacaagccca   
        s  w  g   q  p  h   g  g  g  w   g  q  g   g  g  t   h  n  q  w   n  k  p   
 
1080  gcaaaccaaa aaccaacctc aagcatgtgg caggggctgc ggcagctggg gcagtagtgg ggggccttgg   
       s  k  p   k  t  n  l   k  h  v   a  g  a   a  a  a  g   a  v  v   g  g  l   
 
1150  tggctacatg ctggggagcg ccatgagcag gcccatgatc cattttggca acgactggga ggaccgctac   
      g  g  y  m   l  g  s   a  m  s   r  p  m  i   h  f  g   n  d  w   e  d  r  y   
 
1220  taccgtgaaa acatgtaccg ctaccctaac caagtgtact acaggccagt ggatcagtac agcaaccaga   
        y  r  e   n  m  y   r  y  p  n   q  v  y   y  r  p   v  d  q  y   s  n  q   
 
1290  acaacttcgt gcacgactgc gtcaatatca ccatcaagca gcacacggtc accaccacca ccaaggggga   
       n  n  f   v  h  d  c   v  n  i   t  i  k   q  h  t  v   t  t  t   t  k  g   
 
1360  gaacttcacc gagaccgatg tgaagatgat ggagcgcgtg gtggagcaga tgtgcgtcac ccagtaccag   
      e  n  f  t   e  t  d   v  k  m   m  e  r  v   v  e  q   m  c  v   t  q  y  q   
       Faktor Xa   SacII 
1430  aaggagtccc aggcctatta cgacgggaga agatccagca tcgagggaag gccgcggctg caggtcgacg   
        k  e  s   q  a  y   y  d  g  r   r  s  s   i  e  g   r  p  r  l   q  v  d   
      myc epitop 
1500  aacaaaaact catctcagaa gaggatctga atgctgtggg ccaggacacg caggaggtca tcgtggtgcc   
       e  q  k   l  i  s  e   e  d  l   n  a  v   g  q  d  t   q  e  v   i  v  v   
 
1570  acactccttg ccctttaagg tggtggtgat ctcagccatc ctggccctgg tggtgctcac catcatctcc   
      p  h  s  l   p  f  k   v  v  v   i  s  a  i   l  a  l   v  v  l   t  i  i  s   
 
1640  cttatcatcc tcatcatgct ttggcagaag aagccacgtt ag 
        l  i  i   l  i  m   l  w  q  k   k  p  r   - 
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VI.2.2  pD-PrP142 
 
translated sequence 
      HA-Tag           SfiI          PrP-142 
 800  tatccatatg atgttccaga ttatgctggg gcccagccgg cccaaggagg gggtacccat aatcagtgga   
        y  p  y   d  v  p   d  y  a  g   a  q  p   a  q  g   g  g  t  h   n  q  w   
 
 870  acaagcccag caaaccaaaa accaacctca agcatgtggc aggggctgcg gcagctgggg cagtagtggg   
       n  k  p   s  k  p  k   t  n  l   k  h  v   a  g  a  a   a  a  g   a  v  v   
 
 940  gggccttggt ggctacatgc tggggagcgc catgagcagg cccatgatcc attttggcaa cgactgggag   
      g  g  l  g   g  y  m   l  g  s   a  m  s  r   p  m  i   h  f  g   n  d  w  e   
 
1010  gaccgctact accgtgaaaa catgtaccgc taccctaacc aagtgtacta caggccagtg gatcagtaca   
        d  r  y   y  r  e   n  m  y  r   y  p  n   q  v  y   y  r  p  v   d  q  y   
 
1080  gcaaccagaa caacttcgtg cacgactgcg tcaatatcac catcaagcag cacacggtca ccaccaccac   
       s  n  q   n  n  f  v   h  d  c   v  n  i   t  i  k  q   h  t  v   t  t  t   
 
1150  caagggggag aacttcaccg agaccgatgt gaagatgatg gagcgcgtgg tggagcagat gtgcgtcacc   
      t  k  g  e   n  f  t   e  t  d   v  k  m  m   e  r  v   v  e  q   m  c  v  t   
    Faktor  Xa    SacII 
1220  cagtaccaga aggagtccca ggcctattac gacgggagaa gatccagcat cgagggaagg ccgcggctgc   
        q  y  q   k  e  s   q  a  y  y   d  g  r   r  s  s   i  e  g  r   p  r  l   
              myc epitop 
1290  aggtcgacga acaaaaactc atctcagaag aggatctgaa tgctgtgggc caggacacgc aggaggtcat   
       q  v  d   e  q  k  l   i  s  e   e  d  l   n  a  v  g   q  d  t   q  e  v   
 
1360  cgtggtgcca cactccttgc cctttaaggt ggtggtgatc tcagccatcc tggccctggt ggtgctcacc   
      i  v  v  p   h  s  l   p  f  k   v  v  v  i   s  a  i   l  a  l   v  v  l  t   
 
1430  atcatctccc ttatcatcct catcatgctt tggcagaaga agccacgtta g 
        i  i  s   l  i  i   l  i  m  l   w  q  k   k  p  r   - 
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VI.2.3  pD-PrP111 
 
translated sequence 
      HA-Tag           SfiI            PrP-110 
 800  tatccatatg atgttccaga ttatgctggg gcccagccgg ccaaagtggg gggccttggt ggctacatgc   
        y  p  y   d  v  p   d  y  a  g   a  q  p   a  k  v   g  g  l  g   g  y  m   
 
 870  tggggagcgc catgagcagg cccatgatcc attttggcaa cgactgggag gaccgctact accgtgaaaa   
       l  g  s   a  m  s  r   p  m  i   h  f  g   n  d  w  e   d  r  y   y  r  e   
 
 940  catgtaccgc taccctaacc aagtgtacta caggccagtg gatcagtaca gcaaccagaa caacttcgtg   
      n  m  y  r   y  p  n   q  v  y   y  r  p  v   d  q  y   s  n  q   n  n  f  v   
 
1010  cacgactgcg tcaatatcac catcaagcag cacacggtca ccaccaccac caagggggag aacttcaccg   
        h  d  c   v  n  i   t  i  k  q   h  t  v   t  t  t   t  k  g  e   n  f  t   
 
1080  agaccgatgt gaagatgatg gagcgcgtgg tggagcagat gtgcgtcacc cagtaccaga aggagtccca   
       e  t  d   v  k  m  m   e  r  v   v  e  q   m  c  v  t   q  y  q   k  e  s   
          Faktor Xa      SacII           myc epitop 
1150  ggcctattac gacgggagaa gatccagcat cgagggaagg ccgcggctgc aggtcgacga acaaaaactc   
      q  a  y  y   d  g  r   r  s  s   i  e  g  r   p  r  l   q  v  d   e  q  k  l   
                PDGFR-TM 
1220  atctcagaag aggatctgaa tgctgtgggc caggacacgc aggaggtcat cgtggtgcca cactccttgc   
        i  s  e   e  d  l   n  a  v  g   q  d  t   q  e  v   i  v  v  p   h  s  l   
 
1290  cctttaaggt ggtggtgatc tcagccatcc tggccctggt ggtgctcacc atcatctccc ttatcatcct   
       p  f  k   v  v  v  i   s  a  i   l  a  l   v  v  l  t   i  i  s   l  i  i   
 
1360  catcatgctt tggcagaaga agccacgtta g 
      l  i  m  l   w  q  k   k  p  r   -   
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VI.2.4  pSALF-PrP209 
 
translated sequence 
       aMLV env 
1620  cctctagact gacatggcgc gttcaacgct ctcaaaaccc cttaaaaata aggttaaccc gcgaggcccc   
      i  l  -  t   d  m  a   r  s  t   l  s  k  p   l  k  n   k  v  n   p  r  g  p   
          SfiI 
1690  ctaatcccct taattcttct gatgctcaga ggggtcagta ctgcttcgcc cggctccagt gcggcccagc   
        l  i  p   l  i  l   l  m  l  r   g  v  s   t  a  s   p  g  s  s   a  a  q   
    PrP-208 
1760  cggccaaaaa gcggccaaag cctggagggt ggaacaccgg tggaagccgg tatcccgggc agggaagccc   
       p  a  k   k  r  p  k   p  g  g   w  n  t   g  g  s  r   y  p  g   q  g  s   
 
1830  tggaggcaac cgttacccac ctcagggtgg cacctggggg cagccccacg gtggtggctg gggacaaccc   
      p  g  g  n   r  y  p   p  q  g   g  t  w  g   q  p  h   g  g  g   w  g  q  p   
 
1900  catgggggca gctggggaca acctcatggt ggtagttggg gtcagcccca tggcggtgga tggggccaag   
        h  g  g   s  w  g   q  p  h  g   g  s  w   g  q  p   h  g  g  g   w  g  q   
 
1970  gagggggtac ccataatcag tggaacaagc ccagcaaacc aaaaaccaac ctcaagcatg tggcaggggc   
       g  g  g   t  h  n  q   w  n  k   p  s  k   p  k  t  n   l  k  h   v  a  g   
 
2040  tgcggcagct ggggcagtag tggggggcct tggtggctac atgctgggga gcgccatgag caggcccatg   
      a  a  a  a   g  a  v   v  g  g   l  g  g  y   m  l  g   s  a  m   s  r  p  m   
 
2110  atccattttg gcaacgactg ggaggaccgc tactaccgtg aaaacatgta ccgctaccct aaccaagtgt   
        i  h  f   g  n  d   w  e  d  r   y  y  r   e  n  m   y  r  y  p   n  q  v   
 
2180  actacaggcc agtggatcag tacagcaacc agaacaactt cgtgcacgac tgcgtcaata tcaccatcaa   
       y  y  r   p  v  d  q   y  s  n   q  n  n   f  v  h  d   c  v  n   i  t  i   
 
2250  gcagcacacg gtcaccacca ccaccaaggg ggagaacttc accgagaccg atgtgaagat gatggagcgc   
      k  q  h  t   v  t  t   t  t  k   g  e  n  f   t  e  t   d  v  k   m  m  e  r   
 
2320  gtggtggagc agatgtgcgt cacccagtac cagaaggagt cccaggccta ttacgacggg agaagatcca   
        v  v  e   q  m  c   v  t  q  y   q  k  e   s  q  a   y  y  d  g   r  r  s   
  Faktor Xa      NotI 
2390  gcatcgaggg aagggcggcc gcaatggcag agagccccca tcaggtcttt aatgtaacct ggagagtcac   
       s  i  e   g  r  a  a   a  m  a   e  s  p   h  q  v  f   n  v  t   w  r  v   
 
2460  caacctgatg actgggcgta ccgccaatgc cacctccctc ctgggaactg tacaagatgc cttcccaaaa   
      t  n  l  m   t  g  r   t  a  n   a  t  s  l   l  g  t   v  q  d   a  f  p  k   
 
2530  ttatattttg atctatgtga tctggtcgga gaggagtggg acccttcaga ccaggaaccg tatgtcgggt   
        l  y  f   d  l  c   d  l  v  g   e  e  w   d  p  s   d  q  e  p   y  v  g   
 
2600  atggctgcaa gtaccccgca gggagacagc ggacccggac ttttgacttt tacgtgtgcc ctgggcatac   
       y  g  c   k  y  p  a   g  r  q   r  t  r   t  f  d  f   y  v  c   p  g  h   
 
2670  cgtaaagtcg gggtgtgggg gaccaggaga gggctactgt ggtaaatggg ggtgtgaaac caccggacag   
      t  v  k  s   g  c  g   g  p  g   e  g  y  c   g  k  w   g  c  e   t  t  g  q   
 
2740  gcttactgga agcccacatc atcgtgggac ctaatctccc ttaagcgcgg taacaccccc tgggacacgg   
        a  y  w   k  p  t   s  s  w  d   l  i  s   l  k  r   g  n  t  p   w  d  t   
 
2810  gatgctctaa agttgcctgt ggcccctgct acgacctctc caaagtatcc aattccttcc aaggggctac   
       g  c  s   k  v  a  c   g  p  c   y  d  l   s  k  v  s   n  s  f   q  g  a   
 
2880  tcgagggggc agatgcaacc ctctagtcct agaattcact gatgcaggaa aaaaggctaa ctgggacggg   
      t  r  g  g   r  c  n   p  l  v   l  e  f  t   d  a  g   k  k  a   n  w  d  g 
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2950  cccaaatcgt ggggactgag actgtaccgg acaggaacag atcctattac catgttctcc ctgacccggc   
        p  k  s   w  g  l   r  l  y  r   t  g  t   d  p  i   t  m  f  s   l  t  r   
 
3020  aggtccttaa tgtgggaccc cgagtcccca tagggcccaa cccagtatta cccgaccaaa gactcccttc   
       q  v  l   n  v  g  p   r  v  p   i  g  p   n  p  v  l   p  d  q   r  l  p   
 
3090  ctcaccaata gagattgtac cggctccaca gccacctagc cccctcaata ccagttaccc cccttccact   
      s  s  p  i   e  i  v   p  a  p   q  p  p  s   p  l  n   t  s  y   p  p  s  t   
 
3160  accagtacac cctcaacctc ccctacaagt ccaagtgtcc cacagccacc cccaggaact ggagatagac   
        t  s  t   p  s  t   s  p  t  s   p  s  v   p  q  p   p  p  g  t   g  d  r   
 
3230  tactagctct agtcaaagga gcctatcagg cgcttaacct caccaatccc gacaagaccc aagaatgttg   
       l  l  a   l  v  k  g   a  y  q   a  l  n   l  t  n  p   d  k  t   q  e  c   
 
3300  gctgtgctta gtgtcgggac ctccttatta cgaaggagta gcggtcgtgg gcacttatac caatcattcc   
      w  l  c  l   v  s  g   p  p  y   y  e  g  v   a  v  v   g  t  y   t  n  h  s   
 
3370  accgctccgg ccaactgtac ggccacttcc caacataagc ttaccctatc tgaagtgaca ggacagggcc   
        t  a  p   a  n  c   t  a  t  s   q  h  k   l  t  l   s  e  v  t   g  q  g   
 
3440  tatgcatggg ggcagtacct aaaactcacc aggccttatg taacaccacc caaagcgccg gctcaggatc   
       l  c  m   g  a  v  p   k  t  h   q  a  l   c  n  t  t   q  s  a   g  s  g   
 
3510  ctactacctt gcagcacccg ccggaacaat gtgggcttgc agcactggat tgactccctg cttgtccacc   
      s  y  y  l   a  a  p   a  g  t   m  w  a  c   s  t  g   l  t  p   c  l  s  t   
 
3580  acggtgctca atctaaccac agattattgt gtattagttg aactctggcc cagagtaatt taccactccc   
        t  v  l   n  l  t   t  d  y  c   v  l  v   e  l  w   p  r  v  i   y  h  s   
 
3650  ccgattatat gtatggtcag cttgaacagc gtaccaaata taaaagagag ccagtatcat tgaccctggc   
       p  d  y   m  y  g  q   l  e  q   r  t  k   y  k  r  e   p  v  s   l  t  l   
 
3720  ccttctacta ggaggattaa ccatgggagg gattgcagct ggaataggga cggggaccac tgccttaatt   
      a  l  l  l   g  g  l   t  m  g   g  i  a  a   g  i  g   t  g  t   t  a  l  i   
 
3790  aaaacccagc agtttgagca gcttcatgcc gctatccaga cagacctcaa cgaagtcgaa aagtcaatta   
        k  t  q   q  f  e   q  l  h  a   a  i  q   t  d  l   n  e  v  e   k  s  i   
 
3860  ccaacctaga aaagtcactg acctcgttgt ctgaagtagt cctacagaac cgcagaggcc tagatttgct   
       t  n  l   e  k  s  l   t  s  l   s  e  v   v  l  q  n   r  r  g   l  d  l   
 
3930  attcctaaag gagggaggtc tctgcgcagc cctaaaagaa gaatgttgtt tttatgcaga ccacacgggg   
      l  f  l  k   e  g  g   l  c  a   a  l  k  e   e  c  c   f  y  a   d  h  t  g   
 
4000  ctagtgagag acagcatggc caaattaaga gaaaggctta atcagagaca aaaactattt gagacaggcc   
        l  v  r   d  s  m   a  k  l  r   e  r  l   n  q  r   q  k  l  f   e  t  g   
 
4070  aaggatggtt cgaagggctg tttaatagat ccccctggtt taccacctta atctccacca tcatgggacc   
       q  g  w   f  e  g  l   f  n  r   s  p  w   f  t  t  l   i  s  t   i  m  g   
 
4140  tctaatagta ctcttactga tcttactctt tggaccttgc attctcaatc gattagttca atttgttaaa   
      p  l  i  v   l  l  l   i  l  l   f  g  p  c   i  l  n   r  l  v   q  f  v  k   
 
4210  gacaggatct cagtagtcca ggctttagtc ctgactcaac aataccacca gctaaaacca ctagaatacg   
        d  r  i   s  v  v   q  a  l  v   l  t  q   q  y  h   q  l  k  p   l  e  y   
 
4280  agccatgata aataaaagat t 
       e  p  -   -  i  k  d  
 
 
  139Appendix 
VI.2.5  pSALF-PrP111 
 
translated sequence 
         aMLV env 
1620  cctctagact gacatggcgc gttcaacgct ctcaaaaccc cttaaaaata aggttaaccc gcgaggcccc   
      i  l  -  t   d  m  a   r  s  t   l  s  k  p   l  k  n   k  v  n   p  r  g  p   
     SfiI 
1690  ctaatcccct taattcttct gatgctcaga ggggtcagta ctgcttcgcc cggctccagt gcggcccagc   
        l  i  p   l  i  l   l  m  l  r   g  v  s   t  a  s   p  g  s  s   a  a  q   
  PrP-110 
1760  cggccaaagt ggggggcctt ggtggctaca tgctggggag cgccatgagc aggcccatga tccattttgg   
       p  a  k   v  g  g  l   g  g  y   m  l  g   s  a  m  s   r  p  m   i  h  f   
 
1830  caacgactgg gaggaccgct actaccgtga aaacatgtac cgctacccta accaagtgta ctacaggcca   
      g  n  d  w   e  d  r   y  y  r   e  n  m  y   r  y  p   n  q  v   y  y  r  p   
 
1900  gtggatcagt acagcaacca gaacaacttc gtgcacgact gcgtcaatat caccatcaag cagcacacgg   
        v  d  q   y  s  n   q  n  n  f   v  h  d   c  v  n   i  t  i  k   q  h  t   
 
1970  tcaccaccac caccaagggg gagaacttca ccgagaccga tgtgaagatg atggagcgcg tggtggagca   
       v  t  t   t  t  k  g   e  n  f   t  e  t   d  v  k  m   m  e  r   v  v  e   
                     Faktor Xa 
2040  gatgtgcgtc acccagtacc agaaggagtc ccaggcctat tacgacggga gaagatccag catcgaggga   
      q  m  c  v   t  q  y   q  k  e   s  q  a  y   y  d  g   r  r  s   s  i  e  g   
          NotI 
2110  agggcggccg caatggcaga gagcccccat caggtcttta atgtaacctg gagagtcacc aacctgatga   
        r  a  a   a  m  a   e  s  p  h   q  v  f   n  v  t   w  r  v  t   n  l  m   
… aMLV-Env 
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VI.2.6  pGem-NP425-PrP111 
 
sequence 
   1  gaatacacga attctcatgc tggatcttct cccgtcgtaa taggcctggg actccttctg gtactgggtg   
  71  acgcacatct gctccaccac gcgctccatc atcttcacat cggtctcggt gaagttctcc cccttggtgg   
 141  tggtggtgac cgtgtgctgc ttgatggtga tattgacgca gtcgtgcacg aagttgttct ggttgctgta   
 211  ctgatccact ggcctgtagt acacttggtt agggtagcgg tacatgtttt cacggtagta gcggtcctcc   
 281  cagtcgttgc caaaatggat catgggcctg ctcatggcgc tccccagcat gtagccacca aggcccccca   
 351  cccttccctg gattgatcca ccaccgccga tatcggcatt gtctagagct acctcaattg caccaccgcc   
 421  tgttggtttg tggtaagcac catccccacc ggacaagttt gccagatgat gtctgagcct ctccttggct   
 491  gtatccgtca ctcctaactc atcttccagg gcactgctga tcttcgattc agcatccttt gccacggctt   
 561  gtcctagtaa gaacatttcc atatcaaggt atgtcccccc tgtgacgtac tgctgcattg ccttgttctg   
 631  tacgacggcg actcccatgg cgtaactcca tagtgcagga taattgcctg gagcaaattc accatgaaca   
 701  gggtccttga ggatacagat aaagggagct ctggggcctt ttgacaggta ggtgtctatg aggcttctaa   
 771  gcttattaat atcgggcctc aggtttgaca acgttagagc tgccatcttt gtctccaccc catatttaat   
 841  agtgttcatg aaggaagcca gccctgcatc tcggatgtag ttcccaacga tctggatgtt cttctctaat   
 911  gtggtgagat cagatcttgc agtattcata gtcacaaggg tctcaaccat gagagataca aggctttgct   
 981  gagatctcat aaccgagcct atcccctcaa ctgtctcccc agtgaaaatt aaggcacctt tcacggtgcc   
1051  gtcttgtctg aacgcctcta acctgttgaa gaaccctttc cttaagccgg cgctgcttgt gatggccttc   
1121  accagcacaa tccagacttg gacaattatt gctcctaggc atgcaggata cccataggtt tgaaggagtg   
1191  tgtcagggtc tgcagcatcc cgttgaccct ggaagagtgg gctcttgttg accataggtc caaacagcca   
1261  ttctgtggtc ctctcatact ccatatctct cgtcttcaca atgaatccgt ctgtcttcgt cctcttaggg   
1331  tctttctcta tgttgtagat cacatatttg acatcggcgt ttactccgtt tgttgtcaag tacaattctg   
1401  gactactgta agccatggca agcagagaga cgaggaaccc tcctctctga gagtgctgct tatctgtgtc   
1471  caatgagtga gctaggaagg tagttgcaat gaataacttg tctgcatcat cagtcacact tgggcctagt   
1541  acgaacactg agactgtgct cctctggccg gggataacag cacctcctcc cgacttatta atactttcgc   
1611  tcctcctaga gctaaatgta tcgaaggtgc tcaacaaccc ggccatcgtg aactttggca gcaaagcaaa   
1681  gggtctggaa cctgctcctc agggtggata ctttgaccct aaggggatcc tctagagtcg acctgcaggc   
1751  atgcaagctt ccggtctccc tatagtgagt cgtattaatt tcgataagcc agctgcatta atgaatcggc   
1821  caacgcgcgg ggagaggcgg tttgcgtatt gggcgctctt ccgcttcctc gctcactgac tcgctgcgct   
1891  cggtcgttcg gctgcggcga gcggtatcag ctcactcaaa ggcggtaata cggttatcca cagaatcagg   
1961  ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa ggccgcgttg   
2031  ctggcgtttt tccataggct ccgcccccct gacgagcatc acaaaaatcg acgctcaagt cagaggtggc   
2101  gaaacccgac aggactataa agataccagg cgtttccccc tggaagctcc ctcgtgcgct ctcctgttcc   
2171  gaccctgccg cttaccggat acctgtccgc ctttctccct tcgggaagcg tggcgctttc tcatagctca   
2241  cgctgtaggt atctcagttc ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa ccccccgttc   
2311  agcccgaccg ctgcgcctta tccggtaact atcgtcttga gtccaacccg gtaagacacg acttatcgcc   
2381  actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga gttcttgaag   
2451  tggtggccta actacggcta cactagaagg acagtatttg gtatctgcgc tctgctgaag ccagttacct   
2521  tcggaaaaag agttggtagc tcttgatccg gcaaacaaac caccgctggt agcggtggtt tttttgtttg   
2591  caagcagcag attacgcgca gaaaaaaagg atctcaagaa gatcctttga tcttttctac ggggtctgac   
2661  gctcagtgga acgaaaactc acgttaaggg attttggtca tgagattatc aaaaaggatc ttcacctaga   
2731  tccttttaaa ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggt ctgacagtta   
2801  ccaatgctta atcagtgagg cacctatctc agcgatctgt ctatttcgtt catccatagt tgcctgactc   
2871  cccgtcgtgt agataactac gatacgggag ggcttaccat ctggccccag tgctgcaatg ataccgcgag   
2941  acccacgctc accggctcca gatttatcag caataaacca gccagccgga agggccgagc gcagaagtgg   
3011  tcctgcaact ttatccgcct ccatccagtc tattaattgt tgccgggaag ctagagtaag tagttcgcca   
3081  gttaatagtt tgcgcaacgt tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg tttggtatgg   
3151  cttcattcag ctccggttcc caacgatcaa ggcgagttac atgatccccc atgttgtgca aaaaagcggt   
3221  tagctccttc ggtcctccga tcgttgtcag aagtaagttg gccgcagtgt tatcactcat ggttatggca   
3291  gcactgcata attctcttac tgtcatgcca tccgtaagat gcttttctgt gactggtgag tactcaacca   
3361  agtcattctg agaatagtgt atgcggcgac cgagttgctc ttgcccggcg tcaatacggg ataataccgc   
3431  gccacatagc agaactttaa aagtgctcat cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc   
3501  ttaccgctgt tgagatccag ttcgatgtaa cccactcgtg cacccaactg atcttcagca tcttttactt   
3571  tcaccagcgt ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg   
3641  gaaatgttga atactcatac tcttcctttt tcaatattat tgaagcattt atcagggtta ttgtctcatg   
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3711  agcggataca tatttgaatg tatttagaaa aataaacaaa taggggttcc gcgcacattt ccccgaaaag   
3781  tgccacctga cgtctaagaa accattatta tcatgacatt aacctataaa aataggcgta tcacgaggcc   
3851  ctttcgtctc gcgcgtttcg gtgatgacgg tgaaaacctc tgacacatgc agctcccgga gacggtcaca   
3921  gcttgtctgt aagcggatgc cgggagcaga caagcccgtc agggcgcgtc agcgggtgtt ggcgggtgtc   
3991  ggggctggct taactatgcg gcatcagagc agattgtact gagagtgcac catatcgacg ctctccctta   
4061  tgcgactcct gcattaggaa gcagcccagt agtaggttga ggccgttgag caccgccgcc gcaaggaatg   
4131  gtgcaaggag atggcgccca acagtccccc ggccacgggg cctgccacca tacccacgcc gaaacaagcg   
4201  ctcatgagcc cgaagtggcg agcccgatct tccccatcgg tgatgtcggc gatataggcg ccagcaaccg   
4271  cacctgtggc gccggtgatg ccggccacga tgcgtccggc gtagaggatc tggctagcga tgaccctgct   
4341  gattggttcg ctgaccattt ccggggtgcg gaacggcgtt accagaaact cagaaggttc gtccaaccaa   
4411  accgactctg acggcagttt acgagagaga tgatagggtc tgcttcagta agccagatgc tacacaatta   
4481  ggcttgtaca tattgtcgtt agaacgcggc tacaattaat acataacctt atgtatcata cacatacgat   
4551  ttaggtgaca ctata 
 
VI.2.7  pGem-NP454-PrP111 
 
 
sequence 
   1  gaatacacga attctcatgc tggatcttct cccgtcgtaa taggcctggg actccttctg gtactgggtg   
  71  acgcacatct gctccaccac gcgctccatc atcttcacat cggtctcggt gaagttctcc cccttggtgg   
 141  tggtggtgac cgtgtgctgc ttgatggtga tattgacgca gtcgtgcacg aagttgttct ggttgctgta   
 211  ctgatccact ggcctgtagt acacttggtt agggtagcgg tacatgtttt cacggtagta gcggtcctcc   
 281  cagtcgttgc caaaatggat catgggcctg ctcatggcgc tccccagcat gtagccacca aggcccccca   
 351  cccttccctc gattgatcca ccaccgccgt ggccaccact cacctgacgt gcccatcttt caccactttc   
 421  tccaccccaa cccctagcgt cctggtccgc atgagcttct gtttctaggt cgatatcggc attgtctaga   
 491  gctacctcaa ttgcaccacc gcctgttggt ttgtggtaag caccatcccc accggacaag tttgccagat   
 561  gatgtctgag cctctccttg gctgtatccg tcactcctaa ctcatcttcc agggcactgc tgatcttcga   
 631  ttcagcatcc tttgccacgg cttgtcctag taagaacatt tccatatcaa ggtatgtccc ccctgtgacg   
 701  tactgctgca ttgccttgtt ctgtacgacg gcgactccca tggcgtaact ccatagtgca ggataattgc   
 771  ctggagcaaa ttcaccatga acagggtcct tgaggataca gataaaggga gctctggggc cttttgacag   
 841  gtaggtgtct atgaggcttc taagcttatt aatatcgggc ctcaggtttg acaacgttag agctgccatc   
 911  tttgtctcca ccccatattt aatagtgttc atgaaggaag ccagccctgc atctcggatg tagttcccaa   
 981  cgatctggat gttcttctct aatgtggtga gatcagatct tgcagtattc atagtcacaa gggtctcaac   
1051  catgagagat acaaggcttt gctgagatct cataaccgag cctatcccct caactgtctc cccagtgaaa   
1121  attaaggcac ctttcacggt gccgtcttgt ctgaacgcct ctaacctgtt gaagaaccct ttccttaagc   
1191  cggcgctgct tgtgatggcc ttcaccagca caatccagac ttggacaatt attgctccta ggcatgcagg   
1261  atacccatag gtttgaagga gtgtgtcagg gtctgcagca tcccgttgac cctggaagag tgggctcttg   
1331  ttgaccatag gtccaaacag ccattctgtg gtcctctcat actccatatc tctcgtcttc acaatgaatc   
1401  cgtctgtctt cgtcctctta gggtctttct ctatgttgta gatcacatat ttgacatcgg cgtttactcc   
1471  gtttgttgtc aagtacaatt ctggactact gtaagccatg gcaagcagag agacgaggaa ccctcctctc   
1541  tgagagtgct gcttatctgt gtccaatgag tgagctagga aggtagttgc aatgaataac ttgtctgcat   
1611  catcagtcac acttgggcct agtacgaaca ctgagactgt gctcctctgg ccggggataa cagcacctcc   
1681  tcccgactta ttaatacttt cgctcctcct agagctaaat gtatcgaagg tgctcaacaa cccggccatc   
1751  gtgaactttg gcagcaaagc aaagggtctg gaacctgctc ctcagggtgg atactttgac cctaagggga   
1821  tcctctagag tcgacctgca ggcatgcaag cttccggtct ccctatagtg agtcgtatta atttcgataa   
1891  gccagctgca ttaatgaatc ggccaacgcg cggggagagg cggtttgcgt attgggcgct cttccgcttc   
1961  ctcgctcact gactcgctgc gctcggtcgt tcggctgcgg cgagcggtat cagctcactc aaaggcggta   
2031  atacggttat ccacagaatc aggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca   
2101  ggaaccgtaa aaaggccgcg ttgctggcgt ttttccatag gctccgcccc cctgacgagc atcacaaaaa   
2171  tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc ccctggaagc   
2241  tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg gatacctgtc cgcctttctc ccttcgggaa   
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2311  gcgtggcgct ttctcatagc tcacgctgta ggtatctcag ttcggtgtag gtcgttcgct ccaagctggg   
2381  ctgtgtgcac gaaccccccg ttcagcccga ccgctgcgcc ttatccggta actatcgtct tgagtccaac   
2451  ccggtaagac acgacttatc gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag   
2521  gcggtgctac agagttcttg aagtggtggc ctaactacgg ctacactaga aggacagtat ttggtatctg   
2591  cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat ccggcaaaca aaccaccgct   
2661  ggtagcggtg gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt   
2731  tgatcttttc tacggggtct gacgctcagt ggaacgaaaa ctcacgttaa gggattttgg tcatgagatt   
2801  atcaaaaagg atcttcacct agatcctttt aaattaaaaa tgaagtttta aatcaatcta aagtatatat   
2871  gagtaaactt ggtctgacag ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc tgtctatttc   
2941  gttcatccat agttgcctga ctccccgtcg tgtagataac tacgatacgg gagggcttac catctggccc   
3011  cagtgctgca atgataccgc gagacccacg ctcaccggct ccagatttat cagcaataaa ccagccagcc   
3081  ggaagggccg agcgcagaag tggtcctgca actttatccg cctccatcca gtctattaat tgttgccggg   
3151  aagctagagt aagtagttcg ccagttaata gtttgcgcaa cgttgttgcc attgctacag gcatcgtggt   
3221  gtcacgctcg tcgtttggta tggcttcatt cagctccggt tcccaacgat caaggcgagt tacatgatcc   
3291  cccatgttgt gcaaaaaagc ggttagctcc ttcggtcctc cgatcgttgt cagaagtaag ttggccgcag   
3361  tgttatcact catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa gatgcttttc   
3431  tgtgactggt gagtactcaa ccaagtcatt ctgagaatag tgtatgcggc gaccgagttg ctcttgcccg   
3501  gcgtcaatac gggataatac cgcgccacat agcagaactt taaaagtgct catcattgga aaacgttctt   
3571  cggggcgaaa actctcaagg atcttaccgc tgttgagatc cagttcgatg taacccactc gtgcacccaa   
3641  ctgatcttca gcatctttta ctttcaccag cgtttctggg tgagcaaaaa caggaaggca aaatgccgca   
3711  aaaaagggaa taagggcgac acggaaatgt tgaatactca tactcttcct ttttcaatat tattgaagca   
3781  tttatcaggg ttattgtctc atgagcggat acatatttga atgtatttag aaaaataaac aaataggggt   
3851  tccgcgcaca tttccccgaa aagtgccacc tgacgtctaa gaaaccatta ttatcatgac attaacctat   
3921  aaaaataggc gtatcacgag gccctttcgt ctcgcgcgtt tcggtgatga cggtgaaaac ctctgacaca   
3991  tgcagctccc ggagacggtc acagcttgtc tgtaagcgga tgccgggagc agacaagccc gtcagggcgc   
4061  gtcagcgggt gttggcgggt gtcggggctg gcttaactat gcggcatcag agcagattgt actgagagtg   
4131  caccatatcg acgctctccc ttatgcgact cctgcattag gaagcagccc agtagtaggt tgaggccgtt   
4201  gagcaccgcc gccgcaagga atggtgcaag gagatggcgc ccaacagtcc cccggccacg gggcctgcca   
4271  ccatacccac gccgaaacaa gcgctcatga gcccgaagtg gcgagcccga tcttccccat cggtgatgtc   
4341  ggcgatatag gcgccagcaa ccgcacctgt ggcgccggtg atgccggcca cgatgcgtcc ggcgtagagg   
4411  atctggctag cgatgaccct gctgattggt tcgctgacca tttccggggt gcggaacggc gttaccagaa   
4481  actcagaagg ttcgtccaac caaaccgact ctgacggcag tttacgagag agatgatagg gtctgcttca   
4551  gtaagccaga tgctacacaa ttaggcttgt acatattgtc gttagaacgc ggctacaatt aatacataac   
4621  cttatgtatc atacacatac gatttaggtg acactata 
 
VI.2.8  pGem-NP523-HA 
 
 
   1  gaatacacga attcgagctc ggtacctcaa taatctggaa catcatatgg atacatatgc   
  61  tcgaggattc ctcctatccc agctactgct gcggcatcgt catcttcgtc gtgatcgaca   
 121  ccgttattgc ggccttcatc tccatgggtt gcagaatcct cttgccgtct ctctgcgagt   
 181  ctcatggcta ttcttctctc tatgtctgat acatcctcat cattggtttc ctcctctaac   
 241  cgttcagccc catgtagtgt gacaaagtgg ccaccactca cctgacgtgc ccatctttca   
 301  ccactttctc caccccaacc cctagcgtcc tggtccgcat gagcttctgt ttctaggtcg   
 361  atatcggcat tgtctagagc tacctcaatt gcaccaccgc ctgttggttt gtggtaagca   
 421  ccatccccac cggacaagtt tgccagatga tgtctgagcc tctccttggc tgtatccgtc   
 481  actcctaact catcttccag ggcactgctg atcttcgatt cagcatcctt tgccacggct   
 541  tgtcctagta agaacatttc catatcaagg tatgtccccc ctgtgacgta ctgctgcatt   
 601  gccttgttct gtacgacggc gactcccatg gcgtaactcc atagtgcagg ataattgcct   
 661  ggagcaaatt caccatgaac agggtccttg aggatacaga taaagggagc tctggggcct   
 721  tttgacaggt aggtgtctat gaggcttcta agcttattaa tatcgggcct caggtttgac   
 781  aacgttagag ctgccatctt tgtctccacc ccatatttaa tagtgttcat gaaggaagcc   
 841  agccctgcat ctcggatgta gttcccaacg atctggatgt tcttctctaa tgtggtgaga   
 901  tcagatcttg cagtattcat agtcacaagg gtctcaacca tgagagatac aaggctttgc   
 961  tgagatctca taaccgagcc tatcccctca actgtctccc cagtgaaaat taaggcacct   
1021  ttcacggtgc cgtcttgtct gaacgcctct aacctgttga agaacccttt ccttaagccg   
1081  gcgctgcttg tgatggcctt caccagcaca atccagactt ggacaattat tgctcctagg   
1141  catgcaggat acccataggt ttgaaggagt gtgtcagggt ctgcagcatc ccgttgaccc   
1201  tggaagagtg ggctcttgtt gaccataggt ccaaacagcc attctgtggt cctctcatac   
1261  tccatatctc tcgtcttcac aatgaatccg tctgtcttcg tcctcttagg gtctttctct   
1321  atgttgtaga tcacatattt gacatcggcg tttactccgt ttgttgtcaa gtacaattct   
1381  ggactactgt aagccatggc aagcagagag acgaggaacc ctcctctctg agagtgctgc   
1441  ttatctgtgt ccaatgagtg agctaggaag gtagttgcaa tgaataactt gtctgcatca   
1501  tcagtcacac ttgggcctag tacgaacact gagactgtgc tcctctggcc ggggataaca   
1561  gcacctcctc ccgacttatt aatactttcg ctcctcctag agctaaatgt atcgaaggtg   
1621  ctcaacaacc cggccatcgt gaactttggc agcaaagcaa agggtctgga acctgctcct   
1681  cagggtggat actttgaccc taaggggatc ctctagagtc gacctgcagg catgcaagct   
1741  tccggtctcc ctatagtgag tcgtattaat ttcgataagc cagctgcatt aatgaatcgg   
1801  ccaacgcgcg gggagaggcg gtttgcgtat tgggcgctct tccgcttcct cgctcactga   
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1861  ctcgctgcgc tcggtcgttc ggctgcggcg agcggtatca gctcactcaa aggcggtaat   
1921  acggttatcc acagaatcag gggataacgc aggaaagaac atgtgagcaa aaggccagca   
1981  aaaggccagg aaccgtaaaa aggccgcgtt gctggcgttt ttccataggc tccgcccccc   
2041  tgacgagcat cacaaaaatc gacgctcaag tcagaggtgg cgaaacccga caggactata   
2101  aagataccag gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc cgaccctgcc   
2161  gcttaccgga tacctgtccg cctttctccc ttcgggaagc gtggcgcttt ctcatagctc   
2221  acgctgtagg tatctcagtt cggtgtaggt cgttcgctcc aagctgggct gtgtgcacga   
2281  accccccgtt cagcccgacc gctgcgcctt atccggtaac tatcgtcttg agtccaaccc   
2341  ggtaagacac gacttatcgc cactggcagc agccactggt aacaggatta gcagagcgag   
2401  gtatgtaggc ggtgctacag agttcttgaa gtggtggcct aactacggct acactagaag   
2461  gacagtattt ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa gagttggtag   
2521  ctcttgatcc ggcaaacaaa ccaccgctgg tagcggtggt ttttttgttt gcaagcagca   
2581  gattacgcgc agaaaaaaag gatctcaaga agatcctttg atcttttcta cggggtctga   
2641  cgctcagtgg aacgaaaact cacgttaagg gattttggtc atgagattat caaaaaggat   
2701  cttcacctag atccttttaa attaaaaatg aagttttaaa tcaatctaaa gtatatatga   
2761  gtaaacttgg tctgacagtt accaatgctt aatcagtgag gcacctatct cagcgatctg   
2821  tctatttcgt tcatccatag ttgcctgact ccccgtcgtg tagataacta cgatacggga   
2881  gggcttacca tctggcccca gtgctgcaat gataccgcga gacccacgct caccggctcc   
2941  agatttatca gcaataaacc agccagccgg aagggccgag cgcagaagtg gtcctgcaac   
3001  tttatccgcc tccatccagt ctattaattg ttgccgggaa gctagagtaa gtagttcgcc   
3061  agttaatagt ttgcgcaacg ttgttgccat tgctacaggc atcgtggtgt cacgctcgtc   
3121  gtttggtatg gcttcattca gctccggttc ccaacgatca aggcgagtta catgatcccc   
3181  catgttgtgc aaaaaagcgg ttagctcctt cggtcctccg atcgttgtca gaagtaagtt   
3241  ggccgcagtg ttatcactca tggttatggc agcactgcat aattctctta ctgtcatgcc   
3301  atccgtaaga tgcttttctg tgactggtga gtactcaacc aagtcattct gagaatagtg   
3361  tatgcggcga ccgagttgct cttgcccggc gtcaatacgg gataataccg cgccacatag   
3421  cagaacttta aaagtgctca tcattggaaa acgttcttcg gggcgaaaac tctcaaggat   
3481  cttaccgctg ttgagatcca gttcgatgta acccactcgt gcacccaact gatcttcagc   
3541  atcttttact ttcaccagcg tttctgggtg agcaaaaaca ggaaggcaaa atgccgcaaa   
3601  aaagggaata agggcgacac ggaaatgttg aatactcata ctcttccttt ttcaatatta   
3661  ttgaagcatt tatcagggtt attgtctcat gagcggatac atatttgaat gtatttagaa   
3721  aaataaacaa ataggggttc cgcgcacatt tccccgaaaa gtgccacctg acgtctaaga   
3781  aaccattatt atcatgacat taacctataa aaataggcgt atcacgaggc cctttcgtct   
3841  cgcgcgtttc ggtgatgacg gtgaaaacct ctgacacatg cagctcccgg agacggtcac   
3901  agcttgtctg taagcggatg ccgggagcag acaagcccgt cagggcgcgt cagcgggtgt   
3961  tggcgggtgt cggggctggc ttaactatgc ggcatcagag cagattgtac tgagagtgca   
4021  ccatatcgac gctctccctt atgcgactcc tgcattagga agcagcccag tagtaggttg   
4081  aggccgttga gcaccgccgc cgcaaggaat ggtgcaagga gatggcgccc aacagtcccc   
4141  cggccacggg gcctgccacc atacccacgc cgaaacaagc gctcatgagc ccgaagtggc   
4201  gagcccgatc ttccccatcg gtgatgtcgg cgatataggc gccagcaacc gcacctgtgg   
4261  cgccggtgat gccggccacg atgcgtccgg cgtagaggat ctggctagcg atgaccctgc   
4321  tgattggttc gctgaccatt tccggggtgc ggaacggcgt taccagaaac tcagaaggtt   
4381  cgtccaacca aaccgactct gacggcagtt tacgagagag atgatagggt ctgcttcagt   
4441  aagccagatg ctacacaatt aggcttgtac atattgtcgt tagaacgcgg ctacaattaa   
4501  tacataacct tatgtatcat acacatacga tttaggtgac actata 
VI.3  Alignment pDisplay-PrP plasmids 
pD-PrP111 
Sequencing result using T7 primer 
pD-PrP110       675 cgagctcggatccactagtaacggccgccagtgtgctggaattcggcttg 
seq-pDPrP111      1 .................................................. 
 
pD-PrP110       725 gggatatccaccatggagacagacacactcctgctatgggtactgctgct 
seq-pDPrP111     51 .................................................. 
 
pD-PrP110       775 ctgggttccaggttccactggtgactatccatatgatgttccagattatg 
seq-pDPrP111    101 .................................................. 
 
pD-PrP110       825 ctggggcccagccggccgtggggggccttggtggctacatgctggggagc 
seq-pDPrP111    151 .................................................. 
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pD-PrP110       875 gccatgagcaggcccatgatccattttggcaacgactgggaggaccgcta 
seq-pDPrP111    201 .................................................. 
 
pD-PrP110       925 ctaccgtgaaaacatgtaccgctaccctaaccaagtgtactacaggccag 
seq-pDPrP111    251 .................................................. 
 
pD-PrP110       975 tggatcagtacagcaaccagaacaacttcgtgcacgactgcgtcaatatc 
seq-pDPrP111    301 .................................................. 
 
pD-PrP110      1025 accatcaagcagcacacggtcaccaccaccaccaagggggagaacttcac 
seq-pDPrP111    351 .................................................. 
 
pD-PrP110      1075 cgagaccgatgtgaagatgatggagcgcgtggtggagcagatgtgcgtca 
seq-pDPrP111    401 .................................................. 
 
pD-PrP110      1125 cccagtaccagaaggagtcccaggcctattacgacgggagaagatccagc 
seq-pDPrP111    451 .................................................. 
 
pD-PrP110      1175 atcgagggaaggccgcggctgcaggtcgacgaacaaaaactcatctcaga 
seq-pDPrP111    501 .................................................. 
 
pD-PrP110      1225 agaggatctgaatgctgtgggccaggacacgcaggaggtcatcgtggtgc 
seq-pDPrP111    551 .................................................. 
 
pD-PrP110      1275 cacactccttgccctttaaggtggtggtgatctcagccatcctggccctg 
seq-pDPrP111    601 .................................................. 
 
pD-PrP110      1325 gtggtgctcaccatcatctcccttatcatcctcatcatgctttggcagaa 
seq-pDPrP111    651 .................................................. 
 
pD-PrP110      1375 gaagccacgttaggcggccgctcgagatcagcctcgactgtgccttctag 
seq-pDPrP111    701 .................................................. 
 
pD-PrP110      1425 ttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctgg 
seq-pDPrP111    751 .................................................. 
 
pD-PrP110      1475 aaggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcg 
seq-pDPrP111    801 ...-...................-.........t.......-........ 
 
pD-PrP110      1525 cattgtctgagtaggtgtcattctattctggggggtggggtgg 
seq-pDPrP111    848 ..............-......-....ctg.............. 
 
 
pD-PrP142 
Sequencing result using T7 primer 
pD-PrP142       697 ggccgccagtgtgctggaattcggcttggggatatccaccatggagacag 
seq-pD-PrP14      1 .................................................. 
 
pD-PrP142       747 acacactcctgctatgggtactgctgctctgggttccaggttccactggt 
seq-pD-PrP14     51 .................................................. 
 
pD-PrP142       797 gactatccatatgatgttccagattatgctggggcccagccggcccaagg 
seq-pD-PrP14    101 .................................................. 
 
pD-PrP142       847 agggggtacccataatcagtggaacaagcccagcaaaccaaaaaccaacc 
seq-pD-PrP14    151 .................................................. 
 
pD-PrP142       897 tcaagcatgtggcaggggctgcggcagctggggcagtagtggggggcctt 
seq-pD-PrP14    201 .................................................. 
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pD-PrP142       947 ggtggctacatgctggggagcgccatgagcaggcccatgatccattttgg 
seq-pD-PrP14    251 .................................................. 
 
pD-PrP142       997 caacgactgggaggaccgctactaccgtgaaaacatgtaccgctacccta 
seq-pD-PrP14    301 .................................................. 
 
pD-PrP142      1047 accaagtgtactacaggccagtggatcagtacagcaaccagaacaacttc 
seq-pD-PrP14    351 .................................................. 
 
pD-PrP142      1097 gtgcacgactgcgtcaatatcaccatcaagcagcacacggtcaccaccac 
seq-pD-PrP14    401 .................................................. 
 
pD-PrP142      1147 caccaagggggagaacttcaccgagaccgatgtgaagatgatggagcgcg 
seq-pD-PrP14    451 .................................................. 
 
pD-PrP142      1197 tggtggagcagatgtgcgtcacccagtaccagaaggagtcccaggcctat 
seq-pD-PrP14    501 .................................................. 
 
pD-PrP142      1247 tacgacgggagaagatccagcatcgagggaaggccgcggctgcaggtcga 
seq-pD-PrP14    551 .................................................. 
 
pD-PrP142      1297 cgaacaaaaactcatctcagaagaggatctgaatgctgtgggccaggaca 
seq-pD-PrP14    601 .................................................. 
 
pD-PrP142      1347 cgcaggaggtcatcgtggtgccacactccttgccctttaaggtggtggtg 
seq-pD-PrP14    651 .................................................. 
 
pD-PrP142      1397 atctcagccatcctggccctggtggtgctcaccatcatctcccttatcat 
seq-pD-PrP14    701 .................................................. 
 
pD-PrP142      1447 cctcatcatgctttggcagaagaagccacgttaggcggccgctcgagatc 
seq-pD-PrP14    751 .................................................. 
 
pD-PrP142      1497 agcctcgactgtgccttctagttgccagccatctgttgtttgcccctccc 
seq-pD-PrP14    801 .................................................. 
 
pD-PrP142      1547 ccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaa 
seq-pD-PrP14    851 .................-......-................t........ 
 
pD-PrP142      1597 taaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattct 
seq-pD-PrP14    899 ....-.......-......................-...-.......... 
 
pD-PrP142      1647 gggggg 
seq-pD-PrP14    945 ...... 
 
 
VI.4  Alignement pLenti-DPrP plasmids 
 
VI.5  Alignement pSALF-PrP plasmids 
pS-PrP209 
Sequencing result using EASeq1 primer 
pS-PrP209      1703 ttcttctgatgctcagaggggtcagtactgcggcccagccggccaaaaag 
seq-pS-PrP20    780 .................................................. 
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pS-PrP209      1753 cggccaaagcctggagggtggaacaccggtggaagccggtatcccgggca 
seq-pS-PrP20    730 .................................................. 
 
pS-PrP209      1803 gggaagccctggaggcaaccgttacccacctcagggtggcacctgggggc 
seq-pS-PrP20    680 .................................................. 
 
pS-PrP209      1853 agccccacggtggtggctggggacaaccccatgggggcagctggggacaa 
seq-pS-PrP20    630 .................................................. 
 
pS-PrP209      1903 cctcatggtggtagttggggtcagccccatggcggtggatggggccaagg 
seq-pS-PrP20    580 .................................................. 
 
pS-PrP209      1953 agggggtacccataatcagtggaacaagcccagcaaaccaaaaaccaacc 
seq-pS-PrP20    530 .................................................. 
 
pS-PrP209      2003 tcaagcatgtggcaggggctgcggcagctggggcagtagtggggggcctt 
seq-pS-PrP20    480 .................................................. 
 
pS-PrP209      2053 ggtggctacatgctggggagcgccatgagcaggcccatgatccattttgg 
seq-pS-PrP20    430 .................................................. 
 
pS-PrP209      2103 caacgactgggaggaccgctactaccgtgaaaacatgtaccgctacccta 
seq-pS-PrP20    380 .................................................. 
 
pS-PrP209      2153 accaagtgtactacaggccagtggatcagtacagcaaccagaacaacttc 
seq-pS-PrP20    330 .................................................. 
 
pS-PrP209      2203 gtgcacgactgcgtcaatatcaccatcaagcagcacacggtcaccaccac 
seq-pS-PrP20    280 .................................................. 
 
pS-PrP209      2253 caccaagggggagaacttcaccgagaccgatgtgaagatgatggagcgcg 
seq-pS-PrP20    230 .................................................. 
 
pS-PrP209      2303 tggtggagcagatgtgcgtcacccagtaccagaaggagtcccaggcctat 
seq-pS-PrP20    180 .................................................. 
 
pS-PrP209      2353 tacgacgggagaagatccagcatcgagggaagggcggccgcaatggcaga 
seq-pS-PrP20    130 .................................................. 
 
pS-PrP209      2403 gagcccccatcaggtctttaatgtaacctggagagtcaccaacctgatga 
seq-pS-PrP20     80 .................................................. 
 
pS-PrP209      2453 ctgggcgtaccgccaatgccacctccctcc 
seq-pS-PrP20     30 .............................. 
 
 
pS-PrP111 
Sequencing result using EASeq1 primer 
pS-PrP111      1421 gaccgaccggtggtacctcacccttaccgagtcggcgacacagtgtgggt 
seq-pS-PrP11    766 .................................................. 
 
pS-PrP111      1471 ccgccgacaccagactaagaacctagaacctcgctggaaaggaccttaca 
seq-pS-PrP11    716 .................................................. 
 
pS-PrP111      1521 cagtcctgctgaccacccccaccgccctcaaagtagacggcatcgcagct 
seq-pS-PrP11    666 .................................................. 
 
pS-PrP111      1571 tggatacacgccgcccacgtgaaggctgccgaccccgggggtggaccatc 
seq-pS-PrP11    616 .................................................. 
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pS-PrP111      1621 ctctagactgacatggcgcgttcaacgctctcaaaaccccttaaaaataa 
seq-pS-PrP11    566 .................................................. 
 
pS-PrP111      1671 ggttaacccgcgaggccccctaatccccttaattcttctgatgctcagag 
seq-pS-PrP11    516 .................................................. 
 
pS-PrP111      1721 gggtcagtactgcggcccagccggccgtggggggccttggtggctacatg 
seq-pS-PrP11    466 .................................................. 
 
pS-PrP111      1771 ctggggagcgccatgagcaggcccatgatccattttggcaacgactggga 
seq-pS-PrP11    416 .................................................. 
 
pS-PrP111      1821 ggaccgctactaccgtgaaaacatgtaccgctaccctaaccaagtgtact 
seq-pS-PrP11    366 .................................................. 
 
pS-PrP111      1871 acaggccagtggatcagtacagcaaccagaacaacttcgtgcacgactgc 
seq-pS-PrP11    316 .................................................. 
 
pS-PrP111      1921 gtcaatatcaccatcaagcagcacacggtcaccaccaccaccaaggggga 
seq-pS-PrP11    266 .................................................. 
 
pS-PrP111      1971 gaacttcaccgagaccgatgtgaagatgatggagcgcgtggtggagcaga 
seq-pS-PrP11    216 .................................................. 
 
pS-PrP111      2021 tgtgcgtcacccagtaccagaaggagtcccaggcctattacgacgggaga 
seq-pS-PrP11    166 .................................................. 
 
pS-PrP111      2071 agatccagcatcgagggaagggcggccgcaatggcagagagcccccatca 
seq-pS-PrP11    116 .................................................. 
 
pS-PrP111      2121 ggtctttaatgtaacctggagagtcaccaacctgatgactgggcgtaccg 
seq-pS-PrP11     66 .................................................. 
 
pS-PrP111      2171 ccaatgccacctccct 
seq-pS-PrP11     16 ................ 
 
 
VI.6 Alignement pPrPMo plasmids 
pPrPMo209 
Sequencing result using CB6 primer 
pPrPMo209      6721 gcggcccagccggccaaaaagcggccaaagcctggagggtggaacaccgg 
seq-pPrPMo20      1 ..........t....................................... 
 
pPrPMo209      6771 tggaagccggtatcccgggcagggaagccctggaggcaaccgttacccac 
seq-pPrPMo20     51 .................................................. 
 
pPrPMo209      6821 ctcagggtggcacctgggggcagccccacggtggtggctggggacaaccc 
seq-pPrPMo20    101 .................................................. 
 
pPrPMo209      6871 catgggggcagctggggacaacctcatggtggtagttggggtcagcccca 
seq-pPrPMo20    151 .................................................. 
 
pPrPMo209      6921 tggcggtggatggggccaaggagggggtacccataatcagtggaacaagc 
seq-pPrPMo20    201 .................................................. 
 
pPrPMo209      6971 ccagcaaaccaaaaaccaacctcaagcatgtggcaggggctgcggcagct 
seq-pPrPMo20    251 .................................................. 
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pPrPMo209      7021 ggggcagtagtggggggccttggtggctacatgctggggagcgccatgag 
seq-pPrPMo20    301 .................................................. 
 
pPrPMo209      7071 caggcccatgatccattttggcaacgactgggaggaccgctactaccgtg 
seq-pPrPMo20    351 .................................................. 
 
pPrPMo209      7121 aaaacatgtaccgctaccctaaccaagtgtactacaggccagtggatcag 
seq-pPrPMo20    401 .................................................. 
 
pPrPMo209      7171 tacagcaaccagaacaacttcgtgcacgactgcgtcaatatcaccatcaa 
seq-pPrPMo20    451 .................................................. 
 
pPrPMo209      7221 gcagcacacggtcaccaccaccaccaagggggagaacttcaccgagaccg 
seq-pPrPMo20    501 .................................................. 
 
pPrPMo209      7271 atg 
seq-pPrPMo20    551 ... 
 
 
pPrPMo111 
Sequencing result using CB6 primer 
pPrPMo111      6719 ctgcggcccagccggccgtggggggccttggtggctacatgctggggagc 
seq-pPrPMo11      1 .............c.................................... 
 
pPrPMo111      6769 gccatgagcaggcccatgatccattttggcaacgactgggaggaccgcta 
seq-pPrPMo11     51 .................................................. 
 
pPrPMo111      6819 ctaccgtgaaaacatgtaccgctaccctaaccaagtgtactacaggccag 
seq-pPrPMo11    101 .................................................. 
 
pPrPMo111      6869 tggatcagtacagcaaccagaacaacttcgtgcacgactgcgtcaatatc 
seq-pPrPMo11    151 .................................................. 
 
pPrPMo111      6919 accatcaagcagcacacggtcaccaccaccaccaagggggagaacttcac 
seq-pPrPMo11    201 .................................................. 
 
pPrPMo111      6969 cgagaccgatgtgaagatgatggagcgcgtggtggagcagatgtgcgtca 
seq-pPrPMo11    251 .................................................. 
 
pPrPMo111      7019 cccagtaccagaaggagtcccaggcctattacgacgggagaagatccagc 
seq-pPrPMo11    301 .................................................. 
 
pPrPMo111      7069 atcgagggaagggcggccgcagcttcgcccggctccagtcctcatcaagt 
seq-pPrPMo11    351 .................................................. 
 
pPrPMo111      7119 ctataatatcacctgggaggtaaccaatggagatcgggagacggtatggg 
seq-pPrPMo11    401 .................................................. 
 
pPrPMo111      7169 caacttctggcaaccaccctctgtggacctggtggcctgaccttacccca 
seq-pPrPMo11    451 .................................................. 
 
pPrPMo111      7219 gatttatgtatgttagcccaccatggaccatcttattgggggctagaata 
seq-pPrPMo11    501 .................................................. 
 
pPrPMo111      7269 tcaatcccctttttcttctcccccggggcccccttgttgctcagggggca 
seq-pPrPMo11    551 ...........................................a...... 
 
pPrPMo111      7319 gcagcccaggctgttc 
seq-pPrPMo11    601 ................ 
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VI.7 Alignement pNP-Gem-PrP plasmids 
 
pGem-NP425-PrP111 
Sequencing result using pGem4-Seq primer 
 
pGem-NP425-P     11 attctcatgctggatcttctcccgtcgtaataggcctgggactccttctg 
seq-pGemNP42    840 .................................................. 
 
pGem-NP425-P     61 gtactgggtgacgcacatctgctccaccacgcgctccatcatcttcacat 
seq-pGemNP42    790 .................................................. 
 
pGem-NP425-P    111 cggtctcggtgaagttctcccccttggtggtggtggtgaccgtgtgctgc 
seq-pGemNP42    740 .................................................. 
 
pGem-NP425-P    161 ttgatggtgatattgacgcagtcgtgcacgaagttgttctggttgctgta 
seq-pGemNP42    690 .................................................. 
 
pGem-NP425-P    211 ctgatccactggcctgtagtacacttggttagggtagcggtacatgtttt 
seq-pGemNP42    640 .................................................. 
 
pGem-NP425-P    261 cacggtagtagcggtcctcccagtcgttgccaaaatggatcatgggcctg 
seq-pGemNP42    590 .................................................. 
 
pGem-NP425-P    311 ctcatggcgctccccagcatgtagccaccaaggccccccacccttccctg 
seq-pGemNP42    540 .................................................. 
 
pGem-NP425-P    361 gattgatccaccaccgccgatatcggcattgtctagagctacctcaattg 
seq-pGemNP42    490 .................................................. 
 
pGem-NP425-P    411 caccaccgcctgttggtttgtggtaagcaccatccccaccggacaagttt 
seq-pGemNP42    440 .................................................. 
 
pGem-NP425-P    461 gccagatgatgtctgagcctctccttggctgtatccgtcactcctaactc 
seq-pGemNP42    390 .................................................. 
 
pGem-NP425-P    511 atcttccagggcactgctgatcttcgattcagcatcctttgccacggctt 
seq-pGemNP42    340 .................................................. 
 
pGem-NP425-P    561 gtcctagtaagaacatttccatatcaaggtatgtcccccctgtgacgtac 
seq-pGemNP42    290 .................................................. 
 
pGem-NP425-P    611 tgctgcattgccttgttctgtacgacggcgactcccatggcgtaactcca 
seq-pGemNP42    240 .................................................. 
 
pGem-NP425-P    661 tagtgcaggataattgcctggagcaaattcaccatgaacagggtccttga 
seq-pGemNP42    190 .................................................. 
 
pGem-NP425-P    711 ggatacagataaagggagctctggggccttttgacaggtaggtgtctatg 
seq-pGemNP42    140 .................................................. 
 
pGem-NP425-P    761 aggcttctaagcttattaatatcgggcctcaggtttgacaacgttagagc 
seq-pGemNP42     90 .................................................. 
 
pGem-NP425-P    811 tgccatctttgtctccaccccatatttaatagtgttcatg 
seq-pGemNP42     40 ........................................ 
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pGem-NP455-PrP111 
Sequencing result using pGem4-Seq primer 
pGem-NP455-P     10 aattctcatgctggatcttctcccgtcgtaataggcctgggactccttct 
seq-pGemNP45    897 .................................................. 
 
pGem-NP455-P     60 ggtactgggtgacgcacatctgctccaccacgcgctccatcatcttcaca 
seq-pGemNP45    847 .................................................. 
 
pGem-NP455-P    110 tcggtctcggtgaagttctcccccttggtggtggtggtgaccgtgtgctg 
seq-pGemNP45    797 .................................................. 
 
pGem-NP455-P    160 cttgatggtgatattgacgcagtcgtgcacgaagttgttctggttgctgt 
seq-pGemNP45    747 .................................................. 
 
pGem-NP455-P    210 actgatccactggcctgtagtacacttggttagggtagcggtacatgttt 
seq-pGemNP45    697 .................................................. 
 
pGem-NP455-P    260 tcacggtagtagcggtcctcccagtcgttgccaaaatggatcatgggcct 
seq-pGemNP45    647 .................................................. 
 
pGem-NP455-P    310 gctcatggcgctccccagcatgtagccaccaaggccccccacccttccct 
seq-pGemNP45    597 .................................................. 
 
pGem-NP455-P    360 cgattgatccaccaccgccgtggccaccactcacctgacgtgcccatctt 
seq-pGemNP45    547 .................................................. 
 
pGem-NP455-P    410 tcaccactttctccaccccaacccctagcgtcctggtccgcatgagcttc 
seq-pGemNP45    497 .................................................. 
 
pGem-NP455-P    460 tgtttctaggtcgatatcggcattgtctagagctacctcaattgcaccac 
seq-pGemNP45    447 .................................................. 
 
pGem-NP455-P    510 cgcctgttggtttgtggtaagcaccatccccaccggacaagtttgccaga 
seq-pGemNP45    397 ......----------.................................. 
 
pGem-NP455-P    560 tgatgtctgagcctctccttggctgtatccgtcactcctaactcatcttc 
seq-pGemNP45    357 .................................................. 
 
pGem-NP455-P    610 cagggcactgctgatcttcgattcagcatcctttgccacggcttgtccta 
seq-pGemNP45    307 .................................................. 
 
pGem-NP455-P    660 gtaagaacatttccatatcaaggtatgtcccccctgtgacgtactgctgc 
seq-pGemNP45    257 ....a---------................t................... 
 
pGem-NP455-P    710 attgccttgttctgtacgacggcgactcccatggcgtaactccatagtgc 
seq-pGemNP45    216 .................................................. 
 
pGem-NP455-P    760 aggataattgcctggagcaaattcaccatgaacagggtccttgaggatac 
seq-pGemNP45    166 ....................-............................. 
 
pGem-NP455-P    810 agataaagggagctctggggccttttgacaggtaggtgtctatgaggctt 
seq-pGemNP45    117 .................................................. 
 
pGem-NP455-P    860 ctaagcttattaatatcgggcctcaggtttgacaacgttagagctgccat 
seq-pGemNP45     67 ..........................-....................... 
 
pGem-NP455-P    910 ctttgtctccaccccatatt 
seq-pGemNP45     18 ..............a..... 
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pGem-NP523-HA 
Sequencing result using pGem4-Seq primer 
pGem-NP523-H     50 gatacatatgctcgaggattcctcctatcccagctactgctgcggcatcg 
seq-pGem-NP5     76 .................................................. 
 
pGem-NP523-H    100 tcatcttcgtcgtgatcgacaccgttattgcggccttcatctccatgggt 
seq-pGem-NP5    126 .................................................. 
 
pGem-NP523-H    150 tgcagaatcctcttgccgtctctctgcgagtctcatggctattcttctct 
seq-pGem-NP5    176 .................................................. 
 
pGem-NP523-H    200 ctatgtctgatacatcctcatcattggtttcctcctctaaccgttcagcc 
seq-pGem-NP5    226 .................................................. 
 
pGem-NP523-H    250 ccatgtagtgtgacaaagtggccaccactcacctgacgtgcccatctttc 
seq-pGem-NP5    276 .................................................. 
 
pGem-NP523-H    300 accactttctccaccccaacccctagcgtcctggtccgcatgagcttctg 
seq-pGem-NP5    326 .................................................. 
 
pGem-NP523-H    350 tttctaggtcgatatcggcattgtctagagctacctcaattgcaccaccg 
seq-pGem-NP5    376 .................................................. 
 
pGem-NP523-H    400 cctgttggtttgtggtaagcaccatccccaccggacaagtttgccagatg 
seq-pGem-NP5    426 .................................................. 
 
pGem-NP523-H    450 atgtctgagcctctccttggctgtatccgtcactcctaactcatcttcca 
seq-pGem-NP5    476 .................................................. 
 
pGem-NP523-H    500 gggcactgctgatcttcgattcagcatcctttgccacggcttgtcctagt 
seq-pGem-NP5    526 .................................................. 
 
pGem-NP523-H    550 aagaacatttccatatcaaggtatgtcccccctgtgacgtactgctgcat 
seq-pGem-NP5    576 ............................t..................... 
 
pGem-NP523-H    600 tgccttgttctgtacgacggcgactcccatggcgtaactccatagtgcag 
seq-pGem-NP5    626 .................................................. 
 
pGem-NP523-H    650 gataattgcctggagcaaattcaccatgaacagggtccttgaggatacag 
seq-pGem-NP5    676 .................................................. 
 
pGem-NP523-H    700 ataaagggagctctggggccttttgacaggtaggtgtctatgaggcttct 
seq-pGem-NP5    726 .................................................. 
 
pGem-NP523-H    750 aagcttattaatatcgggcctcaggtttgacaacgttagagctgccatct 
seq-pGem-NP5    776 .................................................. 
 
pGem-NP523-H    800 ttgtctccaccccatatttaatagtgttcatgaaggaagccagccctgca 
seq-pGem-NP5    826 .................................................. 
 
pGem-NP523-H    850 tctcggatgtagttcccaacgatctggatgttcttctctaatgtggtgag 
seq-pGem-NP5    876 ........................................-......... 
 
pGem-NP523-H    900 atcagatcttgcagtattcatagtc 
seq-pGem-NP5    925 ......................... 
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IX Abbreviations 
aa   amino  acid 
aMLV   amphotropic murine leukemia virus 
Asn   asparagines 
bp   base  pair 
BSE    bovine spongiform encephalopathy  
Ch    brain homogenate of Chandler scrapie strain-infected mice 
CWD    chronic wasting disease  
CJD    Creutzfeldt-Jakob disease  
d   days 
DNA   desoxyribonucleic  acid 
EGF    epidermal growth factor 
EGF
D    epidermal growth factor fusion protein with platelet derived growth  
factor receptor transmembrane domain 
eMLV   ecotropic murine leukemia virus 
FITC   fluorescence  isothiocyanate 
GPI    glycosyl phosphatidyl inositol  
h   hours 
HA    immunological tag derived from hemagglutinine A 
HG    brain homogenate of unifected mice 
HEK-293FT  human embryonic kidney cells, fast growing subclone 
Ig   immune  globuline 
IPA   immune  peroxidase  assay 
µg   microgramm 
min   minutes 
ml   milliliter 
MLV    murine leukaemia virus 
mPrP    murine prion protein 
mPrP209  murine prion protein containing amino acids 23 to 231 
mPrP142  murine prion protein containing amino acids 90 to 231 
mPrP111  murine prion protein containing amino acids 121 to 231 
moi    multiplicity of infection 
myc    immunological tag derived from the human c-myc protooncogene 
N2a    murine neuroblastoma cell line 
  162Abbreviations 
NP    nucleocapsid protein of the Sendai virus 
NP-PrP  prion protein fused to the nucleocapsid protein of the Sendai virus 
p30   MLV-derived  capsid  protein 
PDGFR  platelet derived growth factor receptor 
PDGFR-TM  platelet derived growth factor receptor transmembrane domain 
PIPLC   phospholipase C 
PK   proteinase  K 
PMCA   protein misfolding cyclic amplification 
PrPMo   PrP-coding  MLV-Variant 
Prnp   prion  protein  gene 
PrP   prion  protein   
PrP
c   cellular  prion  protein 
PrP
D    prion protein fusion protein with platelet derived growth  
factor receptor transmembrane domain 
PrP
D111  prion protein aa 121-231 fusion protein with platelet derived growth  
factor receptor transmembrane domain 
PrP
D142  prion protein aa 90-231 fusion protein with platelet derived growth  
factor receptor transmembrane domain 
PrP
D209  prion protein aa 23-231 fusion protein with platelet derived growth  
factor receptor transmembrane domain 
PrP
E    prion protein fusion protein with the murine leukaemia virus derived  
envelope protein 
PrP
E111  prion protein aa 121-231 fusion protein with the murine leukaemia  
virus derived envelope protein 
PrP
E209  prion protein aa 23-231 fusion protein with the murine leukaemia  
virus derived envelope protein 
PrP-res  proteinase K resistant form of the prion protein 
PrP
Sc    pathogenic isoform of the prion protein 
RT   reverse  transcriptase 
SDS   sodium  dodecyle  sulfate 
SDS-PAGE  sodium dodecyle sulfate polyacrylamid gelelectrophoresis 
sec   seconds 
SP   signal  peptide 
SU    soluble unit of the retroviral envelope protein 
SV40   simian  virus  40 
  163Abbreviations 
TM    transmembrane domain of the retroviral envelope protein 
TSE    transmissible spongiform encephalopathies  
VLP(s) virus-like  particles(s) 
Wt   wild-type 
Wt-eMLV  wild-type ecotropic murine leukaemia virus 
6H4    PrP-specific monoclonal antibody 
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